USRE38970E1 - Indolyl or indolinyl derivatives and medicinal use thereof as ACAT or lipid peroxidation inhibitors - Google Patents

Indolyl or indolinyl derivatives and medicinal use thereof as ACAT or lipid peroxidation inhibitors Download PDF

Info

Publication number
USRE38970E1
USRE38970E1 US10/609,224 US60922498A USRE38970E US RE38970 E1 USRE38970 E1 US RE38970E1 US 60922498 A US60922498 A US 60922498A US RE38970 E USRE38970 E US RE38970E
Authority
US
United States
Prior art keywords
formula
alkyl
dimethylpropanamide
group
dimethylindolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US10/609,224
Inventor
Shoji Kamiya
Hiroaki Shirahase
Hiroshi Matsui
Shohei Nakamura
Katsuo Wada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyoto Pharmaceutical Industries Ltd
Original Assignee
Kyoto Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyoto Pharmaceutical Industries Ltd filed Critical Kyoto Pharmaceutical Industries Ltd
Application granted granted Critical
Publication of USRE38970E1 publication Critical patent/USRE38970E1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Abstract

A heterocyclic derivative of the formula (I)
Figure USRE038970-20060207-C00001
wherein each symbol is as defined in the specification, and pharmaceutically acceptable salts thereof. The compound (I) of the present invention and pharmaceutically acceptable salts thereof exhibit superior ACAT inhibitory activity and lipoperoxidation inhibitory activity in mammals, and are useful as ACAT inhibitors and lipoperoxidation inhibitors. Specifically, they are useful for the prophylaxis and treatment of arteriosclerosis, hyperlipemia, arteriosclerosis in diabetes, and cerebrovascular and cardiovascular ischemic diseases.

Description

This is a national stage of international application no. PCT/JP96/02852 filed Sep. 30, 1996.
TECHNICAL FIELD
The present invention relaters to novel heterocyclic derivatives and pharmaceutical use thereof. More particularly, the present invention relates to novel heterocyclic derivatives having an indoline ring, indole ring or tetrahydroquinoline ring, which derivatives having an inhibitory activity on aryl CoA: cholesterol acyltransferase (hereinafter ACAT) and lipoperoxidation inhibitory activity, and to pharmaceutical use thereof.
BACKGROUND ART
It is a well-known fact that arteriosclerosis is an extremely important factor causing various circulatory diseases, and active studies have been undertaken in an attempt to achieve suppression of the evolution of arterial sclerosis or regression thereof. In particular, although the usefulness of a pharmaceutical agent which reduces cholesterol in blood or arterial walls has been acknowledged, an ideal pharmaceutical agent exhibiting positive clinical effects while causing less side-effects has not been realized. A pharmaceutical agent which directly inhibits deposition of cholesterol in arterial walls has been desired as a pharmaceutical agent which effectively prevents or treats arterial sclerosis, and studies in this field are thriving. Yet, an ideal pharmaceutical agent has not been developed.
In recent years, it has been clarified that cholesterol in blood is accumulated in arterial walls in the ester form thereof, and that it significantly evolves arteriosclerosis. A decrease in cholesterol level in blood leads to the reduction of accumulation of cholesterol ester in arterial walls, and is effective for the suppression of evolution of arteriosclerosis and regression thereof.
Cholesterol in food is esterified in mucous membrane of small intestine, and taken into blood as chylomicron. ACAT is known to play an important role in the generation of cholesterol ester in mucous membrane of small intestine. Thus, if esterification of cholesterol can be suppressed by inhibiting ACAT in mucous membrane of small intestine, absorption of cholesterol by mucous membrane and into blood can be presumably prevented to ultimately result in lower cholesterol level in blood.
In arterial walls, ACAT esterifies cholesterol and causes accumulation of cholesterol ester. Inhibition of ACAT in arterial walls is expected to effectively suppress accumulation of cholesterol ester.
From the foregoing, it is concluded that an ACAT inhibitor will make an effective pharmaceutical agent for hyperlipemia and arteriosclerosis, as a result of suppression of absorption of cholesterol in small intestine and accumulation of cholesterol in arterial walls.
Conventionally, there have been reported, for example, as such ACAT inhibitors, amide and urea derivatives [J. Med. Chem., 29: 1131 (1986), Japanese Patent Unexamined Publication Nos. 117651/1990, 7259/1990, 234839/1992, 327564/1992 and 32666/1993]. However, creation and pharmacological studies of these compounds have been far from sufficient.
Meanwhile, hyperoxidation of low density lipoprotein (LDL) is also highly responsible for intracellular incorporation of cholesterol accumulated as cholesterol ester in arterial walls. In addition, it is known that hyperoxidation of lipids in a living body is deeply concerned with the onset of arteriosclerosis and cerebrovascular and cardiovascular ischemic diseases.
Accordingly, a compound having both an ACAT inhibitory activity and lipoperoxidation inhibitory activity is highly useful as a pharmaceutical product, since it effectively reduces accumulation of cholesterol ester in arterial walls and inhibits lipoperoxidation in living organisms, thereby preventing and treating various vascular diseases caused thereby.
It is therefore an object of the present invention to provide a compound having ACAT inhibitory activity and lipoperoxidation inhibitory activity, as well as pharmaceutical use thereof, particularly ACAT inhibitor and lipoperoxidation inhibitor.
DISCLOSURE OF THE INVENTION
The present inventors have conducted intensive studies to achieve the above-mentioned objects and found that a certain heterocyclic derivative having an indoline ring, indole ring or tetrahydroquinoline ring is superior in water solubility as compared to conventional ACAT inhibitors, and has lipoperoxidation inhibitory activity in addition to strong ACAT inhibitory activity, and that said compound permits superior oral absorption, strong anti-hyperlipemia effect and anti-arteriosclerosis effect, which resulted in the completion of the present invention.
Thus, the present invention relates to heterocyclic derivatives of the formula (I)
Figure USRE038970-20060207-C00002
wherein
    • one of R1, R2 and R5 is hydroxy, carboxy, alkoxycarbonyl, a group of the formula —NR9R10 wherein R9 and R10 are each independently hydrogen atom or lower alkyl, or alkyl or alkenyl substituted by hydroxy, acidic group, alkoxycarbonyl or a group of the formula —NT9R10 wherein R9 and R10 are each independently hydrogen atom or lower alkyl, and the other two are each independently hydrogen atom, lower alkyl or lower alkoxy;
    • either R3 or R4 is a group of the formula —NHCOR7 wherein R7 is alkyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl or a group of the formula —NHR8 wherein R8 is alkyl, cycloalkyl, cycloalkylalkyl, aryl or arylalkyl, and the other is hydrogen atom, lower alkyl or lower alkoxy;
    • R6 is alkyl, alkenyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, cycloalkylalkyl or arylalkyl; and
    • Z is a binding group forming a 5- or 6-membered ring together with nitrogen atom substituted by R6, carbon atom of benzene ring to which said nitrogen atom binds and carbon atom adjacent to said carbon atom,
      and pharmaceutically acceptable salts thereof.
The present invention also relates to pharmaceutical compositions. ACAT inhibitors and lipoperoxidation inhibitors containing the above-mentioned heterocyclic derivative or a pharmaceutically acceptable salt thereof.
In the present specification, each symbol denotes the following.
Lower alkyl at R1, R1a, R1b, R1c, R2, R2c, R3, R3a, R3b, R3c, R4, R4c, R5, R5c, R9, R9c, R10 and R10c may be linear or branched and has 1 to 6 carbon atoms. Examples thereof include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tent-butyl, pentyl, isopentyl, neopentylhexyl an the like.
Lower alkoxy at R1, R1b, R1c, R2, R2a, R3, R3b, R3c, R4, R4c, R5 and R5c may be linear or branched and has 1 to 6 carbon atoms. Examples thereof include methoxy, ethoxy propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy, isopentyloxy, neopentyloxy, hexyloxy and the like.
Alkyl at R6, R6a, R6b, R6c, R7, R7a, R7b, R7c, R8, R8b and R8c may be linear or branched and preferably has 1 to 20 carbon atoms. Examples thereof include methyl, ethyl propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, nonadecyl, icosyl, 1,1-dimethylpropyl, 1,1-dimethylbutyl, 1,1-dimethylhexyl, 1,1-dimethylheptyl, 3,3-dimethylbutyl, 4,4-dimethylbutyl and the like.
In alkoxyalkyl at R6, R6b, R6c, R7, R7b and R7c, the alkoxy moiety thereof preferably has 1 to 6 carbon atoms and alky moiety thereof preferably has 1 to 6 carbon atoms. Examples of alkoxyalkyl include ethoxybutyl, ethoxyhexyl, butoxybutyl, butoxyhexyl, hexyloxybutyl, hexyloxyhexyl and the like.
In alkylthioalkyl at R6, R6b, R6c, R7, R7b and R7c, both alkyl moieties preferably have 1 to 6 carbon atoms Examples of alkylthioalkyl include ethylthioethyl ethylthiohexyl, butylthiobutyl, butylthiohexyl, hexylthiobutyl, hexylthiohexyl and the like.
Cycloalkyl at R6, R6a, R6b, R6c, R7, R7a, R7b, R7c, R8, R8b and R8c preferably has 3 to 8 carbon atoms. Examples thereof include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl and the like.
In cycloalkylalkyl at Rd, Rda, Rdb, Rdc, R7, R7a, R7b, R7c, R8, R8b, and R8c its cycloalkyl moiety preferably has 3 to 6 carbon atoms and alkyl moiety preferably has 1 to 3 carbon atoms. Examples of cycloalkylalkyl include cyclopropylmethyl, cyclobutylmethyl, cyclopropylmethyl, cyclohexylmethyl, cyclopropylethyl, cyclopropylpropyl, cyclopropylmethyl, cyclooctlmethyl and the like.
Examples of aryl at R7, R7b, R7c, R8, R8b, and R8c include phenyl, naphthyl and the like.
Arylalkyl at R6, R6b, R6c, R7, R7b, R7c, R8, R8b and R8c has the aforementioned aryl moiety and its alkyl moiety preferably has 1 to 4 carbon atoms. Examples of arylalkyl include benzyl, 1-phenylethyl, 2-phenylethyl, 1-phenylpropyl, 2-phenylpropyl, 3-phenylpropyl and the like.
Alkenyl at R6, R6b and R6c may be linear or branched and preferably has 3 to 12 carbon atoms. Examples thereof include propenyl, isopropenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, 3,3-dimethyl-2-propenyl and the like.
Acidic group at R1, R2 and R3 is exemplified by carboxy, sulfonic acid group, phosphoric acid group and the like. Examples of alkoxycarbonyl at R1, R1c, R2, R2b, R2c, R5 and R5c include methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, sec-butoxycarbonyl, tert-butoxycarbonyl and the like.
Alkyl to be substituted at R1, R2, R2a, R2b and R3 may be linear or branched and preferably has 1 to 8 carbon atoms. Examples thereof include methyl, ethyl, propyl, butyl, pentyl, hexyl, 1,1-dimethylethyl, 2,2-dimethylpropyl and the like. Examples of substituted alkyl include hydroxymethyl, hydroxyethyl, carboxymethyl, carboxyethyl, carboxypropyl, ethoxycarbonylmethyl, dimethylaminomethyl, dimethylaminoethyl, sulfomethyl, phosphonomethyl and the like.
Alkenyl to be substituted at R1, R2 and R3 may be linear or branched and preferably has 2 to 8 carbon atoms. Examples thereof include vinyl, propenyl, isopropenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, 3,3-dimethyl-2-propenyl and the lace. Examples of substituted alkenyl include carboxyvinyl, carboxypropenyl, hydroxypropenyl and the like.
Z is preferably
Figure USRE038970-20060207-C00003
In the compounds of the present invention, {circle around (1)} when one of R1, R2 and R5 is alkyl or alkenyl substituted by hydroxy, acidic group, alkoxycarbonyl or a group of the formula —NR9R10 wherein R9 and R10 are each independently hydrogen atom or lower alkyl, and the other two are independently hydrogen atom, lower alkyl or lower alkoxy, the compound may be (a) indoline or indole derivative, or (b) tetrahydroquinoline derivative.
    • (a) When the compound of the present invention is indoline or indole derivative, preferable compound is that of the above-mentioned formula (I) wherein one of R1, R2 and R5 is alkyl substituted by hydroxy, carboxy, alkoxycarbonyl or a group of the formula —NR9R10 wherein R9 and R10 are each independently lower alkyl, and the other two are independently hydrogen atom, lower alkyl or tower alkoxy either R3 or R4 is a group of the formula —NHCOR7 wherein R7 is alkyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl or a group of the formula —NHR8 wherein R8 is alkyl, and the other is hydrogen atom, lower alkyl or lower alkoxy; and R6 is as defined above.
A more preferable compound is that of the above-mentioned formula (I) wherein R2 and R3 are each independently hydrogen atom, lower alkyl or lower alkoxy; either R2 or R3 is alkyl substituted by hydroxy, carboxy, alkoxycarbonyl or a group of the formula —NR9R10 wherein R9 and R10 are each independently lower alkyl, and the other is hydrogen atom, lower alkyl or lower alkoxy; R4 is a group of the formula —NHCOR7 wherein R7 is alkyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl or a group of the formula —NHR8 wherein R8 is alkyl; and R6 is as defined above.
A still more preferable compound is that of the above-mentioned formula (I) wherein R1 and R3 are each independently hydrogen atom, lower alkyl or lower alkoxy; either R2 or R3 is alkyl substituted by hydroxy, carboxy, alkoxycarbonyl or a group of the formula —NR9R10 wherein R9 and R10 are each independently lower alkyl, and the other is hydrogen atom; R4 is a group of the formula —NHCOR7 wherein R7 is alkyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl or a group of the formula —NHR8 wherein R8 is alkyl; and R6 is as defined above.
A still more preferable compound is that of the above-mentioned formula (I) wherein R1 and R3 am each independently hydrogen atom or lower alkyl; either R2 or R5 is alkyl substituted by hydroxy, carboxy, alkoxycarbonyl or a group of the formula —NR9R10 wherein R9 and R10 are each independently lower alkyl, and the other is hydrogen atom R4 is a group of the formula —NHCOR7 wherein R7 is alkyl cycloalkyl or cycloalkylalkyl; and R6 is alkyl, cycloalkyl or cycloalkylalkyl.
A still more preferable compound is that of the above mentioned formula (I) wherein R1 and R3 are each independently hydrogen atom or lower alkyl; R2 is alkyl substituted by hydroxy, carboxy, alkoxycarbonyl or a group of the formula —NR9R10 wherein R9 and R10 are each independently lower alkyl, and R5 is hydrogen atom; R4 is a group of the formula —NHCOR7 wherein R7 is alkyl, cycloalkyl or cycloalkylalkyl; and R6 is alkyl, cycloalkyl or cycloalkylalkyl.
A still more preferable compound is that of the following formula (IIa):
Figure USRE038970-20060207-C00004
wherein R3a is hydrogen atom or lower alkyl; R3a is lower alkyl; R2a is alkyl substituted by hydroxy or carboxy R4a is a group of the formula —NHCOR7a wherein R7a is alkyl, cycloalkyl or cycloalkylalkyl:: and R6a is alkyl, cycloalkyl or cycloalkylalkyl.
A still more preferable compound is that of the above formula (IIa) wherein R3a is hydrogen atom or lower alkyl; R3a is lower alkyl; R2a is alkyl substituted by hydroxy or carboxy; R4a is a group of the formula —NHCORla wherein R7a is alkyl; and R6a is alkyl.
Examples of the most preferable compound include N-(1-hexyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide, N-(1-heptyl-5-carboxymethyl -4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide, N-(1-octyl-5-carboxymethyl-4,5-dimethylindolin-7-yl)-2,2-dimethylpropanamide, N-(1-nonyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide, N-(1-decyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide, N-(1-undecyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide, N-(1-dodecyl-5-carboxymethyl-4,6-dimethylinodolin-7-yl)-2,2-dimethylpropanamide, N-(1-hexyl-5-hydroxymethyl-6-methylindolin-7-yl)-2,2-dimethylpropanamide, N-(1-hexyl-5-hydroxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide, N-(1-heptyl-5-hydroxymethyl-6-methylindolin-7-yl)-2,2-dimethylpropanamide, N-(1-heptyl-5-hydroxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide, N-(1-octyl-5-hydroxymethyl-6-methylindolin-7-yl)-2,2-dimethylpropanamide, N-(1 -octyl-5-hydroxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide and the like, and pharmaceutically acceptable salts thereof.
    • (b) When the compound of the present invention is a tetrahydroquinoline derivative, a compound of the following (IIb) is preferable.
      Figure USRE038970-20060207-C00005
      wherein R1b and R3b are each independently hydrogen atom, lower alkyl or lower alkoxy; R2b is alkyl substituted by hydroxy, carboxy or alkoxycarbonyl; R4b is a group of the formula —NHCOR7b wherein R7b is alkyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl or a group of the formula —NHR8b wherein R8b is alkyl, cycloalkyl, cycloalkylalkyl, aryl or arylalkyl; and R8b is alkyl, alkenyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, cycloalkylalkyl or arylalkyl.
A still more preferable compound is that of the formula (IIb) wherein R1b and R3b are each independently lower alkyl or lower alkoxy; R2b is alkyl substituted by hydroxy, carboxy or alkoxycarbonyl; R4b is a group of the formula —NHCOR7b wherein R7b is alkyl, cycloalkylalkyl, arylalkyl or a group of the formula —NHR8b wherein R8b is alkyl; and Rdb is alkyl, alkoxyalkyl, alkylthioalkyl or cycloalkylalkyl.
A still more preferable compound is that of the formula (IIb) wherein R1b and R3b are each independently lower alkyl; R2b is alkyl substituted by hydroxy or carboxy; R4b is a group of the formula —NHCOR7b herein R4b is alkyl; and R6b is alkyl.
Examples of the most preferable compound include N-(1-hexyl-6-carboxymethyl-5,7-dimethyl-1,2,3,4-tetrahydroquinolin-8-yl)-2,2-dimethylpropanamide, N-(1-heptyl-6-carboxymethyl-5,7-dimethyl-1,2,3,4-tetrahydroquinolin-8-yl)-2,2-dimethylpropanamide, N-(1-octyl-6-carboxymethyl-5,7-dimethyl-1,2,3,4-tetrahydroquinolin-8-yl)-2,2-dimethylpropanamide, N-(1-nonyl-6-carboxymethyl-5,7-dimethyl-1,2,3,4-tetrahydroquinolin-8-yl)-2,2-dimethylpropanamide, N-(1-decyl-6-carboxymethyl-5,7-dimethyl-1,2,3,4-tetrahydroquinolin-8-yl)-2,2-dimethylpropanamide, N-(1-hexyl-6-hydroxymethyl-5,7-dimethyl-1,2,3,4-tetrahydroquinolin-8-yl)-2,2-dimethylpropanamide, N-(1-heptyl-6-hydroxymethyl-5,7-dimethyl-1,2,3,4-tetrahydroquinolin-8-yl-2,2-dimethylpropanamide, N-(1-octyl-6-hydroxymethyl-5,7-dimethyl-1,2,3,4-tetrahydroquinolin-8-yl)-2,2-dimethylpropanamide, N-(1-nonyl-6-hydroxymethyl-5,7-dimethyl-1,2,3,4-tetrahydroquinolin-8-yl)-2,2-dimethylpropanamide, N-(1-decyl-6-hydroxymethyl-5,7-dimethyl-1,2,3,4-tetrahydroquinolin-8-yl)-2,2-dimethylpropanamide and the like, and pharmaceutically acceptable salts thereof.
{circle around (2)} When the compound of the present invention is that wherein one of R1, R2 and R4 is hydroxy, carboxy, alkoxycarbonyl or a group of the formula —NR9R10 wherein R9 and R10 are each independently hydrogen atom or lower alkyl, and the other two are independently hydrogen atom, lower alkyl or lower alkoxy, the compound of the following formula (IIc) is preferable.
Figure USRE038970-20060207-C00006
wherein one of R1c, R2c and R5c is hydroxy, carboxy alkoxycarbonyl or a group of the formula —NR9CR10C wherein R9c and R10c are each independently hydrogen atom or lower alkyl, and the other two are each independently hydrogen atom, lower alkyl or lower alkoxy; either R3c or R4c is a group of the formula —NHCOR7C wherein R7c is alkyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl cycloalkylalkyl, aryl, arylalkyl or a group of the formula —NHR8c wherein R8c is alkyl, cycloalkyl, cycloalkylalkyl aryl or arylalkyl, and the other is hydrogen atom, lower alkyl or lower alkoxy; and Rc is alkyl, alkenyl, alkoxyalkyl alkylthioalkyl, cycloalkyl, cycloalkylalkyl or arylalkyl.
More preferable compound is a compound of the above formula (IIc) wherein R1c and R 3c are each independently hydrogen atom, lower alkyl or lower alkoxy; R2c is carboxy R4c is a group of the formula —NHCOR wherein R7c is alkyl, cycloalkyl or cycloalkylalkyl; R5c is hydrogen atom and R6c is alkyl, cycloalkyl or cycloalkylalkyl.
A still more preferable compound is a compound of the above formula (IIc) wherein R1c is hydrogen atom or lower alkyl; R3c is lower alkyl; R2c is carboxy; R4c is a group of the formula —NHCOR7c wherein R7c is alkyl; R5c is hydrogen atom; and R6c is alkyl.
Examples of the mast preferable compound include N-(1-hexyl-5-carboxy-6-methylindolin-7-yl)-2,2-dimethylpropanamide, N-(1-octyl-5-carboxy-6-methylindolin-7-yl)-2,2-dimethylpropanamide, N-(1-decyl-5-carboxy-6-methylindolin-7-yl)-2,2-dimethylpropanamide, N-(1-hexyl-5-carboxy-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide, N-(1-octyl-5-carboxy-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide, N-(1-decyl-5-carboxy-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide and the like, and pharmaceutically acceptable salt thereof.
The compound (I) may form pharmaceutically acceptable salts. When compound (I) has a basic group, it an form acid addition salts. The acid to germ such acid addition salts is subject to no particular limitation as long as it can form a salt with a basic moiety and is a pharmaceutically acceptable acid. Examples of such acid include inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, nitric add and the like, and organic scuds such as oxalic acid, fumaric acid, maleic acid, citric acid, tartaric acid, methanesulphonic acid, toluenesulphonic acid and the like.
When compound (I) has an acidic group such as carboxy, it can form, for example, alkali metal salts such as sodium salt, potassium salt and the like; alkaline earth metal salts such as calcium salt, magnesium salt and the hate; and organic base salts such as triethylamine salt, dicyclohexylamine salt, pyridine salt and the like.
The compound (I) of the present invention and pharmaceutically acceptable salts thereof can be produced by any one of the following methods 1 to 7.
Figure USRE038970-20060207-C00007
Figure USRE038970-20060207-C00008
Figure USRE038970-20060207-C00009
Figure USRE038970-20060207-C00010
Figure USRE038970-20060207-C00011
Figure USRE038970-20060207-C00012
Figure USRE038970-20060207-C00013
In each of the above formulas, R6, R7, R8, R9 and R10 are each as defined above; R11 and R12 are each independently hydrogen atom, lower alkyl or lower alkoxy; R13 is amino protecting group; R14 is alkyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, cycloalkylalkyl, aryl or arylalkyl; R15 is alkyl or alkenyl substituted by halogen atom; R16 is alkyl or alkenyl substituted by hydroxy, protected hydroxy, acidic group, protected acidic group, alkoxycarbonyl or —NR18R19 wherein R18 and R19 are each independently hydrogen atom, lower alkyl or amino protecting group; R17 is alkyl or alkenyl substituted by hydroxy, acidic group, alkoxycarbonyl or —NR9R10; R20 is protected carboxy; R21 is protected hydroxy; and R22 is —NR 18R19 wherein R18 and R19 are as defined above.
Amino protecting group at R13, R18 and R19 is, for example, formyl, monochloroacetyl, dichloroacetyl, trifluoroacetyl, methoxycarbonyl, ethoxycarbonyl, benzyloxycarbonyl, p-nitrobenzyloxycarbonyl, diphenylmethyloxycarbonyl, methoxymethyloxycarbonyl, 2,2,2-trichloroethoxycarbonyl, trimethylsilyl, 2-methylsulfonylethyloxycarbonyl, tert-butoxycarbonyl or trityl.
Hydroxy protecting group at R16 and R21 is, for example, formyl, acetyl, monochloroacetyl, dichloroacetyl, trifluoroacetyl, methoxycarbonyl, ethoxycarbonyl, benzyloxycarbonyl, 2,2,2-trichloroethoxycarbonyl, benzoyl, trityl, tetrahydropyranyl, trimethylsilyl or the like.
Acidic group protecting group at R16 and R20 is, when carboxy protecting group, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, tert-amyl, benzyl, p-nitrobenzyl, p-methoxybenzyl, benzhydryl, p-nitrophenyl, methoxymethyl, ethoxymethyl, benzyloxymethyl, methylthiomethyl, trityl, 2,2,2-trichloroethyl, trimethylsilyl, diphenylmethoxybenzene-sulfonylmethyl, dimethylaminoethyl and the like.
The above-mentioned protecting groups can be removed by a method known per se, and the method for removing them may be determined according to the kind of the protecting group. Exemplified am a decomposition by an acid (e.g., that by an acid such as hydrochloric acid, trifluoroacetic acid and the like for formyl, tert-butoxycarbonyl, trityl, tetrahydropyranyl and the like); a decomposition by a base (e.g., that by a base such as sodium hydroxide, potassium hydroxide, sodium carbonate, sodium bicarbonate and the like for acetyl, dichloroacetyl, trifluoroacetyl and the like); and catalytic reduction (e.g., decomposition by palladium-carbon and the like for benzyl, benzyloxycarbonyl and the like). The production methods of the objective compounds of the present invention and starting material compound are described in detail in the following.
Production Method 1
The compound (IV) can be produced by reducing compound (III) [J. Eric Nordlander, et al., J. Org. Chem., 46, 778-782 (1981), Robin D. Clark, et al., Heterocycle, 22, 195-221 (1994), Vernon H. Brown, et al., J. Heterocycle. Chem., 6(4), 539-543 (1969)]to introduce an indoline skeleton, protecting amino, introducing nitro on benzene ring by a method known per se, and reducing nitro using a catalyst such as palladium-carbon.
The compound (VII) can be produced by reacting compound (IV) with compound (V) or reactive derivative thereof at carboxy group, or compound (VI).
Said reaction is generally carried out in an inert solvent. Examples of the inert solvent include acetone, dioxane, acetonitrile, chloroform, benzene, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine, water and mixed solvents thereof.
In addition, a base such as triethylamine, pyridine, 4-dimethylaminopyridine, potassium carbonate and the like can be used.
The reaction temperature: is generally −10-160° C., preferably 0-60° C., and reaction time is generally from 30 min to 10 hr.
The compound (V) can be subjected to the instant reaction as a free carboxylic acid or a reactive derivative thereof, and the both modes are encompassed in the present invention. That is, it is used in this reaction as a free acid or a salt such as sodium, potassium, calcium, triethylamine, pyridine and the like, or as a reactive derivative such as its acid halide (e.g., acid chloride, acid bromide and the like), acid anhydride, mixed acid anhydride [e.g., substituted phosphoric acid (dialkyl phosphate and the like), alkyl carbonate (monoethylcarbonate and the like) and the like], active amide (amide with imidazole and the like), ester (cyanomethyl ester, 4-nitrophenyl ester etc.), and the like.
When compound (V) is used as a free acid or a salt in this reaction, a condensing agent is preferably used. Examples of the condensing agent include dehydrating agents such as N,N′-disubstituted carbodiimides (e.g., N,N′-dicyclohexylcarbodiimide); carbodiimide compounds (e.g., 1-ethyl-3-(3′-dimethylaminopropyl)carbodiimide, N-cyclohexyl-N′-morpholinoethyl carbodiimide and N-cyclohexyl-N′-(4-diethylaminocyclohexyl) carbodiimide); azolide compounds (e.g., N,N′-carbonyldiimidazole and N,N′-thionyldiimidazole); and the like. When these condensing; agents are used, the reaction is considered to proceed via a reactive derivative of carboxylic acid. The compound (VIII) an be produced by halo-genoalkylation of compound (VII) [R. C. Fuson et al., Org. React., 1, 63 (1969), G. A. Olah et al., “Fricdel Crafts and Related Reactions” Vol. 2. 659 (1964)].
The compound (IX) can be produced by converting halogenoalkyl of compound (VIII) to hydroxy, an acidic group such as carboxy or a group of the formula —NR9R10 by a substituent conversion reaction known per se, and if necessary, introducing a corresponding protecting group.
The compound (XII) can lie produced by eliminating the amino protecting group at R13 of compound (IX) by a method known per se to give compound (X) and by N-alkylation using compound (XI).
Said N-alkylation can be generally carried out in an inert solvent. Examples of the inert solvent include acetone, dioxane, acetonitrile, chloroform, benzene, methylene chloride, ethylene chloride, tetrahydrofuran, ethyl acetate, N,N-dimethylformamide, pyridine, water and mixed solvents thereof.
In addition, a base such as triethylamine, pyridine, 4-dimethylaminopyridine, potassium carbonate and the like can be used.
The reaction temperature is generally −10-100° C., preferably 0-60° C., and reaction time is generally from 30 min to 10 hr.
The compound (Ia) can be produced by eliminating the protecting group at R16 of compound (XII) by a method known per se.
Production Method 2
The compound (XIII) can be produced by hydroxyalkylation of compound (III) [Adof H. Phlipp., et al., J. Med. Chem., 19(3), 391-395 (1976)], reducing, introducing an indoline skeleton, protecting amino, and halogenating hydroxy.
The compound (XIV) can be produced from compound (XIII) according to the method for obtaining compound (IX) from compound (VIII) as described in Production Method 1.
The compound (XV) can be produced from compound (XIV) by introducing nitro and reducing nitro by a method known per se.
The compound (XVI) can be produced from compound (XV) according to the method for obtaining compound (VII) from compound (IV) as described in Production Method 1.
The compound (Ib) can be produced from compound (XVI) via compound (XVII) and compound (XIII) according to the method for obtaining compound (Ia) from compound (IX) as described in Production Method 1.
Production Method 3
The compound (XIX) can be produced by oxidation of compound (X) by a method known per se (e.g., oxidation using chloranil, palladium-carbon and the like).
The compound (Ic) an be produced from compound (XIX) via compound (XX) according to the method for obtaining compound (Ia) from compound (X) as described in Production Method 1.
Production Method 4
The compound (XXI) can be produced by reducing 2,3-dihydroquinolin-4-One derivative [J. R Merchant, et al., J. Chem. Soc. Perkin I, 932-935 (1972)]using a reducing agent such as lithium aluminum hydride-aluminum chloride and the like.
The compound (XXIII) can be produced from compound (XXII) by protecting amino of compound (XXI) by a method known per se to give compound (XXII) and according to the method for obtaining compound (VIII) from compound (VII) as described in Production Method 1.
The compound (XXV) can be produced from compound (XXIII) via compound (XXIV) according to the method for obtaining compound (XII) from compound (VIII) via compound compound(IX) and compound (X) as described in Production Method 1.
The compound (XXVI) an be produced from compound (XXV) by introducing nitro and reducing nitro by a method known per se.
The compound (XXVII) an be produced from compound (XXVI) according to The method for obtaining compound (VII) from compound (IV) as described in Production Method 1.
The compound (Id) an be produced from compound (XXVII) according to the method for obtaining compound (Ice) from compound (XII) as described in Production Method 1.
Production Method 5
The compound (XXIX) an be produced from compound (XXVIII) (W. G. Gall, et al., J. Org. Chem., 20,1538 (1955)] according to the method for obtaining compound (XII) from compound (X) as described in Production Method 1.
The compound (XXX) an be produced by converting halogen of compound (XXIX) to cyano by a method known per se, hydrolysis of cyano, and introducing a protecting group into the obtained carboxy.
The compound (XXXI) can be produced from compound (XXX) by reducing nitro of compound (XXX) by a method known per se, and according to the method for obtaining compound (VII) from compound (IV) as described in Production Method 1.
The compound (Ie) can be produced by eliminating the protecting group al R20 of compound (XXXI) by a method known per se.
Production Method 6
The compound (XXXII) cm be produced by converting amino of compound (IV) to hydroxy by a method known per se and introducing a protecting group into hydroxy.
The compound (XXXIII) can be produced from compound (XXXII) by introducing nitro and reducing nitro by a method known per se.
The compound (XXXIV) can be produced from compound (XXXIII) according to the method for obtaining compound (VII) from compound (IV) as described in Production Method 1.
The compound (XXXV) can be produced from compound (XXXIV) according to the method for obtaining compound (XII) from compound (IX) via compound (X) as describe in Production Method 1.
The compound (If) can be produced by eliminating the protecting group at R21 of compound (XXXV) by a method known per se.
Production Method 7
The compound (XXXVI) can be produced by alkylation of amino or by introducing a protecting group of amino of compound (IV) by a method :known per se.
The compound (XXXVII) can be produced from compound (XXXVI) by introducing nitro and reducing nitro by a method known per se.
The compound (XXXVII) can be produced from compound (XXXVII) according, to the method for obtaining compound (VII) from compound (IV) as described in Production Method 1.
The compound (XXXIX) can be produced from compound (XXXVIII) according to the method for obtaining compound (XII) from compound (IX) via compound (X) as described in Production Method 1.
The compound (Ig) can be produced by eliminating the protecting group at R22 of compound (XXXIX) by a method known per se.
The compound (I) of the present invention obtained by the above methods can be purified by a method conventionally known such as chromatography and recrystallization.
Said compound (I) can be converted to pharmaceutically acceptable salts by a method known per se.
A pharmaceutical composition containing the compound (I) of the present invention or a pharmaceutically acceptable salt thereof can further contain additives. Examples of the additive include excipients (e.g., starch, lactose, sugar calcium carbonate and calcium phosphate), binders (e.g., starch, gum arabic, carboxymethylcellulose, hydroxypropylcellulose and crystalline cellulose), lubricants (e.g., magnesium stearate and talc:), and disintegrators (e.g., carboxymethyl-cellulose calcium and talc), and the like.
The above-mentioned ingredients am minced and the mixture is prepared into oral preparations such as capsules, tablets, fine granules, granules; and dry syrups, or parenteral preparations such as injections and suppositories by a method known per se.
While the dose of the compound (I) of the present invention and pharmaceutically acceptable salts thereof varies depending on administration targets, symptoms and others, when, for example, orally administered to adult patients of hypercholesterolemia, it is generally 0.1 mg-50 mg/kg body weight per dose which is administered about 1 to 3 time(s) a day.
The compound (I) of the present invention and pharmaceutically acceptable salts thereof exhibit superior ACAT inhibitory activity and lipoperoxidation inhibitory activity in mammals (e.g., human, cow, horse, dog, cat, rabbit, rat, mouse, hamster etc.) and are useful as ACAT inhibitors and lipoperoxidation inhibitors. In other words, they are useful for the prophylaxis and treatment of arteriosclerosis, hyperlipemia, arteriosclerosis in diabetes, cerebrovascular and cardiovascular ischemic diseases, and the like.
The present invention is described in more detail by way of Examples, to which the present invention is not limited.
EXAMPLE 1 N-(1-octyl-5-hydroxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide
  • (1) N-(1-Acetyl-5-chloromethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide (7.0 g) was dissolved in a mixed solvent (50 ml) of CH3CN/DMF-1/1. Potassium acetate (12.0 g) was added and the mixture was stirred at 60° C. for 1 hr. CH3CN was evaporated under reduced pressure and AcOEt (200 ml) was added. After washing with water, the mixture was dried over anhydrous sodium sulfate, and AcOEt was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: CHCl3/MeOH=1/0-10/1) to give 7.5 g of N-(1-acetyl-5-acetoxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide.
    1H-NMR (CDCl3) δ:
    1.27 (9H, s, —C(CH3)3), 2.04 (3H, s, OCOCH3), 2.23, 2.26, 2.30 (9H, s×3, —CH,x2, >NCOCH3), 3.00 (2H, hr, Indoline C3—H), 4.05 (2H, by, Indoline C2—H), 5.20 (2H, s, —CH2O—), 9.10 (1H, br, >NH).
  • (2) N-(1-Acetyl-5-acetoxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide (7.5 g) was dissolved in EtOH (70 ml) and a solution of NaOH (8.3 g) in water (20 ml) was added, which was followed by refluxing for 10 hr. EtoH was evaporated under reduced pressure and CHCl3 (200 ml) was added. After washing with water, the mixture was dried over anhydrous sodium sulfate and CHCl3 was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: CHCl3/MeOH=1/0-10/1) to give 3.0 g of N-(5-hydroxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide.
    1H-NMR (CDCl3) δ:
    1.35 (9H, s, —C(CH3)3), 2.23, 2.26 (6H, s×2, —CH3×2), 2.99 (2H, t, J=8.5 Hz, Indoline C3—H), 3.58 (2H, t, J=8.5 Hz, Indoline C2—H), 4.65 (2H, s, —CH2OH), 7.10 (2H, br, OH, >NH).
  • (3) N-(5-Hydroxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide (1.5 g) was dissolved in DMF (15 ml) and 1-iodooctane (2.6 g) and K2CO3 (1.5 g) were added, which was followed by stirring under a nitrogen atmosphere at 50° C. for 2 hr. AcOEt (200 ml) was added, and the mixture was washed with water and dried over anhydrous sodium sulfate. AcOEt was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: CHCl3/MeOH=1/0-10/1) to give 1.0 g of the title compound.
    IR (Nujol) cm−1: 1652, 1600, 1508.
    1H-NMR (CDCl3) δ:
    0.70-1.10 (3H, br, −4CH2)7CH,), 1.10-1.70 (12H, m, —CH2(CH2)(6CH3) 1.37 (9H, s, —C(CH3)3), 2.14, 2.22 (6H, s×2, —H3x2), 2.87 (2H, t, J=8.5 Hz, Indoline C3—H), 3.14 (2H, t, J=7.5 Hz, >NCH2), 3.42 (2H, t, J=8.5 Hz, Indoline C2—H), 4.62 (2H, s, CH2OH), 6.86 (2H, br, OH, >NH).
EXAMPLE 2 N-(1-octyl-5-dimethylaminomethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide
  • (1) N-(1-Acetyl-5-chloromethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide (2.0 g) was dissolved in CHCl3 (40 ml) and (CH3)2NH.HCl (3.5 g) and K2CO3 (11.8 g) were added, which was, followed by stirring at room temperature for 4 hr. CHCl3 (300 ml) was added, and the mixture was washed successively with 2N-hydrochloric acid, 2N aqueous NaOH and saturated brine, and dried over anhydrous sodium sulfate. CHCl3 was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: CHCl3/MeOH=10/1-1/1) to give 700 mg of N-(1-acetyl-5-dimethylaminomethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide.
    3H-NMR (CDCl3) δ:
    1.26 (9H, s, —C(CH3)3), 2.12, 2.15 (6H, s×2, —CH3×2), 2.24 (6H, s, —N-(CH3)2), 2.31 (3H, s, >NCOCH3), 3.00 (2H, br, Indoline C3—H), 3.35 (2H, s, >NCH2—), 4.15 (2H, br, Indoline C2—H), 9.23 (1H, br, >NH).
  • (2) N-(1-Acetyl-5-dimethylaminomethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide (1.0 g) was dissolved in MeOH (10 ml) and a solution of NaOH (580 mg) in water (3 ml) was added, which was followed by stirring at 60° C. for 2 hr. MeOH was evaporated under reduced pressure and CHCl3 (100 ml) was added. The mixture was washed with saturated brine and dried over anhydrous sodium sulfate. CHCl3 was evaporated under reduced pressure to give 700 mg of N-(5-dimethylaminomethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide.
    1H-NMR (CDCl3) δ:
    1.30 (9H, s, —C(CH3)3), 2.19 (12H, s, —CH3×2, —N-(CH3)3), 3.00 (2H, t, J=8.5 Hz, Indoline C3—H), 3.28 (2H, s, >NCH2—), 3.55 (2H, t, J=8.5 Hz, Indoline C2—H), 4.40 (1H, br, >NH), 7.20 (1H, br, >NH).
  • (3) N-(5-Dimethylaminomethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide (700 mg) was dissolved in DMF (7 ml) and Na (P=6096, 160 mg) was added under a nitrogen atmosphere at 5° C. After stirring at the same temperature for 30 min, 1-iodooctane (240 mg) was added, which was followed by stirring at 30° C. for 3 hr. AcOEt (200 ml) was added, and the mixture was washed with water and dried over anhydrous sodium sulfate. AcOEt was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: CHCl3/MeOH=10/1-3/1) to give 500 mg of the title compound.
    IR (Nujol) cm−3: 1654, 1600
    1H-NMR (CDCl3) δ:
    0.70-1.10 (3H, br, —(CH2)7CH3), 1.10-1.70 (12H, m, —CH2(CH2)6CH3), 1.33 (9H, s, —(CH3)3), 2.00, 2.09 (6H, s×2, —CH3×2), 2.23 (6H, s, —N-(CH3)2), 2.85 (2H, t, J=8.5 Hz, Indoline C3—H), 3.18 (2H, br-t, >NCH2—), 3.31 (2H, s, —,CH2N<), 3.38 (2H, t, J=8.5 Hz, Indoline C2—H), 6.84 (1H, br, >NH).
EXAMPLE 3 N-(1-octyl-5-ethoxycarbonylmethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide
  • (1) 1-Acetyl-5-bromo-4,6-dimethyl-7-nitroindoline (30 g) was dissolved in a mixture (600 ml) of CHCl3/MeOH=1/1 and 5% Pd-C (5.0 g) was added, which was followed by catalytic hydrogenation at 35° C. The precipitate was collected by filtration together with Pd-C, and dissolved in CHCl3 (300 ml). The mixture was washed with saturated aqueous solution of sodium hydrogencarbonate. The solvent was evaporated under reduced pressure from the filtrate and CHCl3 (300 ml) was added. The mixture was washed with saturated aqueous solution of sodium hydrogencarbonate and combined with the layer of above-mentioned CHCl3. The combined CHCl3 layer was washed with saturated brine and dried over anhydrous sodium sulfate. CHCl3 was evaporated under reduced pressure and the residue was dissolved in CHCl3 (150 ml). Thereto were successively added at 10° C. pivaloyl chloride (11.7 g) and Et3N (10.8 g). The mixture was stirred at room temperature for 1 hr and CHCl3 (200 ml) was added. The mixture was washed successively with 5% aqueous citric acid and water, and dried over anhydrous sodium sulfate. CHCl3 was evaporated under reduced pressure and the obtained crude residue was washed with cool Et2O (100 ml) to give 21 g of N-(1-acetyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide.
    IR (Nujol)cm31 1; 1676, 1639, 1581.
    1H-NMR (CDCl3) δ:
    1.24 (9H, s, —C(CH3)3), 2.17 (6H, s, —CH3×2), 2.30 (3H, s, >NCOCH,), 2.99 (2H, t, J=8-5 Hz, Indoline C3—H) 4.10 (2H, t, J=-8.5 Hz, Indoline C2—H), 6.87 (1H, s, Indoline C3—H), 9.10 (1H, br, >NH).
  • (2) N-(1-Acetyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide (20.0 g) was dissolved in conc. hydrochloric acid (100 ml), and 35% formalin (8.5 g) and zinc chloride (1.8 g) were added. The mixture was stirred at 40-50° C. for 2 hr while blowing hydrogen chloride therein. The reaction mixture was poured into ice water and extracted with CHCl3 (400 ml). The CHCl3 layer was washed twice with saturated brine and dried over anhydrous sodium sulfate. CHCl3 was evaporated under reduced pressure to give 21 g of N-(1-acetyl-5-chloroethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide.
    IR (Nujol)cm−1: 1679, 1645, 1587.
    1H-NMR (CDCl3) δ:
    1.27 (9H, s, —C(CH3)3) 2.25 (3H, s, (3H, s —CH3), 2.30 (6H, s, —CH3, >NCOCH3), 3.00 (2H, br, Indoline C3—H), 4.05 (2H, br, Indoline C2—H), 4.68 (2H, s, —CH2Cl), 9.16 (1H, br, >NH).
  • (3) N-(1-Acetyl-5-chloromethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide (21 g) was suspended in CH3CN (150 ml), and NaCN (8.1 g) and 18-crown-6 (870 mg) were added, which was followed by refluxing for 15 hr. CH3CN was evaporated under reduced pressure and CHCl3 (300 ml) was added. The mixture was washed with water and dried over anhydrous sodium sulfate. CHCl3 was evaporated under reduced pressure. The obtained residue was washed with boiling MeOH to give 15.5 g of N-(1-acetyl-5-cyanomethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide.
    IR (Nujol)cm−1: 2232, 1678, 1639.
    1H-NMR (CDCl3) δ:
    1.27 (9H, s, —C(CH3)3), 2.26, 230, 2.40 (9H, s×3, CH3×2, >NCOCH3) 3.00 (2H, br, Indoline C3—H), 3.66 (2H, s, —CH2CN), 4.05 (2H, br, Indoline C2—H), 9.21 (1H, br, >NH).
  • (4) N-(1-Acetyl-5-cyanomethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide (5.0 g) was suspended in n-PrOH (25 ml) and a solution of NaOH(9.6 g) in water (10 ml) was added, which was followed by stirring at 90° C. for 8 hr in an autoclave under a nitrogen atmosphere. The aqueous layer was separated, and the organic layer was neutralized with 2N-hydrochloric acid. The solvent was evaporated under reduced pressure. The residue was suspended in EtOH (200 ml), and 10N HCl-EtOH (7.2 ml) was added, which was followed by refluxing for 1 hr. EtOH was evaporated under reduced pressure, and the mixture was neutralized with saturated aqueous solution of sodium hydrogencarbonate and extracted with AcOEt (200 ml). The AcOEt layer was washed with water and dried over anhydrous sodium sulfate. AcOEt was evaporated under reduced pressure and the residue was purified by silica gel column chromatography (eluent: CHCl3/MeOH=1/0-20/1) to give 3.0 g of N-(5-ethoxycarbonylmethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide.
    IR (Nujol)cm−3: 1732, 1654.
    1H-NMR (CDCl3) δ:
    1.34 (9H, s, —C(CH3)3) 2.14, 2.18 (6H, s×2, —CH3×2), 2.99 (2H, t, J=8.5 Hz, Indoline C3—H), 3.56 (2H, t, 1-8.5 Hz, Indoline C2—H), 3.60 (2H, s, —CH2CO2—), 4.11 (2H, q, J=7.8 Hz, —CH2CH3), 4,20 (1H, br, >NH), 7.00 (1H, br, >NH).
  • (5) N-(5-Ethoxycarbonylmethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide (3.5 g) was dissolved in DMF (15 ml), and 1-iodooctane (5.0 g) and K2CO3 (2.9 g) were added, which was followed by stirring under a nitrogen atmosphere at 50° C. for 2 hr. AcOEt (200 ml) was added, and the mixture was washed with water and dried over anhydrous sodium sulfate. AcOEt was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: CHCl3/MeOH=1/0-0/1) to give 3.5 g of the title compound.
    IR (Neat) cm−1: 1732, 1654, 1600.
    3H-NMR (CDCl3) δ:
    0.70-1.10 (3H, br, —(CH2)7CH3), 1.10-1.70 (15H, m, —CH2CH3. —CH2(CH2)6CH3), 133 (9H, s, —C(CH3)3), 2.04, 2.13 (6H, s×2; —-CH 3×2), 2.87 (2H, t, J=8.5 Hz, Indoline C3—H), 3.12 (2H, t, J=75 Hz, >NCH2—), 3.39 (2H, t, J=8.5 Hz, Indoline C2—H), 3.58 (2H, s, —CH2CO2—), 4.12 (2H, q, J=7.5 Hz, —CH2CH3), 6.79 (1H, br, >NH).
EXAMPLE 4 N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide
N-(1-octyl-5-ethoxycarboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide (3.5 g) was dissolved in EtOH (50 ml) and a solution of NaOH (1.6 g) in water (20 ml) was added, which was followed by stirring at 60° C. for 1 hr. EtOH was evaporated under reduced pressure. The residue was dissolved in water (20 ml) and the mixture was washed with AcOEt (20 ml). The aqueous layer was neutralized with 2N-hydrochloric acid and extracted with AcOEt (50 ml). The AcOEt layer was washed with saturated brine and dried over anhydrous sodium sulfate. AcOEt was evaporated under reduced pressure to give 2.4 g of the title compound.
IR (Nujol)cm−1: 1732, 1651, 1,600.
1H-NMR (CDCl3) δ:
0.70-1.10 (3H, br, —(CH2)7CH3), 1.10-1.70 (12H, m, —CH2(CH2)6CH3), 1.33 (9H, s, —C(CH3), 2.01, 2.15 (6H, s×2, —CH3×2), 2.70-3.20 (4H, m, Indoline C3—H, >NCH2—), 3.41 (2H, t, J=8.5 Hz, Indoline C2—H), 3.56 (2H, s, —CH2CO2H), 7.60 (hH, br, >NH), 7.90 (1H, br, —CO2H).
EXAMPLE 5 N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide.hydrochloride
N-(1-octyl-5-ethoxycarbonylmethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide (3.5 g) was dissolved in EtOH (50 ml) and a solution of NaOH (1.6 g) in water (20 ml) was added, which was followed by stirring at 60° C. for 1 hr. EtOH was evaporated under reduced pressure. The residue was dissolved in water (20 ml) and the mixture was washed with AcOEt (20 ml). The aqueous layer was adjusted to pH 1-2 with hydrochloric acid and extracted with AcOEt (50 ml). The AcOEt layer was washed with saturated brine and dried over anhydrous sodium sulfate. AcOEt was evaporated under reduced pressure to give 2.0 g of the title compound.
IR (Nujol)cm−1: 1722, 1654.
3H-NMR (CDCl3) δ:
0.70-1.10 (3H, br, —(CH2)7CH3), 1.10-1.70 (12H, m, —CH2(CH2)6CH3), 1.39 (9H, s, —C(CH3)3, 2.06, 2.26 (6H, s×2, —CH3×2), 2.90-3.30 (4H, m, Indoline C3—H, >NCH2—), 3.50-3.90 (2H, br-t, Indoline C3—H), 3.72 (2H, s, —CH2CO2H), 6.00-7.00 (1H, br, HCl), 9.05 (2H, br, >NH, —CO2H).
EXAMPLE 6 N-(1-octyl-5-carboxymethyl-4,6-dimclbylindolin-7-yl)-2,2-dimethylpropanamide.sulfate
N-(1-octyl-5-ethoxycarbonylmethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide (4.0 g) was dissolved in EtOH (57 ml) and a solution of NaOH (1.8 g) in water (23 ml) was added, which was followed by stirring at 60° C. for 1 hr. EtOH was evaporated under reduced pressure. The residue was dissolved in water (30 ml) and the mixture was washed with AcOEt (30 ml). The aqueous layer was adjusted to pH 1-2 with sulfuric acid and extracted with AcOEt (50 ml). The AcOEt layer was washed with saturated brine and dried over anhydrous sodium sulfate. AcOEt was evaporated under reduced pressure to give 2.5 g of the title compound.
IR (Nujol)cm−1: 1718, 1654, 1637.
3H-NMR (CDCl3) δ:
0.70-1.10 (3H, br, —(CH2)7CH3), 1.10-1.70 (12H, m, —CH2(CH2)6CH3), 1.33 (9H, s, —C(CH3)3), 2.02, 2.16 (6H, s×2, —CH3×2), 2.80-3.30 (4H, m, Indoline C3—H, >NCH2—), 3.30-3.70 (2H, br-t, Indoline C2—H), 3.59 (2H, s, CH2CO2H), 6.00-7.00 (2H, br, H2SO4), 7.20 (1H, br, —CO2H), 8.30 (1H, br, >NH.
EXAMPLE 7 N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide.nitrate
N-(1-octyl-5-ethoxycarbonylmethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide (3.0 g) was dissolved in EtOH (42 ml) and a solution of NaOH (1.4 g) in water (17 ml) was added, which was followed by stirring at 60° C. for 1 hr. EtOH was evaporated under reduced pressure. The residue was dissolved in water (20 ml) and the mixture was washed with AcOEt (20 ml). The aqueous layer was adjusted to pH 1-2 with nitric acid and extracted with AcOEt (50 ml). The AcOEt layer was washed with saturated brine and dried over anhydrous sodium sulfate. AcOEt was evaporated under reduced pressure to give 2.0 g of the title compound.
IR (Nujol)cm−1: 1724, 1654
3H-NMR (CDCl3) δ:
0.70-1.10 (3H, br, —(CH2),CH3), 1.10-1.70 (12H, m, —CH2(CH2) 6CH3), 1.33 (9H, s, —(CH3)3). 2.02, 2.21 (6H, s×2, CH3×2), 2.80-3.30 (4H, m, Indoline C3—H, >NCH2—), 3.50-3.80 (2H, br-t, Indoline C2—H), 3.64 (2H, s, CH2CO2H), 6.00-7.00 (1H, br, HNO3), 9.03 (2H, br, >NH, —CO2H).
EXAMPLE 8 N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide.sodium Salt
N-(1-Octyl-5-ethoxycarbonylmethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide (3.5 g) was dissolved in EtOH (50 ml) and a solution of NaOH (1.6 g) in water (20 ml) was added, which was followed by stirring at 60° C. for 1 hr. EtOH was evaporated under reduced pressure. The residue was dissolved in water (20 ml) and the mixture was adsorbed onto DIAION® HP-21 (70 ml). After washing with water, the mixture was elided with 50% aqueous methanol. The objective fraction was concentrated under reduced pressure. The residue was freeze-dried to give 1.0 g of the title-compound.
IR (Nujol)cm−1: 1630, 1605.
1H-NMR (CDCl3) δ:
0.70-1.10 (3H, br, —(CH2)7(CH3), 1.10-1.70 (12H, m, —CH2(CH2)6CH3), 1.38 (9H, s, —C(CH3)3), 1.93, 2.08 (6H, s×2, —CH3×2), 2.70-3.20 (4H, m, Indoline C3—H, >NCH2 ), 3.30-3.40 (2H, br-t, Indoline C2-H), 3.15 (2H, s, —CH2CO2Na), 8.54 (1H, br, >NH).
EXAMPLE 9 N-[(1-octyl-3-(2-hydroxyethyl)-4,6-dimethylindolin-7-yl)]-2,2-dimethylpropanamide
  • (1) 4,6-Dimethylindole (130 g) was dissolved in Et2O (130 ml), and oxalyl chloride (23.0 g) was dropwise added at 0° C. The mixture was stirred at room temperature for 5 hr, and Et2O was evaporated under reduced pressure. EtOH (200 ml) was added to the residue and the mixture was stirred at room temperature for 15 hr. EtOH was evaporated under reduced pressure. The residue was dissolved in CHCl3 (200 ml). After washing with water, the mixture was dried over anhydrous sodium sulfate. CHCl3 was evaporated under reduced pressure. The obtained residue was added to a suspension of LiAIH4 (17.0 g) in Et2O (200 ml), which was hollowed by refluxing for 2 hr. The reaction mixture eras poured into ice water and extracted with AcOEt (200 ml). The AcOEt layer was washed with water and dried over anhydrous sodium sulfate. AcOEt was evaporated under reduced pressure. The residue was purified try silica gel column chromatography, (eluent: CHCl3/MeOH=50/1-10/1) to give 13.0 g of 3-(2-hydroxyethyl)-4,6-dimethylindole.
    IR (Nujol)cm−1: 1456, 1377.
    1H-NMR (CDCl3) δ:
    239, 2.63 (6H, s×2, —CH3×2), 3.13 (2H, J=7.0 Hz, —CH2CH2OH), 3.86 (2H, t, J=7.0 Hz, —CH2CH2OH), 6.69 (1H, s, Indole C3—H), 6.91 (2H, m, Indole C2—H, C7—H), 6.92 (1H, br, —OH), 7.90 (1H, hr, >NH).
  • (2) 3-(2-Hydroxyethyl)-4,6-dimethylindole (13.0 g) was dissolved in AcOH (100 ml) and NaBH3CN (8.7 g) was added by portions under ice cooling. After stirring at the same temperature for 1 hr, the reaction mixture was poured into ice water and neutralized with aqueous NaOH. The mixture was extracted with CHCl3 (200 ml). The CHCl3 layer was washed with water and dried over anhydrous sodium sulfate. CHCl3 was evaporated under reduced pressure. The residue was dissolved in benzene (100 ml), and Ac2O (15 g) and Et3N (8.3 g) were added, which was followed by stirring at room temperature for 1 hr. AcOEt (200 ml) was added and the mixture was washed successively with saturated aqueous solution of sodium hydrogencarbonate, 5% aqueous citric acid and saturated brine, and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: CHCl3/MeOH=50/1-10/1) to give 13.0 g of 1-acetyl-3-(2-acetoxyethyl)-4,6-dimethylindoline.
    IR (Nujol)cm−1: 1652, 1460.
    1H-NMR (CDCl3) δ:
    1.60-2.20 (2H, m, —CH2CH2O—), 2.04 (3H, s, —OCOCH3), 2.24 (3H, s, >NCOCH3), 2.24, 2.30 (6H, s×2, —CH3×2), 3.34 (1H, m, Indoline C3—H), 3.94 (2H, m, Indoline C2—H), 4.12 (2H, t, J=7.1 Hz, —CH2CH2O—), 6.67 (1H, s, Indoline C3—H), 7.90 (1H, s, Indoline C7—H).
  • (3) 1-Acetyl-3-(2-acetoxyethyl)-4,6-dimethylindoline (2.0 g) was dissolved in AcOH (40 ml) and Br2 (1.9 g) was added, which was followed by stirring at room temperature for 30 min. The reaction mixture was poured into ice water and precipitate was collected by filtration. The precipitate was dissolved in CHCl3, and the mixture was washed with water and dried over anhydrous sodium sulfate. CHCl3 was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: CHCl3/MeOH=50/1-10/1) to give 2.7 g of crude crystals of 1-acetyl-3-(2-acetoxyethyl)-5-bromo-4,6-dimethylindoline. The crude crystals were added by portions to a mixture of nitric acid (0.47 ml), AcOH (10 ml) and conc. hydrochloric acid (10 ml) under ice-cooling, and the mixture was stirred at the same temperature for 4 hr. The reaction mixture was poured into ice water and precipitate was collected by filtration. The precipitate was dissolved in CHCl3 After washing with water, the mixture was dried over anhydrous sodium sulfate and CHCl3 was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: CHCl3/MeOH=50/1-10/1) to give 1.4 g of 1-acetyl-3-(2-acetoxyethyl)-5-bromo-4,6-dimethyl-7-nitroindoline.
    1H-NMR (DMSO-d6) δ:
    1.60-2.20 (2H, m, —CH2CH2O—), 1.99 (3H, s, —OCOCH3), 2.21 (3H, s, >NCOCH3), 2.38 (6H, s, —CH3×2), 3.40 (1H, m, Indoline C3—H), 4.11 (2H, t, J=7.0 Hz, —CH2CH2O—), 4.14 (2H, d,1-8.5 Hz, indoline C2—H).
  • (4) 1-Acetyl-3-(2-acetoxyethyl)-5-bromo-4,6-dimethyl-7-nitroindoline (1.4 g) was dissolved in benzene (20 ml) and 5% Pd-C (500 mg) was added, which was followed by catalytic hydrogenation at room temperature under atmospheric pressure. Pd-C was filtered off and benzene was evaporated under reduced pressure. The residue was dissolved in CHCl3 (50 ml) and the mixture was washed successively with saturated aqueous solution of sodium hydrogencarbonate and saturated brine, and dried over anhydrous sodium sulfate. Pivaloyl chloride (440 mg) and Et3N (448 mg) were added to the obtained solution and the mixture was stirred at room temperature for 30 min. The mixture was washed successively with 5% aqueous citric acid and saturated brine, and dried over anhydrous sodium sulfate. CHCl3 was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: CHCl3/MeOH=50/1-10/1) to give 1.0 g of N-[1-acetyl-3-(2-acetoxyethyl)-4,6-dimethylindolin-7-yl]-2,2-dimethylpropanamide.
    IR (Nujol)cm−1: 1730, 1649.
    1H-NMR (CDCl3) δ:
    1.27 (9H, s, —C(CH3)3), 1.60-2.20 (2H, m, —CH2CH2O—), 2.06 (3H, s, —OCOCH,), 2.17, 2.22 (6H, s, —CH3×2), 2.30 (3H, s, >NCOCH,), 3.10 (1H, m, Indoline C3—H), 4.03 (2H, d, J=8.5 Hz, Indoline C2—H), 4.14 (1H, t, J=7.0 Hz, —CH2CH2O—), 6.88 (1H, s, Indoline C3—H), 9.00 (1H, br, >NH)
  • (5) N-[1-Acetyl-3-(2-acetoxyethyl)-4,6-dimethylindolin-7-yl]-2,2-dimethylpropanamide (4.0 g) was dissolved in ROM (40 ml) and a solution of NaOH (22 g) in water (10 ml) was added, which was followed by stirring at 60° C. for 10 hr. EtOH was evaporated under reduced pressure, and CHCl3 (100 ml) was added. After washing with water, the mixture was dried over anhydrous sodium sulfate, and CHCl3 was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: CHCl3/MeOH=50/1-10/1) to give 1.6 g of N-[3-(2-hydroxyethyl)-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide.
    1H-NMR (CDCl3) δ:
    1.34 (9H, s, —C(CHCl3)3), 1.60-2.20 (2H, m, —CH2CH2OH), 2.17, 2.19 (6H, s×2, —CH3×2), 3.20-3.80 (7H, m, Indoline C2—H, C3—H, >NH, —CH2CH2OH), 6.45 (1H, s, Indoline C3—H), 7.20 (1H, br, —CONH—).
  • (6) N-[3-(2-Hydroxyethyl)-4,6-dimethylindolin-7-yl]-2,2-dimethylpropanamide (1.6 g) was dissolved in DMF (15 ml) and 1-iodooctane (3.9 g) and K2CO3 (2.3 g) were added, which was followed by stirring at 70° C. for 10 hr. AcOEt (200 ml) was added, and the mixture was washed with water and dried over anhydrous sodium sulfate. AcOEt was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: benzene/AcOEt=5/11-1/2) to give 300 mg of the title compound.
    IR (Nujol)cm−: 1645, 1600.
    1H-NMR (CDCl3) δ:
    0.70-1.00 (3H, br-t, —CH2),CH3), 1.33 (9H, s, —(CH3)3), 1.00-2.00 (14H, m, —CCH2)6CH3, —CH2CH2OH), 2.07, 2.16 (6H, s×2, —CH3×2), 2.60-3.60 (8H, m, Indoline C2—H, C3—H, >NCH2—, —CH2OH), 6.44 (1H, s, Indoline C5—H), 6.78 (1H, br, —CONH—).
EXAMPLE 10 N-[(1-octyl-3-(2-methioxycarbonylethyl)-4,6-dimethylindolin-7-yl)]-2,2-dimethylpropanamide
  • (1) 1-Acetyl-3(2-acetoxyethyl-4,6-dimethylindoline (2.0 g) was dissolved in a mixture of CHCl3/MeOH=1/1 (25 ml), and a solution of NaOH (1.5 g) in water (5 ml) was added, which was followed by stirring at room temperature for 1 hr. The solvent was evaporated under reduced pressure. CHCl3 (100 ml) was added, and the mixture was washed with water and dried over anhydrous sodium sulfate. CHCl3 was evaporated under reduced pressure. The residue was purified try silica get column chromatography (eluent: CHCl3/MeOH=50/1-10/1) to give 1.2 g of 1-acetyl-3-(2-hydroxyethyl)-4,6-dimethylindoline.
    1H-NMR (CDCl3) δ:
    1.60-2.00 (3H, m, —CH2CH2OH), 2.26, 2.30, 2.39 (9H, s×3, —CH3×2, >NCOCH3), 3.50 (1H, m, Indoline C3—H), 3.77 (2H, t, J=7.0 Hz, —CH2CH20H), 3.97 (2H, m, Indoline C2—H), 6.67 (1H, s, Indoline; C5—H), 7.89 (1H, s, Indoline C7—H).
  • (2) 1-Acetyl-3-(2-hydroxyethyl)-4,6-dimethylindoline (7.0 g) and CBr4 (9.9 g) were dissolved in CH2CN (70 ml), and Ph3P (9.4 g) was added, which was followed by stirring at room temperature for 30 min. CH3CN was evaporated under reduced pressure. AcOEt (100 ml) was added, and the mixture war washed with water and dried over anhydrous sodium sulfate. AcOEt was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: benzene/AcOEt=50/1-10/1) to give 5.4 g of 1-acetyl-3(2-bromoethyl)-4,6-dimethylindoline.
    IR (Nujol)cm −1: 1650, 1460.
    1H-NMR (CDR) δ:
    1.84-2.20 (2H, m, —CH2CH2Br), 2.23, 226, 2.30 (9H, s×3, —CH3×2, >NCOCH3), 3.42 (2H, t, 1-7.0 Hz, —CH2CH2Br), 3.20-3.60 (1H, m, Indoline C3—H), 4.00 (2H, m, Indoline C2—H), 6.68 (1H, s, Indoline C3—H), 7.89 (1H, s, Indoline C7—H).
  • (3) 1-Acetyl-3-(2-bromoethyl)-4,6-dimethylindoline (5.4 g), NaCN (3.7 g) and 18-crown-6 (480 mg) were suspended in CH3CN (50 ml), and the suspension was refluxed for 15 hr. CH3CN was evaporated under reduced pressure. CHCl3 (100 ml) was added, and the mixture was washed with water and dried over anhydrous sodium sulfate. CHCl3 was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: CHCl3(MeOH=50/1-10/1) to give 4.5 g of 1-acetyl-3-(2-cyanoethyl)-4,6-dimethylindoline.
    IR (Nujol)cm−1: 2364, 1647.
    1H-NMR (CDCl3) δ:
    1.70-2.20 (2H, m, —CH2CH2CN), 2.26, 2.31 (9H, s×3, —CH32, >NCOCH3), 2.20-2.40 (2H, m, —CH2CH2CN), 3.44 (1H, m, Indoline C3—H), 3.70-4.20 (2H, m, Indoline C2—H), 6.69 (1H, s, Indoline Cs H), 7.90 (1H, s, Indoline C7—H).
  • (4) 1-Acetyl-3-(2-cyanoethyl)-4,6-dimethylindoline (4.5 g) was dissolved in EtOH (150 ml), and a solution of KOH (10.4 g) in water (50 ml) was added, which was followed by refluxing for 15 hr. E[OH was evaporated under reduced pressure, and the aqueous layer was adjusted to weak acidic with 6N hydrochloric acid and extracted with CHCl3 (100 ml). The CHCl3 layer was washed with water and dried over anhydrous sodium sulfate. CHCl3 was evaporated under reduced pressure. The residue was dissolved in CHCl3 (20 ml) and Ac2O (1.9 g) was added, which was followed by stirring at room temperature for 1 hr. CHCl3 (100 ml) was added, and the mixture was washed with water and dried over anhydrous sodium sulfite. CHCl3 was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: CHCl3(MeOH=50/1-10/1) to give 3.4 g of 1-acetyl-3-(2-carboxyethyl)-4,6-dimethylindoline.
    1H-NMR (CDCl3) δ:
    1.60-2.20 (2H, m, —CH2CH2CO2H), 2.26, 2.31 (9H, s×3, —CH32, >NCOCH3), 2.20-2.40 (2H, m, —CH2CH2CO2H), 3.37 (1H, m, Indoline C3—H), 3.80-4.10 (2H, m, Indoline C2—H), 6.68 (1H, s, Indoline C3—H), 7.50 (1H, br, —CO2H), 7.78 (1H, Indoline C7—H).
  • (5) 1-Acetyl-3-(2-carboxyethyl)-4,6-dimethylindoline (3.4 g) was dissolved in EtOH (50 ml) and 10N HCl-EtOH (3.9 ml) was added, which was followed by refluxing for 30 min. ETOH was evaporated under reduced pressure and AcOEt (100 ml) was added. After washing with water, the mixture was dried over anhydrous sodium sulfate. AcOEt was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: CHCl3/MeOH=50/1-10/1) to give 3.3 g of 1-acetyl-3-(2-ethoxycarbonylethyl)-4,6-dimethylindoline.
    1H-NMR (CDCl3) δ:
    1.24 (3H, t, J=7.1 Hz, —CH2CH,), 1.60-2.20 (2H, m, —CH2CH2CO2—), 2.22, 2.27, 2.30 (9H, s×3, —CH3×2, >NCOCH3), 2.00, 2.20 (2H, m, —CH2CH2CO2—), 3.10-3.30 (1H, m, Indoline C3—H), 3.90 (2H, m, Indoline C2—H), 4.10 (2H, q, J=7.1 Hz, —CH2CH3), 6.76 (1H, s, Indoline C3—H), 7.90 (1H, s, Indoline C2—H).
  • (6) 1-Acetyl-3-(2-ethoxycarbonylethyl)-4,6-dimethylindoline (3.3 g) was dissolved in AcOH (30 ml) and Br2 (0.93 ml) was added, which was followed by stirring for 30 min. The reaction mixture was poured into ice water and precipitated aside crystals were collected by filtration. The obtained crystals were dissolved in CHCl3 (100 ml). After washing wilt water, the mixture was dried over anhydrous sodium sulfate. CHCl3 was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: CHCl3/MeOH=50/1-10/1) to give 3.0 g of 1-acetyl-5-bromo-3-(2-ethoxycarbonylethyl)-4,6-dimethylindoline.
    IR (Nujol)cm−1: 1729, 1641.
    1H-NMR (CDCl3) δ:
    1.24 (3H, t, J=7.1 Hz, —CH2CH3), 1.60-2.20 (2H, m, —CH2CH2CO2—), 2.00-2.20 (2H, m, —CH2CH2CO2—), 2.21 (3H, s, >NCOCH3), 2 .36, 2.39 (6H, s×2, —CH3×2), 3.10-3.60 (1H, m, Indoline C3—H), 3.90 (2H, m, Indoline C2—H), 4.10 (2H, q, J=7.1 Hz, —CH2CH3), 8.08 (1H, s, Indoline C7—H).
  • (7) To a mixture of AcOH (10 ml), conc. sulfuric acid (10 ml) and nitric acid (0.55 ml) was added by portions 1-acetyl-5-bromo-3-(2-ethoxycarbonylethyl)-4,6-dimethylindoline (3.0 g) at 0° C., and the mixture was stirred at the same temperature for 5 hr. The reaction mixture was poured into ice water and extracted with CHCl3 (100 ml). After washing with water, the mixture was dried over anhydrous sodium sulfate. CHCl3 was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: CHCl3/MeOH=50/1-10/1) to give 2.7 g of 1-acetyl-5-bromo-3-(2-ethoxycarbonylethyl)-4,6-dimethyl-7-nitroindoline.
    1H-NMR (CDCl3) δ:
    1.26 (3H, t, J=7.1 Hz, —CH2CH3), 1.60-2.20 (2H, m, —CH2CH2CO2—), 2.00-2.20 (2H, m, —CH2CH2CO2—), 2.23 (3H, s, >NCOCH3), 2.44-2.47 (6H, s×2, —CH3×2), 3.10-3.60 (1H, m, Indoline C2—H), 4.00 (2H, m, Indoline C2—H), 4.10 (2H, q, J=7.1 Hz, —CH2CH3).
  • (8) 1-Acetyl-5-bromo-3-(2-ethoxycarbonylethyl)-4,6-dimethyl-7-nitroindoline (2.7 g) was dissolved in benzene (100 ml), and 5% Pd-C (500 mg) was added, which was followed by catalytic hydrogenation at room temperature under atmospheric pressure. PdC was filtered off and benzene was evaporated under reduced pressure. CHCl3 (100 ml) was added to the residue, and the mixture was washed successively with saturated aqueous solution of sodium hydrogencarbonate tend saturated brine and dried over anhydrous sodium sulfate. CHCl3 was evaporated under reduced pressure. The residue was dissolved in CHCl3 (20 ml) and pivaloyl chloride (790 mg) and Et3N (80 mg) were added, which was followed by stirring at room temperature for 30 min. CHCl3 (100 ml) was added, and the mixture was washed successively with 5% aqueous citric acid and saturated brine and dried over anhydrous sodium sulfate. CHCl3 was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: CHCl3/MeOH=50/1-10/1) to give 2.6 g of N-[1-acetyl-3-(2-ethoxycarbonylethyl)-4,6-dimethylindolin-7-yl]-2,2-dimethylpropanamide.
    1H-NMR (CDCl3) δ:
    1.25 (9H, s, —C(CH3)3), 1.26(3H, t, J=7.1 Hz, —CH2CH3), 1.60-2.20 (2H, m, —CH2CH2CO2—), 2.00-2.20 (2H, m, CH2CH2CO2—), 2.17, 2.20, 2.27 (9H, s×3, —CH3×2, >NCOCH3), 3.00-3.20 (1H, m, Indoline C3—H), 3.90 (2H, m, Indoline C2—H), 4.10 (2H, q, J=7.1 Hz, —CH2CH3), 6.88 (1H, s, Indoline C3—H), 9.00 (1H, br, —CONH—).
  • (9) N-[1-Acetyl-3-(2-ethoxycarbonylethyl)-4,6-dimethylindolin-7-yl]-2,2-dimethylpropanamide (2.6 g) was dissolved in EtOH (40 ml), and a solution of KOH (13 g) in water (10 ml) was added, which was followed by refluxing for 20 hr. EtOH was evaporated under reduced pressure, and the mixture was adjusted to pH 5 with 2N hydrochloric acid and extracted with CHCl3 (100 ml). The CHCl3 layer was washed with water and dried over anhydrous sodium sulfate. CHCl3 was evaporated under reduced pressure to give 1.5 g of N-(3-(2-carboxyethyl)-4,6-dimethylindolin-7-yl]-2,2-dimethylpropanamide.
    1H-NMR (CDCl3) δ:
    1.33 (9H, s, —C(CH3)3), 1.60-2.20 (2H, m, —CH2CH2CO2H), 2.14, 2.26 (6H, s×3, —CH3×2), 2.20-2.40 (2H, m, —CH2CH2CO2H), 3.10-3.80 (3H, m, Indoline C2—H, C3—H), 6.44 (1H, s, Indoline C5—H), 6.74 (2H, br, —CO2H, >NH).
  • (10) N-(3-(2-Carboxyethyl)-4,6-dimethylindolin-7-yl]-2,2-dimethylpropanamide (1.5 g) was dissolved in AcOEt (10 ml) and a solution of CH2N2 in ether was added. AcOEt (100 ml) was added, and after washing with water, the mixture was dried over anhydrous sodium sulfate. AcOEt was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: CHCl3/MeOH=50/1-10/1) to give 1.0 g of N-[3-(2-methoxycarbonylethyl)-4,6-dimethylindolin-7-yl]-2,2-dimethylpropanamide.
    1H-NMR (CDCl3) δ:
    1.34 (9H, s, —C(CH3)3), 1.60-2.20 (2H, m, —CH2CH2CO2—), 2.15, 2.23 (6H, s×2, —CH3×2), 2.20-2.40 (2H, m, —CH2CH2CO2CH3), 3.10-3.80 (3H, m, Indoline C2—H, C3—H), 3.64 (2H, s, —COdCH3), 6.40 (1H, s, Indoline C5—H), 7.05 (1H, br, >NH).
  • (11) N-[3-(2-Methoxycarbonylethyl)-4,6-dimethylindolin-7-yl]-2,2-dimethylpropanamide (1.0 g) was dissolved in DMF (10 ml) and 1-iodooctane (1.44 g) and K2CO3 (830 mg) were added, which was followed by stirring at 40° C. for 10 hr. AcOEt (100 ml) was added, and after washing with water, the mixture was dried over anhydrous sodium sulfate. AcOEt was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: benzene/AcOEt=20/1-5/1) to give 1.1 g of the title compound.
    IR (Nujol) cm−1: 1730,1620.
    1H-NMR (CDCl3) δ:
    0.70-1.00 (3H, br-t, —(CH2)6CH3), 1.32 (9H, s, —C(CH3)3), 1.00-1.60 (12H, m, —(CH2)6CH3), 1.60-2.20 (2H, m, —CH2CH2CO2—), 2.05, 2.18 (6H, s×2, —CH3×2), 2.20-2.40 (2H, m, —CH2CH2CO2CH3), 3.10-3.80 (5H, m, Indoline C2—H, C3—H, >NCH2), 3.64 (3H, s, —CO2CH3), 6.38 (1H, s, Indoline C3—H), 6.70 (1H, br, —CONH—).
EXAMPLE 11 N-[(1-octyl-3-(2-carboxyethyl)-4,6-dimethylindolin-7-yl)]-2,2-dimethylpropanamide
N-[(1-octyl-3-(2-methoxycarbonylethyl)-4,6-dimethylindolin-7-yl)]-2,2-dimethylpropanamide (1.1 g) was dissolved in EtOH (10 ml) and a solution of NaOH (494 mg) in water (3 ml) was added, which was followed by stirring at roam temperature for 30 min. EtOH was evaporated under reduced pressure and CHCl3 (50 ml) was added. After washing successively with 5% aqueous citric acid and saturated brine, the mixture was dried over anhydrous sodium sulfate. CHCl3 was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: CHCl3/MeOH=50/1-10/1) to give 800 mg of the title compound.
IR (Nujol) cm−1: 1700, 1680.
1H-NMR (CDCl3) δ:
0.70-1.00 (3H, br-t, —(CH2)7CH4), 1.38 (9H, s, —C(CH3)3), 1.00-1.60 (12H, m, —(CH2)6CH3), 1.60-2.20 (2H, m, —CH2CH2CO2H), 2.07, 2.16 (6H, s×2, —CH3×2), 2.20-2.40 (2H, m, CH2CH2CO2H), 3.10-3.80 (3H, m, Indoline C2—H, C3—H), 3.27 (2H, br-t, >NCH2—), 6.45 (1H, s, Indoline C3—H), 7.20 (1H, br, —CONH—), 7.60 (1H, br, —CO2H).
EXAMPLE 12 N-(1-octyl-5-carboxymethyl-4,6-dimethylindol-7-yl)-2,2-dimethylpropanamide
  • (1) N-(5-ethoxycarbonylmethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide (1.0 g) was dissolved in xylene (75 ml), and 10% Pd-C,(250 mg) was added, which was followed by refluxing for 1 hr. Pd-C was filtered off and xylene was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: benzene-CHCl3) to give 0.9 g of N-(5-ethoxycarbonylmethyl-4,6-dimethylindol-7-yl)-2,2-dimethylpropanamide.
    IR (Nujol) cm−1: 1732, 1629.
    1H-NMR (CDCl3) δ:
    1.23 (3H, t, J=7.0 Hz, —CH2CH3), 1.40 (9H, s, —C(CH3)3), 2.32 (3H, s, —CH2), 2.52 (3H, s, 3.80 (2H, m, —CH2CO2—), 4.13 (2H, q, J=7.0 HZ, —CH2CH3), 6,50 (1H, t, J=2.0 Hz, Indole C3—H), 7.11 (1H, t, J=2.0 Hz, Indole C2—H), 7.35 (1H, br, —CONH—), 8.88 (1H, hr, >NH).
  • (2) N-(5-Ethoxycarbonylmethyl-4,6-dimethylindol-7-yl)-2,2-dimethylpropanamide (1.45 g) was dissolved in DMF (10 ml) and NaH (P-60%, 132 mg) was added under a nitrogen atmosphere, which was followed by stirring at room temperature for 1 hr. Then, 1-iodooctane (1.06 g) was added and the mixture was stirred at the same temperature for 2 hr. The reaction mixture was poured into ice water. The mixture was extracted with AcOEt (100 ml), washed with water and dried over anhydrous sodium sulfate. AcOEt was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: benzene/AcOEt-1/0-1/1) to give 1.02 g of N-(1-octyl-5-ethoxycarbonylmethyl-4,6-dimethylindol-7-yl)-2,2-dimethylpropanamide.
    IR (Nujol) cm−1: 1735, 1651.
    1H-NMR (CDCl3) δ:
    0.70-1.10 (3H, br-t, —(CH2)7CH3), 1.10-1.70 (15H, m, —CH2CH3, —(CH2)6CH3), 1.38 (9H, s, —C(CH3)3), 2.21 (3H, s, —CH3), 2.47 (3H, s, —CH3), 3.79 (2H, m, —CH2CH2—) 3.90-4.30 (4H, m, —CH2CH3 , >NCH 2—), 6.42 (1H, t, J=3.5 Hz, Indole C3—H), 6.91 (1H, t, J=3.5 Hz, Indole C2—H), 7.12 (1H, hr, —CONH—).
  • (3) N-(1-octyl-5-ethoxycarbonylmethyl-4,6-dimethylindol-7-yl)-2,2-dimethylpropanamide (3.5 g) was dissolved in EtOH (50 ml), and a solution of NaOH (1.6 g) in water (20 ml) was added, which was followed by stirring at 60° C. for 1 hr. EtOH was evaporated under reduced pressure, and the residue was dissolved in water (20 ml), and washed with AcOEt (10 ml). The aqueous layer was neutralized with 2N HCl and extracted with AcOEt (50 ml). The AcOEt layer was washed successively with saturated brine and dried over anhydrous sodium sulfate. AcOEt was evaporated under reduced pressure to give 2.0 g of the title compound.
    IR (Nujol) cm−1: 1705, 1647.
    1H-NMR (CDCL2) δ:
    0.70-1.10 (3H, hr, —(CH2)7CH3), 1.10-1.70 (12H, m, —CH2(CH2)6CH3), 1.33 (9H, s, —C(CH3)3), 2.10 (3H, s, —CH3), 2.39 (3H, s, —CH3), 3.65 (1H, br, —CO2H), 4.07 (2H, br-t, >NCH2—), 4.15 (2H, s, —CH2CO2—), 6.38 (1H, t, J=3.5 Hz, Indole C3—H), 6.89 (1H, t, J=3.5 Hz, Indole C2—H), 7.25 (11H, hr, —CONH).
EXAMPLES 13-119
According to the method as described in any of the above-mentioned Examples 1-12, the compounds of Tables 1-9 were obtained.
TABLE 1
Figure USRE038970-20060207-C00014
Example R1 R2 R3 R7 R6
13 —CH3 —CH2CO2H —CH3 —C(CH3)3 —(CH2)4CH3
14 —CH3 —CH2CO2H —CH3 —C(CH3)3
Figure USRE038970-20060207-C00015
15 —CH3 —CH2CO2H —CH3 —C(CH3)3 —(CH2)2CH(CH3)2
16 —CH3 —CH2CO2H —CH3 —C(CH3)3 —CH2CH—C(CH3)2
17 —CH3 —CH2CO2H —CH3 —C(CH3)3 —(CH2)2OCH2CH3
18 —CH3 —CH2CO2H —CH3 —C(CH3)3 —(CH2)5CH3
19 —CH3 —CH2CO2H —CH3 —C(CH3)3
Figure USRE038970-20060207-C00016
20 —CH3 —CH2CO2H —CH3 —C(CH3)3
Figure USRE038970-20060207-C00017
21 —CH3 —CH2CO2H —CH3 —C(CH3)3 —(CH2)3CH(CH3)2
22 —CH3 —CH2CO2H —CH3 —C(CH3)3 —CH2CH(CH2CH3)2
23 —CH3 —CH2CO2H —CH3 —C(CH3)3 —(CH2)2O(CH2)7CH3
24 —CH3 —CH2CO2H —CH3 —C(CH3)3 —(CH2)6CH3
25 —CH3 —CH2CO2H —CH3 —C(CH3)3
Figure USRE038970-20060207-C00018
26 —CH3 —CH2CO2H —CH3 —C(CH3)3 —(CH2)4CH(CH3)2
TABLE 2
Figure USRE038970-20060207-C00019
Example R1 R2 R3 R7 R6
27 —CH3 —CH2CO2H —CH3 —C(CH3)3 —(CH2)2CH(CH2CH3)2
28 —CH3 —CH2CO2H —CH3 —C(CH3)3 —(CH2)2O(CH2)3CH3
29 —CH3 —CH2CO2H —CH3 —C(CH3)3
Figure USRE038970-20060207-C00020
30 —CH3 —CH2CO2H —CH3 —C(CH3)3 —(CH2)5CH(CH3)2
31 —CH3 —CH2CO2H —CH3 —C(CH3)3 —(CH2)5CH(CH2CH3)2
32 —CH3 —CH2CO2H —CH3 —C(CH3)3 —(CH2)2O(CH2)4CH 3
33 —CH3 —CH2CO2H —CH3 —C(CH3)3 —(CH2)8CH3
34 —CH3 —CH2CO2H —CH3 —C(CH3)3 —(CH2)6CH(CH3)2
35 —CH3 —CH2CO2H —CH3 —C(CH3)3 —(CH2)4CH(CH2CH3)2
36 —CH3 —CH2CO2H —CH3 —C(CH3)3 —(CH2)8CH2
37 —CH3 —CH2CO2H —CH3 —C(CH3)3 —(CH2)7CH(CH3)2
38 —CH3 —CH2CO2H —CH3 —C(CH3)3 —(CH2)20CH3
39 —CH3 —CH2CO2H —CH3 —C(CH3)3 —(CH2)8CH(CH3)2
40 —CH3 —CH2CO2H —CH3 —C(CH3)3 —(CH2)11CH3
41 —CH3 —CH2CO2H —CH3 —C(CH3)3 —(CH2)9CH(CH3)2
TABLE 3
Figure USRE038970-20060207-C00021
Example R1 R2 R3 R7 R6
42 —CH3 —CH2CO2H —CH3 —C(CH3)2C4H9 —(CH2)5CH3
43 —CH3 —CH2CO2H —CH3 —C(CH3)2C4H9 —(CH2)6CH3
44 —CH3 —CH2CO2H —CH3 —C(CH3)2C4H9 —(CH2)7CH3
45 —CH3 —CH2CO2H —CH3 —C(CH3)2C6H13 —(CH2)5CH3
46 —CH3 —CH2CO2H —CH3 —C(CH3)2C6H13 —(CH2)6CH3
47 —CH3 —CH2CO2H —CH3 —C(CH3)2C6H13 —(CH2)7CH3
48 —CH3 —CH2CO2H —CH3 —C(CH3)2C8H17 —(CH2)5CH3
49 —CH3 —CH2CO2H —CH3 —C(CH3)2C8H17 —(CH2)6CH3
50 —CH3 —CH2CO2H —CH3 —C(CH3)2C8H17 —(CH2)7CH3
51 —CH2CH3 —CH2CO2H —CH2CH3 —C(CH3)3 —(CH2)5CH3
52 —CH2CH3 —CH2CO2H —CH2CH3 —C(CH3)3 —(CH2)6CH3
53 —CH2CH3 —CH2CO2H —CH2CH3 —C(CH3)3 —(CH2)7CH3
54 —CH2CH3 —CH2CO2H —CH2CH3 —C(CH3)3 —(CH2)8CH3
55 —CH2CH3 —CH2CO2H —CH2CH3 —C(CH3)3 —(CH2)9CH3
56 —OCH3 —CH2CO2H —OCH3 —C(CH3)3 —(CH2)5CH3
57 —OCH3 —CH2CO2H —OCH3 —C(CH3)3 —(CH2)6CH3
58 —OCH3 —CH2CO2H —OCH3 —C(CH3)3 —(CH2)7CH3
59 —OCH3 —CH2CO2H —OCH3 —C(CH3)3 —(CH2)8CH3
60 —OCH3 —CH2CO2H —OCH3 —C(CH3)3 —(CH2)9CH3
61 —CH3 —CH2OH —CH3 —C(CH3)3 —(CH2)5CH3
62 —CH3 —CH2OH —CH3 —C(CH3)3 —(CH2)6CH3
TABLE 4
Figure USRE038970-20060207-C00022
Ex-
am-
ple R1 R2 R3 R7 R6
63 —CH3 —CH2OH —CH3 —C(CH3)3 —(CH2)8CH3
64 — CH3 —CH2OH —CH3 —C(CH3)3 —(CH2)9CH3
65 —CH3 —CH2N(CH3)2 —CH3 —C(CH3)3 —(CH2)5CH3
66 —CH3 —CH2N(CH3)2 —CH3 —C(CH3)3 —(CH2)6CH3
67 —CH3 —CH2N(CH3)2 —CH3 —C(CH3)3 —(CH2)8CH3
68 —CH3 —CH2N(CH3)2 —CH3 —C(CH3)3 —(CH2)9CH3
69 —H —CH2CO2H —CH3 —C(CH3)3 —(CH2)5CH3
70 —H —CH2CO2H —CH3 —C(CH3)3 —(CH2)6CH3
71 —H —CH2CO2H —CH3 —C(CH3)3 —(CH2)7CH3
72 —H —CH2CO2H —CH3 —C(CH3)3 —(CH2)8CH3
73 —H —CH2CO2H —CH3 —C(CH3)3 —(CH2)9CH3
74 —H —CH2OH —CH3 —C(CH3)3 —(CH2)5CH3
75 —H —CH2OH —CH3 —C(CH3)3 —(CH2)6CH3
76 —H —CH2OH —CH3 —C(CH3)3 —(CH2)7CH3
77 —H —CH2OH —CH3 —C(CH3)3 —(CH2)8CH3
78 —H —CH2OH —CH3 —C(CH3)3 —(CH2)9CH3
79 —H —CH2N(CH3)2 —CH3 —C(CH3)3 —(CH2)5CH3
80 —H —CH2N(CH3)2 —CH3 —C(CH3)3 —(CH2)6CH3
81 —H —CH2N(CH3)2 —CH3 —C(CH3)3 —(CH2)7CH3
82 —H —CH2N(CH3)2 —CH3 —C(CH3)3 —(CH2)8CH3
83 —H —CH2N(CH3)2 —CH3 —C(CH3)3 —(CH2)9CH3
TABLE 5
Figure USRE038970-20060207-C00023
Example R1 R2 R3 R7 R5 R6
84 —CH3 —H —CH3 —C(CH3)3 —(CH2)2CO2H —(CH2)5CH3
85 —CH3 —H —CH3 —C(CH3)3 —(CH2)2CO2H —(CH2)6CH3
86 —CH3 —H —CH3 —C(CH3)3 —(CH2)2OH —(CH2)5CH3
87 —CH3 —H —CH3 —C(CH3)3 —(CH2)2OH —(CH2)6CH3
88 —CH3 —H —CH3 —C(CH3)3 —(CH2)2N(CH3)2 —(CH2)5CH3
89 —CH3 —H —CH3 —C(CH3)3 —(CH2)2N(CH3)2 —(CH2)6CH3
90 —CH3 —H —CH3 —C(CH3)3 —(CH2)2N(CH3)2 —(CH2)7CH3
TABLE 6
Figure USRE038970-20060207-C00024
Example R1 R2 R3 R7 R6
91 —CH3 —CH2CO2H —CH3 —(CH2)3CH3 —(CH2)7CH3
92 —CH3 —CH2CO2H —CH3 —(CH2)3CH3 —(CH2)8CH3
93 —CH3 —CH2CO2H —CH3 —(CH2)3CH3 —(CH2)9CH3
94 —CH2CH3 —CH2CO2H —CH2CH3 —(CH2)3CH3 —(CH2)7CH3
95 —CH2CH3 —CH2CO2H —CH2CH3 —(CH2)3CH3 —(CH2)8CH3
96 —CH2CH3 —CH2CO2H —CH2CH3 —(CH2)3CH3 —(CH2)9CH3
97 —OCH3 —CH2CO2H —OCH3 —(CH2)3CH3 —(CH2)7CH3
98 —OCH3 —CH2CO2H —OCH3 —(CH2)3CH3 —(CH2)8CH3
99 —OCH3 —CH2CO2H —OCH3 —(CH2)3CH3 —(CH2)9CH3
TABLE 7
Figure USRE038970-20060207-C00025
Example R1 R2 R3 R7 R6
100 —CH3 —CH2CO2H —CH3 —C(CH3)3 —(CH2)8CH3
101 —CH3 —CH2CO2H —CH3 —C(CH3)3 —(CH2)9CH3
102 —CH2CH3 —CH2CO2H —CH2CH3 —C(CH3)3 —(CH2)7CH3
103 —CH2CH3 —CH2CO2H —CH2CH3 —C(CH3)3 —(CH2)8CH3
104 —CH2CH3 —CH2CO2H —CH2CH3 —C(CH3)3 —(CH2)9CH3
105 —OCH3 —CH2CO2H —OCH3 —C(CH3)3 —(CH2)7CH3
106 —OCH3 —CH2CO2H —OCH3 —C(CH3)3 —(CH2)8CH3
107 —OCH3 —CH2CO2H —OCH3 —C(CH3)3 —(CH2)9CH3
TABLE 8
Figure USRE038970-20060207-C00026
Example R1 R2 R3 R7 R6
108 —CH3 —CH2CO2H —CH3 —(CH2)9CH3 —(CH2)7CH3
109 —CH3 —CH2CO2H —CH3 —(CH2)9CH3 —(CH2)7CH3
110 —CH3 —CH2CO2H —CH3
Figure USRE038970-20060207-C00027
 		—(CH2)7CH3
111 —CH3 —CH2CO2H —CH3
Figure USRE038970-20060207-C00028
 		—(CH2)7CH3
112 —CH3 —CH2CO2H —CH3
Figure USRE038970-20060207-C00029
 		—(CH2)7CH3
113 —CH3 —CH2CO2H —CH3
Figure USRE038970-20060207-C00030
 		—(CH2)7CH3
114 —CH3 —CH2CO2H —CH3 —C(CH3)3 —(CH2)2S(CH2)3CH3
115 —CH3 —CH2CO2H —CH3 —C(CH3)3
Figure USRE038970-20060207-C00031
116 —H —CH2CO2H —CH3 —C(CH3)3 —(CH2)7CH3
TABLE 9
Figure USRE038970-20060207-C00032
Exam-
ple R1 R2 R4 R7 R6
117 —CH2CO2H —CH3 —CH3 —C(CH3)3 —(CH2)5CH3
118 —CH2CO2H —CH3 —CH3 —C(CH3)3 —(CH2)8CH3
119 —CH2CO2H —CH3 —CH3 —C(CH3)3 —(CH2)20CH3
The 1H-NMR values old the compound of the above Examples 13-119 are shown in the following.
Example 13: 0.7-1.1 (3H, br-t), 1.1-1.7 (6H, m), 1.33 (9H, s), 2.01 (3H, s), 2.15 (3H, s), 2.70-3.10 (4H, m), 3.41 (2H, t), 3.56 (2H, s), 7.6-8.1. (2H, br).
Example 14: 0.70-1.70 (8H, m), 1.1-1.7 (6H, m), 1.33 (9H, s), 2.01 (3H, s), 2.15 (3H, s), 2.70-3.10 (3H, m), 3.41 (2H, t), 3.56 (2H, s), 7.6-8.1 (2H, br).
Example 15: 0.87 (6H, d), 1.1-1.8 (3H, m), 133 (9H, s), 2.01 (3H, s), 2.15 (3H, s), 2.70-3.10 (4H, m), 3: 41 (2H, t), 3.56 (2H, s), 7.6-8.1 (2H, br).
Example 16: 1.65 (6H, s), 1.33 (9H, s), 2.01 (3H, s), 2.15 (3H, s), 2.70-3.10 (41, m) 3.41 (2H, t), 3.56 (2H, s), 5.20 (1H, br-t), 7.6-8.1 (2H, br).
Example 17: 1.59 (3H, t), 1.33 (9H, s), 2.01 (3H, s), 2.15 (3H, s), 2.70-3.10 (4H, m), 3.3-3.6 (6H, m), 3.56 (2H, s), 3.56 (2H, s), 7.6-5.1 (2H, br).
Example 18: 0.7-1.1 (3H, br-t), 1.1-1.7 (8H, m), 1.33 (9H, s), 2.01 (3H, s), 2.15 (3H, s), 2.70-3.10 (4H, m), 3.41 (2H, t), 3.56 (2H, s), 7.6-8.1 (2H, br).
Example 19: 0.7-1.70 (10H, m), 1.33 (9H, s), 2.01 (3H, s), 2.15 (3H, s), 2.70-3.10 (3H, m), 3.41 (2H, t), 3.56 (2H, s), 7.6-8.1 (2H, br).
Example 20: 0.7-1.70 (9H, m), 1.33 (9H, s), 2.01 (3H, s), 2.15 (3H, s), 2.70-3.10 (4H, m), 3.41 (2H, t), 3.56 (2H, s), 7.6-8.1 (2H, br).
Example 21: 0.87 (6H, d), 1.1-1.8 (5H, m), 1.33 (9H, s), 2.01 (3H, s), 2.15 (3H, s), 2.70-3.10 (4H, m), 3.41 (2H, t), 3.56 (2H, s), 7.6-8.1 (2H, br).
Example 22: 0.7-1.0 (6H, br-t), 1.0-1.7 (5H, m), 1.33 (9H, s), 2.01 (3H, s), 2.15 (3H, s), 2.70-3.10 (4H, m), 3.41 (2H, t), 3.56 (2H, s), 7.6-8.1 (2H, br).
Example 23: 1.59 (3H, br-t), 1.0-1.7 (2H, m), 1.33 (9H, s), 2.01 (3H, s), 2.15 (3H, s), 2.70-3.10 (4H, m), 3.3-3.6 (6H, m), 3.56 (2H, s), 7.6-8.1 (2H, br).
Example 24: 0.7-1-10 (3H, br-t), 1.1-1.7 (10H, m), 1.33 (9H, s), 2.01 (3H, s), 2.15 (3H, s), 2.70-3.10 (4H, ml 3.41 (2H, t), 3.56 (2H, s), 7.6-73.1 (2H, br).
Example 25: 0.7-1.70 (11H, m), 1.33 (9H, s), 2.01 (3H, s), 2.15 (3H, s), 2.70-3.10 (4H, m), 3.41 (2H, t), 3.56 (2H, s), 7.6-8.1 (2H, br).
Example 26: 0.87 (6H, d), 1.1-1.8 (7H, m), 1.33 (9H, s), 2.01 (3H, s), 2.15 (3H, s), 3.70-3.10 (4H, m), 3.41 (2H, t), 3.56 (2H, s), 7.6-8.1 (2H, br).
Example 27: 1.59 (6H, br-t), 1.1-1.7 (7H, m), 1.33 (9H, s), 2.01 (3H, s), 2.15 (3H, s), 2.70-3.10 (4H, m), 3.41 (2H, t), 3.56 (2H, s), 7.6-8.1 (2H, br).
Example 28: 1.59 (3H, hr-t), 1.0-1.7 (4H, m), 1.33 (9H, s), 2.01 (3H, s), 2.15 (3H, s), 2.70-3.10 (4H, m), 3.3-3.6 (6H, m), 3.56 (2H, s), 7.63.1 (2H, br).
Example 29: 0.7-1.70 (13H, m), 1.33 (9H, s), 2.01 (3H, s), 2.15 (3H, s), 2.70-3.10 (4H, m), 3.41 (2H, t), 3.56 (2H, s), 7.6-8.1 (2H, br).
Example 30: 0.87 (6H, d), 1.1-1.8 (9H, m), 1.33 (9H, s), 2.01 (3H, s), 2.15 (3H, s), 2.70-3.10 (4H, m), 3.41 (2H, t), 3.56 (2H, s), 7.6-8.1 (2H, br).
Example 31: 1.59 (6H, br-t), 1.0-1.7 (9H, m), 1.33 (9H, s), 2.01 (3H, s), 2.15 (3H, s), 2.70-3.10 (4H, m), 3.41 (2H, t), 3.56 (2H, s), 7.6-8.1 (2H, br).
Example 32: 1.59 (3H, br-t ), 1.0-1.7 (6H, m), 1.33 (9H, s), 2.01 (3H, s), 2.15 (3H, s), 2.70-3.10 (4H, m), 3.3-3.6 (6H, m), 3.56 (2H, s), 7.6-8.1 (2H, br).
Example 33: 0.7-1.10 (3H, br-t), 1.1-1.7 (14H, m), 1.33 (9H, s), 2.01 (3H, s), 2.15 (3H, s), 2.70-3.10 (4H, m), 3.41 (2H, t), 3.56 (2H, s), 7.6-8.1 (2H, br).
Example 34: 0.87 (6H, d), 1.1-1.8 (11H, m), 1.33 (9H, s), 2.01 (3H, s), 2.15 (3H, s), 2.70-3.10 (4H, m), 3.41 (2H, t), 3.56 (2H, s), 7.6-5.1 (2H, br).
Example 35: 1.59 (6H, br-t), 1.0-1.7 (11H, m), 1.33 (9H, s), 2.01 (3H, s), 2.15 (3H, s), 2.70-3.10 (4H, m), 3.41 (2H, t), 3.56 (2H, s), 7.6-8.1 (2H, br).
Example 36: 0.7-1.10 (3H, br-t), 1.1-1.7 (16H, m), 1.33 (9H, s), 2.01 (3H, s), 2.15 (3H, s), 2.70-3.10 (4H, m), 3.41 (2H, t), 3.56 (2H, s), 7.6-8.1 (2H, br).
Example 37: 0.87 (6H, d), 1.1-1.8 (13H, m), 1.33 (9H, s), 2.01 (3H, s), 215 (3H, s), 2.70-3.10 (4H, m), 3.41 (2H, t), 3.56 (2H, s), 7.6-8.1 (2H, br).
Example 38: 0.7-1.10 (3H, br-t), 1.1-1.7 (18H, m), 1.33 (9H, s), 2.01 (3H, s), 2.15 (3H, s), 2.70-3.10 (4H, m), 3.41 (2H, t), 3.56 (2H, s), 7.6-51.1 (2H, br).
Example 39: 0.87 (6H, d), 1.1-1.8 (15H, m), 1.33 (9H, s), 2.01 (3H, s), 2.15 (3H, s), 2.70-3.10 (4H, m), 3.41 (2H, t), 3.56 (2H, s), 7.6-8.1 (2H, br).
Example 40: 0.7-1.10 (3H, br-t), 1.1-1.7 (20H, m), 1.33 (9H, s), 2.01 (3H, s), 2.15 (3H, s), 2.70-3.10 (4H, m), 3.41 (2H, t), 3.56 (2H, s), 7.6-8.1 (2H, br).
Example 41: 0.87 (6H, d), 1.1-1.8 (17H, m), 1.33 (9H, s), 2.01 (3H, s), 2.15 (3H, s), 2.10-3.10 (4H, m), 3.41 (2H, t), 3.56 (2H, s) 7.6-8.1 (2H, br).
Example 42: 0.7-1.10 (6H, br-t), 1.1-2.0 (20H, m), 201 (3H, s), 2.15 (3H, s), 2.70-3,10 (4H, m), 3.41 (2H, t), 3.56 (2H, s), 7.6-8.1 (2H, br).
Example 43: 0.7-1.10 (6H, br-t), 1.0-2.0 (21H, m), 201 (3H, s), 2.15 (3H, s), 2.70-3.10 (4H, m), 3.41 (2H, t), 3.56 (2H, s), 7.6-8.1 (2H, br).
Example 44: 0.7-1.10 (6H, br-t), 1.0-2.0 (24H, m), 2.01 (3H, s), 2.15 (3H, s), 2.70-3.10 (4H, m), 3.41 (2H, t), 3.56 (2H, s), 7.6-8.1 (2H, br).
Example 45: 0.7-1.10 (6H, br-t), 1.0-2.0 (24H, m), 2.01 (3H, s), 2.15 (3H, s), 2.70-3.10 (4H, m), 3.41 (2H, t), 3.56 (2H, s), 7.6-8.1 (2H, br).
Example 46: 0.7-1.10 (6H, br-t), 1.0-2.0 (26H, m), 2.01 (3H, s), 2.15 (3H, s), 2.70-3.10 (4H, m), 3.41 (2H, t), 3.56 (2H, s), 7.6-8.1 (2H, br).
Example 47: 0.7-1.10 (6H, br-t), 1.0-2.0 (28H, m), 2.01 (3H, s), 2.15 (3H, s), 2.70-3.10 (4H, m), 3.41 (2H, t), 3.56 (2H, s), 7.6-8.1 (2H, br).
Example 48: 0.7-1.10 (6H, br-t), 1.0-2.0 (28H, m), 2.01 (3H, s), 2.15 (3H, s), 2.70-3.10 (4H, m), 3.41 (2H, t), 3.56 (2H, s), 7.6-8.1 (2H, br).
Example 49: 0.7-1.10 (6H, br-t), 1.0-2.0 (30H, m), 2.01 (3H, s), 2.15 (3H, s), 2.70-3.10 (4H, m), 3.41 (2H, t), 3.56 (2H, s), 7.6-5.1 (2H, br).
Example 50: 0.7-1.10 (6H, br-t), 1.0-2.0 (32H, m), 2.01 (3H, s), 2.15 (3H, s), 2.70-3.10 (4H, m), 3.41 (2H, t), 3.56 (2H, s), 7.6-8.1 (2H, br).
Example 51: 0.7-1.1 (3H, br-t), 1.1-1.7 (14H, m), 1.33 (9H, s), 2.42 (2H, q), 2.46 (2H, q), 2.7-3.1 (4H, m), 3.41 (2H, t), 3.56 (2H, t), 7.6-8.1 (2H, br).
Example 52: 0.7-1.1 (3H, br-t), 1.0-1.7 (16H, m), 1.33 (9H, s), 2.42 (2H, q), 2.46 (2H, q), 2.7-3.1 (4H, m), 3.41 (2H, t), 3.56 (2H, t). 7.6-8.1 (2H, br).
Example 53: 0.7-1.1 (3H, br-t), 1.0-1.7 (18H, m), 1.33 (9H, s), 2.42 (2H, q), 2.46 (2H, q), 2.7-3.1 (4H, m), 3.41 (2H, t), 3.56 (2H, t), 7.6-8.1 (2H, br).
Example 54: 0.7-1.1 (3H, br-t), 1.0-1.7 (20H, m), 1.33 (9H, s), 2.42 (2H, q), 2.46 (2H, q), 2.7-3.1 (4H, m), 3.41 (2H, t), 3.56 (2H, 1), 7.6-8.1 (2H, br).
Example 55: 0.7-1.1 (3H, br-t), 1.0-1.7 (22H, m), 1.33 (9H, s), 2.42 (2H, q), 2.46 (2H, q), 2.7-3.1 (4H, m), 3.41 (2H, t), 3.56 (2H, t), 7.6-8.1 (2H, br).
Example 56: 0.7-1.1 (3H, br-t), 1.1-1.7 (8H, m), 1.33 (9H, s), 2.50-3.10 (4H, m), 3.32 (2H, t), 3.45 (2H, s), 3.73 (3H, s), 3.77 (3H, s), 7.6-8.1 (2H, br).
Example 57: 0.7-1.1 (3H, br-t), 1.0-1.7 (10H, m), 1.33 (9H, s), 2.50-3.10 (4H, m), 3.32 (2H, t), 3.45 (2H, s), 3.73 (3H, s), 3.77 (3H, s), 7-6,8.1 (2H, br).
Example 58: 0.7-1.1 (3H, br-t), 1.0-1.7 (12H, m), 1.33 (9H, s), 2.50-3.10 (4H, m), 3.32 (2H, t), 3.45 (2H, s), 3.73 (3H, s), 3.77 (3H, s), 7.6-8.1 (2H, br).
Example 59: 0.7-1.1 (3H, br-t), 1.11-1.7 (14H, m), 1.33 (9H, s), 2.50-3.10 (4H, m), 3.32 (2H, t), 3.45 (2H, s), 3.73 (3H, s), 3.77 (3H, s), 7.6-5.1 (2H, br).
Example 60: 0.7-1.1 (3H, br-t), 1.0-1.7 (16H, m), 1.33 (9H, s), 2.50-3.10 (4H, m), 3.32 (2H, t), 3.45 (2H, s), 3.73 (3H, s), 3.77 (3H, s), 7.6-8.1 (2H, br).
Example 61: 0.7-1.1 (3H, br-t), 1.1-1.7 (8H, m), 1.33 (9H, s), 2.14 (3H, s), 2.22 (3H, s), 2.70-3.10 (4H, s), 3.41 (2H, t), 4.62 (2H, s), 6.86 (2H, br).
Example 62: 0.7-1.1 (3H, br-t), 1.1-1.7 (10H, m), 1.33 (9H, s), 2.14 (3H, s), 2.22 (3H, s), 2.70-3.10 (4H, m), 3.41 (2H, t), 4.62 (2H, s), 6.86 (2H, br).
Example 63: 0.7-1.1 (3H, br-t), 1.1-1.7 (14H, m), 1.33 (9H, s), 2.14 (3H, s), 2.22 (3H, s), 2.70-3.10 (4H, m), 3.41 (2H, t), 4.62 (2H, s), 6.86 (2H, br).
Example 64: 0.7-1.1 (3H, br-t), 1.1-1.7 (16H, m), 1.33 (9H, s), 2.14 (3H, s), 2.22 (3H, s), 2.70-3.10 (4H, m), 3.41 (2H, t), 4.62 (2H, s), 6.86 (2H, br).
Example 65: 0.7-1.1 (3H, br-t), 1.1-1.7 (8H, m), 1.33 (9H, s), 2.00 (6H, s), 2.09 (3H, s), 2.23 (3H, s), 2.70-3.20 (4H, m), 3.31 (2H, s), 3.38 (2H, t), 6.84 (1H, br).
Example 66: 0.7-1.1 (3H, br-t), 1.1-1.7 (10H, m), 1.33 (9H, s), 2.00 (6H, s), 2.09 (3H, s), 2.23 (3H, s), 2.70-3.20 (4H, m), 3.31 (2H, s), 3.38 (2H, t), 6.84 (1H, br).
Example 67: 0.7-1.1 (3H, br-t), 1.1-1.7 (14H, m), 1.33 (9H, s), 2.00 (6H, s), 2.09 (3H, s), 2.23 (3H, s), 2.70-3.20 (4H, m), 3.31 (2H, s), 3.38 (2H, t), 6.84 (1H, br).
Example 68: 0.7-1.1 (3H, br-t), 1.1-1.7 (16H, m), 1.33 (9H, s), 2.00 (6H, s), 2.09 (3H, s), 2.23 (3H, s), 2.70-3.20 (4H, m), 3.31 (2H, s), 3.38 (2H, t), 6.84 (1H, br).
Example 69: 0.7-1.0 (3H, br), 1.0-1.7 (8H, m), 1.33 (9H, s), 1.97 (3H, s), 2.7-3.1 (4H, m), 3.35 (2H, t), 3.47 (2H, s), 6.90 (1H, s), 7.6-8.1 (2H, br).
Example 70: 0.7-1.0 (3H, br), 1.0-1.7 (10H, m), 1.33 (9H, s), 1.97 (3H, s), 2.7-3.1 (4H, m), 3.35 (2H, t), 3.47 (2H, s), 6.90 (1H, s), 7.6-8.1 (2H, br).
Example 71: 0.7-1.0 (3H, br), 1.0-1.7 (12H, m), 1.33 (9H, s), 1.97 (3H, s), 2.7-3.1 (4H, m), 3.35 (2H, t), 3.47 (2H, s), 6.90 (1H, s), 7.6-8.1 (2H, br).
Example 72: 0.7-1.0 (3H, br), 1.0-1.7 (4H, m), 1.33 (9H, s), 1.97 (3H, s), 2.7-3.1 (4H, m), 3.35 (2H, t), 3.47 (2H, s), 6.90 (1H, s), 7.6-8.1 (2H, br).
Example 73: 0.7-1.0 (3H, br), 1.0-1.7 (16H, m), 1.33 (9H, s), 1.97 (3H, s), 2.7-3.1 (4H, m), 3.35 (2H, t), 3.47 (2H, s), 6.90 (1H, s), 7.6-8.1 (2H, br).
Example 74: 0.7-1.0 (3H, br), 1.0-1.7 (8H, m), 1.33 (9H, s), 2.07 (3H, s), 2.89 (2H, t), 3.09 (2H, t), 3.40 (2H, t), 4.51 (2H, s), 6.90 (1H, s), 7.0-7.4 (2H, br).
Example 75: 0.7-1.0 (3H, br), 1.0-1.7 (10H, m), 1.33 (9H, s), 2.07 (3H, s), 2.89 (2H, t), 3.09 (2H, t), 3.40 (2H, t), 4.51 (2H, s), 6.90 (1H, s), 7.0-7.4 (1H, br).
Example 76: 0.7-1.0 (3H, br), 1.0-1.7 (12H, m), 1.33 (9H, s), 2.07 (3H, s), 2.89 (2H, t), 3.09 (2H, t), 3.40 (2H, t), 4.51 (2H, s), 6.90 (1H, s), 7.0-7.4 (2H, br).
Example 77: 0.7-1.0 (3H, br), 1.0-1.7 (14H, m), 1.33 (9H, s), 2.07 (3H, s), 2.89 (2H, t), 3.09 (2H, t), 3.40 (2H, t), 4.51 (2H, s), 6.90 (1H, s), (1H, s), 7.0-7.4 (2H, br).
Example 78: 0.7-1.0 (3H, br), 1.0-1.7 (16H, m), 1.33 (9H, s), 2.07 (3H, s), 2.89 (2H, t), 3.09 (2H, t), 3.40 (2H, t), 4.51 (2H, s), 6.90 (1H, s), 7.0-7.4 (2H, br).
Example 79: 0.7-1.0 (3H, br), 1.0-1.7 (8H, m), 1.33 (9H, s), 2.08 (3H, s), 2.23 (6H, s), 2.89 (2H, t), 3.14 (2H, t), 3.30 (2H, s), 3.38 (2H, t), 6.84 (1H, s), 6.90 (1H, br).
Example 80: 0.7-1.0 (3H, br), 1.0-1.7 (10H, m), 1.33 (9H, s), 2.08 (3H, s), 2.23 (5H, s), 2.89 (2H, t), 3.14 (2H, t), 3.30 (2H, s), 3.38 (2H, t), 6.84 (1H, s), 6.90 (1H, br).
Example 81: 0.7-1.0 (3H, br), 1.0-1.7 (12H, m), 1.33 (9H, s), 2.08 (3H, s), 2.23 (6H, s), 2.89 (2H, t), 3.14 (2H, t), 3.30 (2H, s), 3.38 (2H, t), 6.84 (1H, s), 6.90 (1H, br).
Example 82: 0.7-1.0 (3H, br), 1.0-1.7 (14H, m), 1.33 (9H, s), 2.08 (3H, s), 2.23 (6H, s), 2.89 (2H, t), 3.14 (2H, t), 3.30 (2H, s), 3.38 (2H, t), 6,84 (1H, s), 6.90 (1H, br).
Example 83: 0.7-1.0 (3H, br), 1.0-1.7 (16H, m), 1.33 (9H, s), 2.08 (3H, s), 2.23 (6H, s), 2.89 (2H, t), 3.14 (2H, t), 3.30 (2H, s), 3.38 (2H, t), 6.84 (1H, s), 6.90 (1H, br).
Example 84: 0.7-1.0 (3H, br-t), 1.00-1.60 (8H, m), 1.38 (9H, s), 1.60-2.20 (2H, m), 2.07 (3H, s), 2.16 (3H, s), 2.20-2.40 (2H, m), 3.10-3.80 (3H, m), 3.27 (2H, br-t), 6.45 (1H, s), 7.20-7.60 (2H, br).
Example 85: 0.7-1.0 (3H, br-t), 1.00-1.60 (10H, m), 1.38 (9H, s), 1.60-2.20 (2H, m), 2.07 (3H, s), 2.16 (3H, s), 2.20-2.40 (2H, m), 3.10-3.80 (3H, m), 3.27 (2H, br-t), 6.45 (1H, s), 7.20-7.60 (2H, br).
Example 86: 0.7-1.0 (3H, br-t), 1.0-2.0 (10H, m), 1.33 (9H, s), 2.07 (3H, s), 2.16 (3H, s), 2.60-3.60 (7H, m), 6.44 (1H, s), 6.78 (2H, br).
Example 87: 0.7-1.0 (3H, br-t), 1.0-2.0 (12H, m), 1.33 (9H, s), 2.07 (3H, s), 2.16 (3H, s), 2.60-3.60 (7H, m), 6.44 (1H, s), 6.78 (2H, br).
Example 88: 0.7-1.0 (3H, br-t), 1.0-2.0 (10H, m), 1.35 (9H, s), 2.07 (3H, s), 1.16 (3H, s), 2.19 (6H, s), 2.21 (2H, t), 2.6-3.6 (5H, m), 6.45 (1H, s), 7.2 (1H, br).
Example 89: 0.7-1.0 (3H, br-t), 1.0-2.0 (12H, m), 1.35 (9H, s), 2.07 (3H, s), 2.16 (3H, s), 2.19 (6H, s), 2.21 (2H, t), 2.6-3.6 (8H, m), 6.45 (1H, s), 7.2 (1H, br).
Example 90: 0.7-1.0 (3H, br-t), 1.0-2.0 (14H, m), 1.35 (9H, s), 2.07 (3H, s), 2.16 (3H, s), 2.19 (6H, s), 2.21 (2H, t), 2.6-3.6 (5H, m), 6.45 (1H, s), 7.2 (1H, br).
Example 91: 0.70-1.10 (6H, m), 1.10-1.90 (16H, m), 2.10 (6H, s), 1.80-2.00 (2H, br-t), 2.00-4.00 (6H, m), 3.55 (2H, s), 4.80 (1H, br), 5.50 (1H, br), 6.40 (1H, br).
Example 92: 0.70-1.10 (6H, m), 1.10-1.90 (18H, m), 2.10 (6H, s), 1.80-2.00 (2H, br-t), 2.00-4.00 (6H, m), 3.55 (2H, s), 4.80 (1H, br), 5.50 (1H, br), 6.40 (1H, br).
Example 93: 0.70-1.10 (6H, m), 1.10-1.90 (20H, m), 2.10 (6H, s), 1.80-2.00 (2H, br-t), 2.00-4.00 (6H, m), 3.55 (2H, s), 4.80 (1H, br), 5.50 (1H, br), 6.40 (1H, br).
Example 94: 0.70-1.10 (6H, m), 1.10-1.90 (22H, m), 2.09 (4H, br-t), 1.80-2.00 (2H, br-t), 2.00-4.00 (6H, m), 3.55 (2H, s), 4.80 (1H, br), 5.50 (1H, br), 6.40 (1H, br).
Example 95: 0.70-1.10 (6H, m), 1.1.0-1.90 (24H, m), 2.09 (4H, br-t), 1.80-2.00 (2H, br), 2.00-4.00 (6H, m), 3.55 (2H, s), 4.80 (1H, br), 5.50 (1H, br), 6.40 (1H, br).
Example 96: 0.70-1.10 (6H, m), 1.10-1.90 (26H, m), 2.09 (4H, br-t), 1.80-2.00 (2H, br-5), 2.00-4.00 (6H, m), 3.55 (2H, s), 4.80 (1H, br), 5.50 (1H, br), 6.40 (1H, br).
Example 97: 0.70-1.10 (6H, m), 1.10-1.90 (16H, m), 1.80-2.00 (2H, br-t), 2.00-4.00 (6H, m), 3.35 (2H, s), 3.74 (3H, s), 3.78 (3H, s), 4.80 (1H, br), 5.50 (1H, br), 6.40 (1H, br).
Example 98: 0.70-1.10 (6H, m), 1.10-1.90 (18H, m), 1.80-2.00 (2H, br-t), 2.00-4.00 (6H, m), 3.35 (2H, s), 3.74 (3H, s), 3.78 (3H, s), 4,80 (1H, br), 5.50 (1H, br), 6.40 (1H, br).
Example 99: 0.70-1.10 (6H, m), 1.10-1.90 (20H, m), 1.84-2.00 (2H, br-t), 2.00-4.00 (6H, m), 3.35 (2H, s), 3.74 (3H, s), 3.78 (3H, s), 4.80 (1H, br), 5.50 (1H, br), 6.40 (1H, br).
Example 100: 0.70-1.10 (3H, br-t), 1.10-1.70 (14H, m), 1.33 (9H, s), 2.10 (3H, s), 2.39 (3H, s), 3.71 (2H, br), 3.99 (2H, br-t), 4.15 (2H, s), 6.38 (1H, d), 6.89 (1H, d).
Example 101: 0.70-1.10 (3H, br-t), 1.10-1.70 (10H, m), 1.33 (9H, s), 2.10 (3H, s), 2.39 (3H, s), 3.71 (2H, br), 3.99 (2H, br-t), 4.15 (2H, s), 638 (1H, d), 6.89 (1H, d).
Example 102: 0.70-1.10 (3H, br-t), 1.10-1.70 (18H, m), 1.33 (9H, s), 2.08 (2H, q), 2.46 (2H, q), 3.71 (2H, br), 3.99 (2H, br-t), 4.15 (2H, s), 6.38 (1H, d), 6.89 (1H, d).
Example 103: 0.70-1.10 (3H, br-t), 1.10-1.70 (20H, m), 1.33 (9H, s), 2.08 (2H, q), 2.46 (2H, q), 3.71 (2H, br), 3.99 (2H, br-t), 4.15 (2H, s), 6.38 (1H, d), 6.89 (1H, d).
Example 104: 0.70-1.10 (3H, br-t), 1.10-1.70 (22H, m), 1.33 (9H, s), 2.42 (2H, q), 2.46 (2H, q), 3.71 (2H, br), 3.99 (2H, br-t), 4.15 (2H, s), 6.38 (1H, d), 6.89 (1H, d).
Example 105: 0.70-1.10 (3H, br-t), 1.10-1.70 (12H, m), 1.33 (9H, s), 3.60 (3H, s), 3.65 (3H, s), 3.71 (2H, br), 3.99 (2H, br-t), 4.15 (2H, s), 6.15 (1H, d), 6.70 (1H, d).
Example 106: 0.70-1.10 (3H, br-t), 1.10-1.70 (14H, m), 1.33 (9H, s), 3.60 (3H, s), 3.65 (3H, s), 3.71 (2H, br), 3.99 (2H, br-t), 4.15 (2H, s), 6.15 (1H, d), 6.70 (1H, d).
Example 107: 0.70-1.110 (3H, br-t), 1.10-1.70 (16H, m), 1.33 (9H, s), 3.60 (3H, s), 3.65 (3H, s), 3.71 (2H, br), 3.99 (2H, br-t), 4.15 (2H, s), 6.15 (1H, d), 6.70 (1H, d).
Example 108: 0.70-1.10 (3H, br-t), 1.10-2.00 (15H, m), 2.01 (3H, s), 2.15 (3H, s), 2.70-3.10 (4H, m), 3.37 (3H, s), 3.40 (2H, t), 3.41 (2H, t), 3.56 (2H, s), 7.60-8.10 (2H, br).
Example 109: 0.70-1.10 (3H, br-t), 1.10-2.00 (15H, m), 2.01 (3H, s), 2.15 (3s), 2.17 (3H, s), 2.45 (2H, s), 2.70-3.10 (4H, m), 3.41 (2H, t), 3.56 (2H, s), 7.60-8.10 (2H, br).
Example 110: 0.70-1.10 (3H, br-t), 1.10-2.00 (23H, m), 2.01 (3H, s), 2.70-3.10 (4H, m), 3.41 (2H, t), 3.56 (2H, s), 7.60-8.10 (2H, br).
Example 111: 0.70-1.10 (3H, br-t), 1.10-2.00 (25H, m), 2.01 (3H, s), 2.15 (3H, s), 2.70-3.10 (4H, m), 3.41 (2H, t), 336 (2H, s), 7.60-9.10 (2H, br).
Example 112: 0.70-1.10 (3H, br-t), 1.10-1.70 (12H, m), 2.01 (3H, s), 2.15 (3H, s), 2.70-3.10 (4H, m), 3.41 (2H, t), 3.56 (2H, s), 7.30-7.80 (3H, m), 7.60-8.10 (2H, br), 8.12 (2H, d).
Example 113: 0.70-1.10 (3H, br-t), 1.10-1.70 (12H, m), 2.01 (3H, s), 2.15 (3H, s), 2.70-3.10 (4H, m), 3.41 (2H, t), 3.53 (2H, s), 3.56 (2H, s), 7.30 (5H, s), 7.60-8.10 (2H, br).
Example 114: 1.59 (3H, br-t), 1.10-1.70 (4H, m), 1.33 (9H, s), 2.01 (3H, s), 2.15 (3H, s), 2.10-2.50 (4H, m), 2.70-3.10 (4H, m), 3.41 (2H, t), 3.56 (2H, s), 7.60-8.10 (2H, br).
Example 115: 1.33 (9H, s) 2.01 (3H, s), 2.15 (3H, s), 3.02 (2H, t), 3.41 (2H, t), 3.56 (2H, s), 4.30 (2H, s), 7.30 (5H, s) 7.60-8.10 (2H, br).
Example 116: 0.70-1.10 (3H, br-t), 1.10-1.60 (15H, m), 134 (9H, s), 2.02 (3H, s), 2.90 (2H, t), 3.13 (2H, t), 3.38 (2H, t), 3.50 (2H, s), 4.12 (2H, q), 6.80 (1H, br), 6.85 (1H, s).
Example 117: 0.70-1.10 (3H, br-t), 1.10-2.00 (5H, m), 1.23 (9H, s), 2.07 (3H, s), 2.24 (3H, s), 2.70-3.10 (4H, m), 3.39 (2H, t), 3.35 (2H, s), 6.60-7.50 (2H, br).
Example 118: 0.70-1.10 (3H, br-t), 1.10-2.00 (12H, m), 1.23 (9H, s), 2.07 (3H, s), 2.24 (3H, s), 2.70-3.10 (4H, m), 3.39 (2H, t), 3.35 (2H, s), 6.60-7.50 (2H, br).
Example 119: 0.70-1.10 (3H, br-t), 1.10-2.00 (16H, m), 1.23 (9H, s), 2.07 (3H, s), 2.24 (3H, s), 2.70-3.10 (4H, m), 3.39 (2H, t), 3.35 (2H, s), 6.60-7.50 (2H, br).
EXAMPLE 120 N-(1-octyl-5-carboxyethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide
  • (1) N-(1-octyl-5-chloroethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide (3.0 g) was dissolved in CH2CN (30 ml), and NaCH (3.7 g) and 18-crown-6 (0.1 g) were added, which was followed by refluxing for 17 hr under a nitrogen atmosphere. CH3CN was evaporated under reduced pressure, and water (100 ml) was added to the obtained residue. The mixture was extracted twice with AcOEt (100 ml). The AcOEt layer was washed with saturated brine (100 ml) and dried over anhydrous sodium sulfate, and AcOEt was evaporated under reduced pressure. The obtained residue was purified by silica gel column chromatography (eluent: AcOEt/benzene-1/10-1/5) to give 1.14 g of N-(1-octyl-5-cyanoethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide.
    IR (Nujol)cm−1: 2243, 1647, 1601.
    1H-NMR (CDCl3) σ:
    0.88 (3H, br-t, J=6.0 Hz,-(CH2),CH3), 1.10-1.90 (12H, m, —CH2(CH2)6CH3), 1.33 (9H, s, —C(CH3)3), 2.05, 2.15 (3H×2, s×2, indoline C4.6 —CH3), 2.38 (2H, t, J=7 Hz, —CH2CN), 2.70-3.30 (6H, m, indoline C3—H2, >NCH2—, —CH2CH2CN), 3.41 (2H, t, J=9 Hz, indoline C2—H2), 6.81 (1H, br, —CONH—).
  • (2) N-1-octyl-5-cyanoethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide (1.14 g) was dissolved in EtOH (26 ml), and a solution of NaOH (1.1 g) in water (7.5 ml) was added, which was followed by refluxing for 14 hr under a nitrogen atmosphere. EtOH was evaporated under reduced pressure. The obtained residue was dissolved in warm water (30 ml) and washed with AcOEt (30 ml). The aqueous layer was neutralized with 2N HCl and extracted with CHCl3 (50 ml). CHCl3 layer was evaporated under reduced pressure to give 830 mg of the title compound.
    IR (Nujol)cm−1: 1724, 1655, 1618.
    1H-NMR (CDCl3) σ:
    0.86 (3H, br-t, J=5.0 Hz, —C(CH2)7CH3), 1.10-2.10 (12H, m, —CH2(CH2)6CH,) 1.42 (9H, s, —C(CH3)3), 2.12, 2.26 (3H×2, s×2, indoline C4,6 —CH3), 2.30-2.60 (2H, m, —CH2O2—), 2.90-3.40 (6H, m, indoline C3—H2, >NCH2—, —CH2CH2CO2—), 3.78 (1H, br, indoline C2—H2), 7.70 (1H, br-CO2H), 9.91 (1H, br, —CONH—).
EXAMPLES 121-123
The compounds of Table 10 were obtained according to the method of the above Example 120.
TABLE 10
Figure USRE038970-20060207-C00033
Example R1 R2 R3 R7 R6
121 —CH3 —CH2CO2H —CH3 —C(CH3)3 —(CH2)6S(CH2)3CH3
122 —CH3 —CH2CO2H —CH3 —C(CH3)3 —(CH2)3S(CH2)3CH3
123 —CH3 —(CH2)3CO2H —CH3 —C(CH3)3 —(CH2)7CH3
The 1H-NMR values of the compounds of the above Examples 121-123 are shown in the following.
Example 121: 0.91 (3H, br-t), 1.00-1.80 (12H, m), 1.37 (9H, s), 1.93 (3H, s), 2.06 (3H, s), 2.47 (4H, br-t), 3.00 (4H, br), 3.30-3.90 (4H, m), 8.60-9.90 (2H, br).
Example 122: 0.90 (3H, br-t), 1.00-1.80 (6H, m), 2.08 (3H, s), 2.21 (3H, s), 2.48 (4H, br-t), 2.90-3.40 (4H, m), 3.40-3.80 (2H, m), 3.61 (2H, s), 7.34 (1H, br), 8.48 (1H, br).
Example 123: 0.86 (3H, br-t), 1.00-150 (12H, m), 1.42 (9H, s), 2.00-2.90 (6H, m), 2.11 (3H, s), 2.23 (3H, s) 2.90-330 (4H, m), 3.70 (2H, br), 6.10 (1H, br), 9.21 (1H, br).
EXAMPLE 124 N-(1-octyl-6-ethoxycarbonylmethyl-5,7-dimethyl-1,2,3,4-tetrahydroquinolin-8-yl)-2,2-dimethylpropanamide
  • (1) 3,5-Xylidine (5.0 g) and acrylonitrile (2.3 g) were dissolved in acetic acid (2ml), and the mixture was stirred at 60° C. for 20 hr. Ethyl acetate (200 ml) was added to the reaction mixture and neutralized with saturated aqueous solution of sodium hydrogencarbonate. The mixture was washed with water and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (client: ethyl acetate/benzene=1/10-1/3) to give 4.5 g of oily β-(3,5-dimethylanilino)propionitrile.
    IR (Nujol) cm−1; 2248, 1602.
    1H-NMR (CDCl3) δ;
    2.24 (6H, s, C3.5—CH3), 2.60 (2H, t, J=7.5 Hz, —CH2CH2CN), 3.48 (2H, t, J=7.5 Hz, —CH2CH2CN), 3.90 (1H, br, >NH), 6.24 (2H, s, C2,6-H), 6.43 (1H, s, C4—H).
  • (2) β-(3,5-Dimethylanilino)propionitrile (4.5 g) was dissolved in ethanol (50 ml), and a solution of NaOH (5.1 g) in water (25 ml) was added, which was followed by refluxing for 4 hr. The solvent was evaporated under reduced pressure. 2N Hydrochloric acid was added to adjust the residue acidic, and the mixture was washed with chloroform (100 ml). The aqueous layer was concentrated to about 20 ml and allowed to stand. The precipitated crystals were collected by filtration and dried to give 4.0 g of β-(3,5-dimethylanilino)propionic acid.
    IR (Nujol) cm−1; 1560.
    1H-NMR (DMSO-d6) δ:
    2.29 (6H, s, C3.5—CH3), 2.73 (2H, t, J=7.5 Hz, —CH2CH2CO—), 3.44 (2H, t, J=7.5 Hz, —CH2CH2CO—), 7.0 (3H, s, C2,4,6—H), 9.80 (2H, br, —CO2H, >NH).
  • (3) β-(3,5-Dimethylanilino)propionic acid (1.2 g) was added by portions to sulfuric acid (60° C., 12 ml), and the mixture was stirred at the same temperature for 0.5 hr. The reaction mixture was poured into ice water (100 ml) and extracted with chloroform (100 ml). After washing with water, the chloroform layer was dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: ethyl acetate/benzene=1/5-1/1) to give 750 mg of 5,7-dimethylquinolone as crystals.
    IR (Nujol) cm−1; 1645, 1614.
    1H-NMR (CDCl3) δ;
    2.19 (3H, s, C3—CH3), 2.57 (3H, s, C7—CH3), 2.63 (2H, t, J=7.5 Hz, C3—H2), 3.49 (2H, t, J=7.5 Hz, C2—H2), 4.39 (11H, br, >NH), 6.32 (2H, s, C6.5—H).
  • (4) Lithium aluminum hydride (687 mg) was suspended in ether (16 ml), and aluminum chloride (4.2 g) was added. A solution of 5,7-dimethylquinolone (1.6 g) in ether (16 ml) was dropwise added and the mixture was refluxed for 0.5 hr. The reaction mixture was poured into ice water (100 ml) and extracted with chloroform (100 ml). After washing with water, the chloroform layer was dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure. The obtained 5,7-dimethyl-1,2,3,4-tetrahydroquinoline was dissolved in chloroform (30 ml), and acetic anhydride (929 mg) was added, which was followed by stirring at room temperature for 1 hr. Chloroform (100 ml) was added to the reaction mixture, and the mixture was washed successively with saturated aqueous solution of sodium hydrogencarbonate and water and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: ethyl acetate/benzene=1/5-1/1) to give 13 g of oily 1-acetyl-5,7-dimethyl-1,2,3,4-tetrahydroquinoline.
    IR (Nujol) cm−1; 1625, 1614.
    1H-NMR (CDCl3) δ;
    1.70-2.10 (2H, m, C3—H2), 2.21 (6H, s×2, —OCH3, Ar—CH,), 2.29 (3H, s, Ar—CH3), 2.54 (2H, t, J=7.1 Hz, C4—H2), 3.77 (2H, t, J=7.1 Hz, C2—H2), 6.83 (2H, s, C6,8—H).
  • (5) 1-Acetyl-5,7-dimethyl-1,2,3,4-tetrahydroquinoline (3.0 g) was dissolved in conc. hydrochloric acid (6 ml), and 35% formaldehyde solution (2.5 g) and zinc chloride (400 mg) were added. The mixture was stirred at 40-50° C. for 2 hr while blowing hydrogen chloride. The reaction mixture was poured into ice water (100 ml) and extracted with chloroform (100 ml). After washing with water, the chloroform layer was dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure. The obtained 1-acetyl-6-chloromethyl-5,7-dimethyl-1,2,3,4-tetrahydroquinoline was dissolved in acetonitrile (30 ml), and sodium cyanide (3.6 g) and 18-crown-6(780 mg) were added, which was followed by refluxing for 5 hr. The solvent was evaporated under reduced pressure, and the residue was extracted with chloroform (100 ml). After washing with water, the chloroform layer was dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: chloroform-chloroform/methanol=10/1) to give 2.4 g of oily 1-acetyl-6-cyanomethyl-5,7-dimethyl-1,2,3,4-tetrahydroquinoline.
    IR (Nujol) cm−1; 2248, 1650.
    1H-NMR (CDCl3) δ;
    1.80-2.20 (2H, m, C3—H2), 2.21, 2.29 (3H×2, s×2, C5.7—CH3), 2.37 (3H, s, —COCH3 x), 2.68 (2H, t, J=7.5 Hz, C4—H2), 3.66 (2H, s, —CH2CN), 3.76 (2H, t, J=7.5 Hz, C2—H2), 7.00 (1H, s, C8—H).
  • (6) 1-Acetyl-6-cyanomethyl-5,7-dimethyl-1,2,3,4-tetrahydroquinoline (2.7 g) was dissolved in ethanol (30 ml), and a solution of NaOH (4.4 g) in water (10 ml) was added, which was followed by refluxing for 10 hr under nitrogen. The solvent was evaporated under reduced pressure, and the residue was extracted with chloroform (100 ml). After washing with water, the chloroform layer was dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure. The obtained 6-carbamoylmethyl-5,7-dimethyl-1,2,3,4-tetrahydroquinoline was dissolved in N,N-dimethylformamide (10 ml), and octyl bromide (1.6 g), potassium carbonate (1.2 g) and potassium iodide (166 mg) were added, which was followed by stirring at 40° C. for 10 hr in nitrogen. The reaction mixture was extracted with ethyl acetate (100 ml). After washing with water, the ethyl acetate layer was dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: chloroform/methanol=50/1-10/1) to give 600 mg of octyl-6-carbamoylmethyl-5,7-dimethyl-1,2,3,4-tetrahydroquinoline as crystals.
    IR (Nujol) cm−1; 1654, 1614.
    1H-NMR (CDCl3) δ;
    0.60-1.10 (3H, br-t, —(CH2)7CH3), 1.10-1.80 (12H, m, —(CH2)6CH3), 1.80-2.10 (2H, m, C3—H2), 2.16, 2.24 (3H×2, s×2, C5.7—CH3), 2.63 (2H, t, J=7.5 Hz, C4—H2), 3.00-3.50 (4H, m, C2—H2, >NCH2—), 3.57 (2H, s, —CH2CO—), 3.44 (2H, br, —CONH2), 6.35 (1H, s, C8—H).
  • (7) 1-Octyl-6-carbamoylmethyl-5,7-dimethyl-1,2,3,4-tetrahydroquinoline (2.5 g) was dissolved in n-propanol (50 ml) and a solution of NaOH (3.0 g) in water (30 ml) was added, which was followed by stirring at 130° C. for 20 hr under nitrogen. The organic layer of the reaction mixture was separated and the solvent was evaporated under reduced pressure. The residue was dissolved in water (300 ml) and washed with ethyl acetate (100 ml). The aqueous layer was adjusted to pH 1-2 with 6N hydrochloric acid and extracted with chloroform (200 ml). The chloroform layer was dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure. The obtained 1-octyl-6-carboxymethyl-5,7-dimethyl-1,2,3,4-tetrahydroquinoline was dissolved in ethanol (50 ml), and conc. hydrochloric acid (4 ml) was added, which was followed by stirring at 70° C. for 1 hr. The solvent was evaporated under reduced pressure. The residue was neutralized with saturated aqueous solution of sodium hydrogencarbonate and extracted with chloroform (100 ml). After washing with water, the chloroform layer was dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: benzene) to give 1.0 g of oily 1-octyl-6-ethoxycarbonylmethyl-5,7-dimethyl-1,2,3,4-tetrahydroquinoline.
    IR (Nujol) cm−1; 1732, 1599.
    1H-NMR (CDCl3) δ;
    0.70-1.00 (3H, br-t, —(CH2)7CH3), 1.10-1.80 (15H, m, —(CH2)6CH, —COCH2CH3), 1.80-2.10 (2H, m, C3—H2), 2.12, 2.26 (3H×2, s×2, C5.7—CH3), 2.62 (2H, t, J=7.5 Hz, C3—H2), 3.00-3.30 (4H, m, C2—H3, >NCH2—), 3.59 (2H, s, —CH2CO—), 4.13 (2H, q, J=7.0 Hz, —COCH2—), 6.33 (1H, s, C8—H).
  • (8) 1-Octyl-6-ethoxycarbonylmethyl-5,7-dimethyl-1,2,3,4-tetrahydroquinoline (1.0 g) was dissolved in acetic anhydride (5 ml), and a solution of 70% nitric acid (517 mg) in acetic anhydride (3 ml), was dropwise added, which was followed by stirring at the same temperature for 0.5 hr. The reaction mixture was poured into ice water (50 ml), neutralized with saturated aqueous solution of sodium hydrogencarbonate, and extracted with chloroform (50 ml). After washing with water, the chloroform layer was dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: n-hexane-ethyl acetate/n-hexane=1/5) to give 700 mg of oily 1-octyl-6-ethoxycarbonylmethyl-5,7-dimethyl-8-nitro-1,2,3,4-tetrahydroquinoline.
    IR (Nujol) cm−1; 1732, 1527.
    1H-NMR (CDCl3) δ;
    0.70-1.00 (3H, br-t, —(CH2)7CH3), 1.10-1.70 (15H, m, —(CH2)6CH3, —COCH2CH3), 1.80-2.10 (2H, m, C3—H2), 2.16 (6H, s, C5.7—CH3), 2.64 (2H, t, J=7.5 Hz, C3—H2), 2.70-3.20 (4H, m, C2—H2, >NCH2—), 3.65 (2H, s, —CH2CO—), 4.13 (2H, q, J=7.0 Hz, —COCH2 —).
  • (9) 1-octyl-6-ethoxycarbonylmethyl-5,7-dimethyl-8-nitro-1,2,3,4-tetrahydroquinoline (700 mg) was dissolved in ethanol (500 ml), and 10% palladium-carbon (200 mg) was added. The mixture was subjected to hydrogenation at room temperature under atmospheric pressure. 10% Palladium-carbon was filtered off and the solvent was evaporated under reduced pressure. The obtained 1-octyl-6-ethoxycarbonylmethyl-5,7-dimethyl-8-amino-1,2,3,4-tetrahydroquinoline was dissolved in chloroform (50 ml). Pivaloyl chloride (207 mg) and triethylamine (192 mg) were added under ice-cooling, and the mixture was stirred at the same temperature for 1 hr. The reaction mixture was washed successively with 5% aqueous citric acid and water, and dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: chloroform-chloroform/methanol=10/1) to give 230 mg of oily title compound.
    IR (Nujol) cm−1; 1732, 1483.
    1H-NMR (CDCl3) δ;
    0.70-1.00 (3H, br-t, —(CH2)7CH3), 1.10-1.70 (15H, m, —(CH2)6CH3, —COCH 2CH3), 1.35 )9H, s, —C(CH3)3), 1.80-2.10 (2H, m, C3—H2), 2.05, 2.11 (3H×2, s×2, C5.7—CH3), 2.40-2.70 (4H, m, C4—H2, >NCH2—), 2.80-2.90 (2H, m, C3—H2), 3.68 (2H, s, —CH2CO—), 4.14 (2H, q, J=7.0 Hz, —COCH2—), 7.35 (1H, br, —CONH—).
EXAMPLE 125 N-(1-octyl-6-carboxymethyl-5,7-dimethyl-1,2,3,4-tetrahydroquinolin-8-yl)-2,2-dimethylpropanamide
N-(1-octyl-6-ethoxycarbonylmethyl-5,7-dimethyl-1,2,3,4-tetrahydroquinolin-8-yl)-2,2-dimethylpropanamide (230 mg) was dissolved in ethanol (5 ml), and a solution of NaOH (100 mg) in water (2 ml) was added, which was followed by stirring at 50° C. for 1 hr. The solvent of the reaction mixture was evaporated under reduced pressure. The residue was dissolved in water (50 ml) and washed with ethyl acetate (20 ml). The aqueous layer was adjusted to pH 1-2 with 2N sulfuric acid and extracted with chloroform. The chloroform layer was dried over anhydrous sodium sulfate. The solvent was evaporated under reduced pressure to give 130 mg of powdery title compound.
TLC; Silica gel 60F254 Art. 5714 (Merck), CHCl3-MeOH (10:1), Rf value 0.5.
IR (Nujol) cm−1; 1732, 1722.
1H-NMR (CDCl3) δ;
0.70-1.00 (3H, br-t, —(CH2)7CH3), 1.10-1.70 (12H, m, —(CH2)6CH3), 1.35 (9H, s, —C(CH3), 1.80-2.10 (2H, M, C3—H2), 2.10 (6H, s, C5.7—CH3), 2.40-2.70 (4H, m, C4—H2, >NCH2—), 2.80-2.90 (2H, m, C2—H2), 3.68 (2H, s, —CH2CO—), 7.35 (1H, br, —CONH—), 9.50 (2H, br, ½H2SO4, —CO2H).
EXAMPLES 126-154
The compounds of Tables 11 and 12 were obtained according to the method of the above Example 124.
TABLE 11
Figure USRE038970-20060207-C00034
Example R1 R2 R3 R7 R6
126 —CH3 —CH2CO2H —CH3 —C(CH3)3 —(CH2)5CH3
127 —CH3 —CH2CO2H —CH3 —C(CH3)3 —CH2CH(CH2CH3)2
128 —CH3 —CH2CO2H —CH3 —C(CH3)3 —(CH2)6CH3
129 —CH3 —CH2CO2H —CH3 —C(CH3)3
Figure USRE038970-20060207-C00035
130 —CH3 —CH2CO2H —CH3 —C(CH3)3 —(CH2)2CH(CH2CH3)2
131 —CH3 —CH2CO2H —CH3 —C(CH3)3 —(CH2)2O(CH2)3CH3
132 —CH3 —CH2CO2H —CH3 —C(CH3)3 —(CH2)7S(CH2)3CH3
133 —CH3 —CH2CO2H —CH3 —C(CH3)3
Figure USRE038970-20060207-C00036
134 —CH3 —CH2CO2H —CH3 —C(CH3)3 —(CH2)3CH(CH2CH3)2
135 —CH3 —CH2CO2H —CH3 —C(CH3)3 —(CH2)3O(CH2)3CH3
136 —CH3 —CH2CO2H —CH3 —C(CH3)3 —(CH2)3S(CH2)3CH3
137 —CH3 —CH2CO2H —CH3 —C(CH3)3 —(CH2)8CH3
138 —CH3 —CH2CO2H —CH3 —C(CH3)3 —(CH2)9CH3
139 —CH2CH3 —CH2CO2H —CH2CH3 —C(CH3)3 —(CH2)5CH3
140 —CH2CH3 —CH2CO2H —CH2CH3 —C(CH3)3 —(CH2)7CH3
141 —CH2CH3 —CH2CO2H —CH2CH3 —C(CH3)3 —(CH2)9CH3
TABLE 12
Figure USRE038970-20060207-C00037
Example R1 R2 R3 R7 R6
142 —OCH3 —CH2CO2H —OCH3 —C(CH3)3 —(CH2)5CH3
143 —OCH3 —CH2CO2H —OCH3 —C(CH3)3 —(CH2)7CH3
144 —OCH3 —CH2CO2H —OCH3 —C(CH3)3 —(CH2)9CH3
145 —CH3 —CH2OH —CH3 —C(CH3)3 —(CH2)5CH3
146 —CH3 —CH2OH —CH3 —C(CH3)3 —(CH2)7CH3
147 —CH3 —CH2OH —CH3 —C(CH3)3 —(CH2)9CH3
148 —CH3 —CH2CO2H —CH3 —C(CH3)2(CH2)3CH3 —(CH2)7CH3
149 —CH3 —CH2CO2H —CH3 —C(CH3)2(CH2)5CH3 —(CH2)7CH3
150 —CH3 —CH2CO2H —CH3
Figure USRE038970-20060207-C00038
 		—(CH2)7CH3
151 —CH3 —CH2CO2H —CH3
Figure USRE038970-20060207-C00039
 		—(CH2)7CH3
152 —CH3 —CH2CO2H —CH3 —NH(CH2)3CH3 —(CH2)5CH3
153 —CH3 —CH2CO2H —CH3 —NH(CH2)3CH3 —(CH2)7CH3
154 —CH3 —CH2CO2H —CH3 —NH(CH2)3CH3 —(CH2)9CH3
The 1H-NMR values of the compounds of the above Examples 126-154 are shown in the following.
Example 126: 0.70-1.00 (3H, br-t), 1.10-1.70 (8H, m), 1.35 (9H, s), 1.80-2.10 (2H, m), 2.10 (6H, s), 2.40-2.70 (4H, m), 2.80-2.90 (2H, m), 3.68 (2H, s), 7.35 (1H, br), 9.50 (2H, br).
Example 127: 0.70-1.00 (6H, br-t), 1.10-1.70 (5H, m), 1.35 (9H, s), 1.80-2.10 (2H, m), 2.10 (6H, s), 2.40-2.70 (4H, m), 2.80-2.90 (2H, m), 3.68 (2H, s), 7.35 (1H, br), 9.50 (2H, br).
Example 128: 0.70-1.00 (3H, br-t), 1.10-1.70 (10H, m), 1.35 (9H, s), 1.80-2.10 (2H, m), 2.10 (6H, s), 2.40-2.70 (4H, m), 2.80-2.90 (2H, m), 3.68 (2H, s), 7.35 (1H, br), 9.50 (2H, br).
Example 129: 0.80-1.70 (11H, m), 1.35 (9H, s), 1.80-2.10 (2H, m), 2.10 (6H, s), 2.40-2.70 (4H, m), 2.80-2.90 (2H, m), 3.68 (2H, s), 7.35 (1H, br), 9.50 (2H, br).
Example 130: 0.70-1.00 (6H, br-t), 1.10-1.70 (7H, m), 1.35 (9H, s), 1.80-2.10 (2H, m), 2.10 (6H, s), 2.40-2.70 (4H, m), 2.80-2.90 (21H, m), 3.68 (2H, s), 7.35 (1H, br), 9.50 (2H, br).
Example 131: 0.70-1.10 (3H, br-t), 1.10-1.70 (4H, m), 1.35 (9H, s), 1.80-2.10 (2H, m), 2.10 (6H, s), 2.40-2.70 (4H, m), 2.80-2.90 (2H, m), 3.30-3.60 (4H, m), 3.68 (2H, s), 7.35 (1H, br), 9.50 (2H, br).
Example 132: 0.70-1.10,(3H, br-t), 1.10-1.70 (4H, m), 1.35 (9H, s), 1.80-2.10 (2H, m), 2.10 (6H, s), 2.40-2.70 (4H, m), 2.80-2.90 (2H, m), 3.20-3.50 (4H, m), 3.68 (2H, s), 7.35 (1H, br), 9.50 (2H, br).
Example 133: 0.80-1.70 (13H, m), 1.35 (9H, s), 1.80-2.10 (2H, m), 2.10 (6H, s), 2.40-2.70 (4H, m), 2.80-2.90 (2H, m), 3.68 (2H, s), 7.35 (1H, br), 9.50 (2H, br).
Example 134: 0.70-1.00 (6H, br-t), 1.10-1.70 (9H, m), 1.35 (9H, s), 1.80-2.10 (2H, m), 2.10 (6H, s), 2.40-2.70 (4H, m), 2.80-2.90 (2H, m), 3.68 (2H, s), 7.35 (1H, br), 9.50 (2H, br).
Example 135: 0.70-1.10 (3H, br-t), 1.10-1.70 (6H, m), 1.35 (9H, s), 1.80-2.10 (2H, m), 2.10 (6H, s), 2.40-2.70 (4H, m), 2.80-2.90 (2H, m), 3.30-3.60 (4m, m), 3.68 (2H, s), 7.35 (1H, br), 9.50 (2H, br).
Example 136: 0.70-1.10 (3H, br-t), 1.10-1.70 (6H, m), 1.35 (9H, s), 1.80-2.l0 (2H, m), 2.10 (6H, s), 2.40-2.70 (4H, m), 2.80-2.90 (2H, m), 3.20-3.50 (4H, m), 3.68 (2H, s), 7.35 (1H, br), 9.50 (2H, br).
Example 137: 0.70-1.10 (1H, br-t), 1.10-1.70 (14H, m), 1.35 (9H, s), 1.80-2.10 (2H, m), 2.10 (6H, s), 2.40-2.70 (4H, m), 2.80-2.90 (2H, m), 3.68 (2H, s), 7.35 (1H, br), 9.50 (2H, br).
Example 138: 0.70-1.10 (3H, br-t), 1.10-1.70 (16H, m), 1.35 (9H, s), 1.80-2.10 (2H, m), 2.10 (6H, s), 2.40-2.70 (4H, m), 2.80-2.90 (2H, m), 3.68 (2H, s), 7.35 (1H, br), 9.50 (2H, br).
Example 139: 0.70-1.10 (3H, br-t), 1.10-1.70 (14H, m), 1.35 (9H, s), 1.80-2.10 (2H, m), 2.40 (2H, q), 2.43 (2H, q), 2.40-2.70 (4H, m), 2.80-2.90 (2H, m), 3.68 (2H, s), 7.35 (1H, br), 9.50 (2H, br).
Example 140: 0.70-1.10 (3H, br-t), 1.10-1.70 (18H, m), 1.35 (9H, s), 1.80-2.10 (2H, m), 2.40 (2H, q), 2.43 (2H, q), 2.40-2.70 (4H, m), 2.80-2.90 (2H, m), 3.68 (2H, s), 7.35 (1H, br), 9.50 (2H, br).
Example 141: 0.70-1.10 (3H, br-t), 1.10-1.70 (22H, m), 1.35 (9H, s), 1.80-2.10 (2H, m), 2.40 (2H, q), 2.43 (2H, q), 2.40-2.70 (4H, m), 2.80-2.90 (2H, m), 3.68 (2H, s), 7.35 (1H, br), 9.50 (2H, br).
Example 142: 0.70-1.10 (3H, br-t), 1.10-1.70 (8H, m), 1.35 (9H, s), 1.80-2.10 (2H, m), 2.40-2.70 (4H, m), 2.80-2.90 (2H, m), 3.52 (2H, s), 3.73 (3H, s), 7.35 (1H, br), 9.50 (2H, br).
Example 143: 0.70-1.10 (3H, br-t), 1.10-1.70 (12H, m), 1.35 (9H, s), 1.80-2.10 (2H, m), 2.40-2.70 (4H, m), 2.80-2.90 (2H, m), 3.52 (2H, s), 3.73 (3H, s), 3.77 (3H, s), 7.35 (1H, br), 9.50 (2H, br).
Example 144: 0.70-1.10 (3H, br-t), 1.10-1.70 (16H, m), 1.35 (9H, s), 1.80-2.10 (2H, m), 2.40-2.70 (4H, m), 2.80-2.90 (2H, m), 3.52 (2H, s), 3.73 (3H, s), 3.77 (3H, s), 7.35 (1H, br), 9.50 (2H, br).
Example 145: 0.70-1.10 (3H, br-t), 1.10-1.70 (8H, m), 1.35 (9H, s), 1.80-2.10 (2H, m), 2.17 (3H, s), 2.23 (3H, s), 2.40-2.70 (4H, m), 2.80-2.90 (2H, m), 4.65 (2H, s), 7.35 (1H, br), 9.50 (2H, br).
Example 146: 0.70-1.10 (3H, br-t), 1.10-1.70 (12H, m), 1.35 (9H, s), 1.80-2.10 (2H, m), 2.17 (3H, s), 2.23 (3H, s), 2.40-2.70 (4H, m), 2.80-2.90 (2H, m), 4.65 (2H, s), 7.35 (1H, br), 9.50 (2H, br).
Example 147: 0.70-1.10 (3H, br-t), 1.10-1.70 (16H, m), 1.35 (9H, s), 1.80-2.10 (2H, m), 2.17 (3H, s), 2.23 (3H, s), 2.40-2.70 (4H, m), 2.80-2.90 (2H, m), 4.65 (2H, s), 7.35 (1H, br), 9.50 (2H, br).
Example 148: 0.70-1.10 (6H, br-t), 1.10-1.70 (18H, m), 1.35 (6H, s), 1.80-2.10 (2H, m), 2.10 (6H, s), 2.40-2.70 (4H, m), 2.80-2.90 (2H, m), 3.68 (2H, s), 7.35 (1H, br), 9.50 (2H, br).
Example 149: 0.70-1.10 (6H, br-t), 1.10-1.70 (22H, m), 1.35 (6H, s), 1.80-2.10 (2H, m), 2.10 (6H, s), 2.40-2.70 (4H, m), 2.80-2.90 (2H, m), 3.68 (2H, s), 7.35 (1H, br), 9.50 (2H, br).
Example 150: 0.70-1.10 (3H, br-t), 1.10-2.00 (27H, m), 2.10 (6H, s), 2.40-2.70 (4H, m), 2.80-2.90 (2H, m), 3.68 (2H, s), 7.35 (1H, br), 9.50 (2H, br).
Example 151: 0.70-1.10 (3H, br-t), 1.10-1.70 (12H, m), 1.80-2.10 (2H, m), 2.10 (6H, s), 2.40-2.70 (4H, m), 2.80-2.90 (2H, m), 3.53 (2H, s), 3.68 (2H, s), 7.30 (5H, s), 7.35 (1H, br), 9.50 (2H, br).
Example 152: 0.70-1.10 (6H, br-t), 1.10-1.70 (12H, m), 1.80-2.10 (2H, m), 2.10 (6H, s), 2.40-2.90 (8H, m), 3.68 (2H, s), 7.35 (1H, br), 9.50 (2H, br).
Example 153: 0.70-1.10 (6H, br-t), 1.10-1.70 (16H, m), 1.80-2.10 (2H, m), 2.10 (6H, s), 2.40-2.90 (8H, m), 3.68 (2H, s), 7.35 (1H, br), 9.50 (2H, br).
Example 154: 0.70-1.10 (6H, br-t), 1.10-1.70 (20H, m), 1.80-2.10 (2H, m), 2.10 (6H, s), 2.40-2.90 (8H, m), 3.68 (2H, s), 7.35 (1H, br), 9.50 (2H, br).
EXAMPLE 155 N-(1-octyl-5carboxy-6-methylindolin-7-yl)-2,2-dimethylpropanamide
  • (1) 5-Bromo-7-methyl-7-nitroindoline (3.6 g) was dissolved in N,N-dimethylformamide (36 ml), and sodium hydride (677 mg) was added, which was followed by stirring at room temperature for 0.5 hr. 1-Iodooctane (3.4 g) was added to the reaction mixture and the mixture was stirred at the same temperature for 24 hr. Ethyl acetate (200 ml) was added to the reaction mixture, and the mixture was washed with water and, dried over anhydrous sodium sulfate. Ethyl acetate was evaporated under reduced pressure. The residue was purified by gel column chromatography (eluent: ethyl acetate/n-hexane=1/100-1/50) to give 4.0 g of oily 1octyl-5-bromo-6-methyl-7-nitroindoline.
    IR (Nujol)cm−1; 1610, 1568.
    1H-NMR (CDCl3) δ;
    0.88 (3H, br-t, J=7 Hz, —(CH2)7CH3), 1.00-1.70 (12H, m, —CH2(CH2)6—), 2.25 (3H, s, indoline C8—CH3) 2.93 (2H, t, J=8 Hz, indoline C3—H2), 2.94 (2H, t, J=7 Hz, >NCH2—), 3.57 (2H, t, J=8 Hz, indoline C2—H2), 7.19 (1H, s, indoline C4—H).
  • (2) 1-Octyl-5-bromo-6-methyl-7-nitroindoline (4.0 g) was dissolved in N-methylpyrrolidone (40 ml), and copper cyanide (1.9 g) was added, which was followed by stirring at 190° C. for 1 hr. Ethyl acetate (100 ml) and water (100 ml) were added to the reaction mixture. The insoluble matter was filtered off. The ethyl acetate layer was washed with water and dried over anhydrous sodium sulfate. Ethyl acetate was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: ethyl acetate/n-hexane=1/5-1/3) to give 2.4 g of oily 1-octyl-5-cyano-6-methyl-7nitroindoline.
    IR (Nujol)cm−1; 2214. 1620.
    1H-NMR (CDCl3) δ;
    0.88 (3H, br-t, J=7 Hz, —(H2)2CH3), 1.00-1.70 (12H, m, —CH2(CH2)6—), 2.38 (3H, s, indoline C6—CH3), 3.03 (2H, t, J=8 Hz, indoline C3—H2), 3.04 (2H, t, J=7 Hz, >NCH2—), 3.73 (2H, t, J=8 Hz, indoline C2—H2), 7.15 (1H, s, indoline C4—H).
  • (3) 1-octyl-5-cyano-6-methyl-7-nitroindoline (2.4 g) was dissolved in n-propanol and a solution of NaOH (3.0 g) in water (10 ml) was added, which was followed by refluxing for 20 hr. n-Propanol was evaporated under reduced pressure and ethyl acetate (100 ml) was added to the residue. The mixture was washed with water and dried over anhydrous sodium sulfate. Ethyl acetate was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: ethyl acetate/benzene/1/5-1/1) to give 1.4 g of 1-octyl-5-carboxy-6-methyl-7-nitroindoline as crystals.
    IR (Nujol)cm−1; 1679, 1620.
    1H-NMR (CDCl3) δ;
    0.88 (3H, br-t, J=7 Hz, —(CH2)7CH3), 1.00-1.70 (12H, m, —CH2(CH2)6—), 2.47 (3H, s, indoline C6—CH3), 3.02 (2H, t, J=8 Hz, indoline C3—H2), 3.03 (2H, t, J=7 Hz, >NCH2—), 3.69 (2H, t, J=8 Hz, indoline C2—H2), 5.00 (1H, br, —O2H), 7.73 (1H, s, indoline C3—H).
  • (4) 1-octyl-5-carboxy-6-methyl-7-nitroindoline (1.4 g) was dissolved in methanol (30 ml), and conc. sulfuric acid (4.1 g) was added, which was followed by refluxing for 4 hr. Methanol was evaporated under reduced pressure. Ethyl acetate (100 ml) was added to the residue. The mixture was washed with water and dried over anhydrous sodium sulfate. Ethyl acetate was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: chloroform/methanol=1/0-10/1) to give 750 mg of 1-octyl-5-methoxycarbonyl-6-methyl-7-nitroindoline as crystals.
    IR (Nujol) cm−1; 1679, 1620.
    1H-NMR (CDCl3) δ;
    0.88 (3H, br-t, J=7 Hz, —(CH2)7CH—), 1.00-1.70 (12H, m, —CH2(CH2)6—), 2.43 (3H, s, indoline C6—CH,), 3.00 (2H, t, J=8 Hz, indoline C3—H2), 3.02 (2H, t, J=7 Hz, >NCH2), 3.66 (2H, t, J=8 Hz, indoline C2—H2), 3.82 (3H, s, —CO2CH,), 7.62 (1H, s, indoline C2—H).
  • (5) 1-octyl-5-methoxycarbonyl-6-methyl-7-nitroindoline (750 mg) was dissolved in ethanol (50 ml), and 10% palladium-carbon (150 mg), which was followed by hydrogenation at 40° C. for 15 hr. 10% Palladium-carbon was filtered off and ethanol was evaporated under reduced pressure. Chloroform (100 ml) was added to the residue. The mixture was washed with water and dried over anhydrous sodium sulfate. Chloroform was evaporated under reduced pressure. The obtained 1-octyl-7-amino-5-methoxycarbonyl-6-methylindoline was dissolved in chloroform (10 ml). Pivaloyl chloride (310 mg) and triethylamine (286 mg) were added under ice-cooling, which was followed by stirring at room temperature for 1 hr. Chloroform (50 ml) was added to the reaction mixture. The mixture was washed successively with 5% aqueous citric acid and water, and dried over anhydrous sodium sulfate. Chloroform was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (eluent: chloroform/methanol=1/0-20/1) to give 580 mg of oily N-(1-octyl-5-methoxycarbonyl-6-methylindolin-7-yl)-2,2-dimethylpropanamide.
    IR (Nujol)cm−1; 1708, 1651.
    1H-NMR (CDCl3) δ;
    0.87 (3H, br-t), 1-7 Hz, —(CH2)7(CH3), 1.00-1.70 (12H, m, —CH2(CH2)6—), 1.34 (9H, s, —C(CH3)3), 2.39 (3H, s, indoline C6—CH,), 2.93 (2H, t, J=8 Hz, indoline C3—H2), 3.25 (2H, t, J=7 Hz, >NCH2), 3.51 (2H, t, J=8 Hz, indoline C2—H 2), 3.79 (3H, s, —CO2CH3), 6.76 (1H, br, —CONH—), 7.55 (1H, s, indoline C4—H).
  • (6) N-(1-octyl-5-methoxycarbonyl-6-methylindolin-7-yl)-2,2-dimethylpropanamide (580 mg) was dissolved in methanol (10 ml) and a solution of NaOH (290 mg) in water (5 ml) was added, which was followed by stirring at 60° C. for 4 hr. Methanol was evaporated under reduced pressure. Water (50 ml) was added to the residue and the mixture was washed with ethyl acetate (20 ml). The aqueous layer was adjusted to pH 6-7 with 2N sulfuric acid and extracted with chloroform (100 ml). The chloroform layer was washed with water and dried over anhydrous sodium sulfate. Chloroform was evaporated under reduced pressure to give 380 mg of the title compound.
    IR (Nujol)cm−1; 1669, 1645, 1615.
    1H-NMR (CDCl3) δ;
    0.79 (3H, br, —(CH2)7CH3), 0.80-1.80 (12H, m, —CH; (CH2)6), 134 (9H, s, —C(CH3)3), 2.38 (3H, s, indoline C6—H3), 2.94 (2H, t, J=8 Hz, indoline C3—H2) 3.27 (2H, t, J=7 Hz, >NCH2—), 3.54 (2H, t, J=8 Hz, indoline C2—H2), 6.80 (2H, br, —CONH—, —CO2H), 7.67 (1H, s, indoline C4—H).
EXAMPLE 156-160
The compounds of Table 13 were obtained according to the method of the above Example 155.
TABLE 13
Figure USRE038970-20060207-C00040
Example R1 R2 R3 R7 R6
156 —H —CO2H —CH3 —C(CH3)3 —(CH2)5CH3
157 —H —CO2H —CH3 —C(CH3)3 —(CH2)9CH3
158 —CH3 —CO2H —CH3 —C(CH3)3 —(CH2)5CH3
159 —CH3 —CO2H —CH3 —C(CH3)3 —(CH2)7CH3
160 —CH3 —CO2H —CH3 —C(CH3)3 —(CH2)9CH3
The 1H-NMR values of the compounds of the above Examples 156-160 are shown in the following.
Example 156: 0.79 (3H, br-t), 0.80-1.80 (8H, m), 1.34 (9H, s), 2.38 (3H, s), 2.94 (2H, t), 3.27 (2H, t), 3.54 (2H, t), 6.80 (2H, br), 7.67 (1H, s).
Example 157: 0.79 (3H, br-t), 0.80-1.80 (16H, m), 1.34 (9H, s), 2.38 (3H, s), 2.94 (2H, t), 3.27 (2H, t), 3.54 (2H, t), 6.80 (2H, br), 7.67 (1H, s).
Example 158: 0.79 (3H, br-t), 0.80-1.80 (8H, m), 1.33 (9H, s), 2.40 (3H, s), 2.45 (3H, s), 2.95 (2H, t), 3.26 (2H, t), 3.54 (2H, t), 6.80 (2H, br).
Example 159: 0.79 (3H, br-t), 0.80-1.80 (12H, m), 1.33 (9H, s), 2.40 (3H, s), 2.45 (3H, s), 2.95 (2H, t), 3.26 (2H, t), 3.54 (2H, t), 6.80 (2H, br).
Example 160: 0.79 (3H, br-t), 0.80-1.80 (16H, m), 1.33 (9H, s), 2.40 (3H, s), 2.45 (3H, s), 2.95 (2H, t), 3.26 (2H, t), 3.54 (2H, t), 6.80 (2H, br).
With the aim of demonstrating the superior properties of the compound of the present invention, ACAT inhibitory activity, serum total cholesterol reducing effect, in vitro plasma lipoperoxidation inhibitory activity, ex vivo plasma lipoperoxidation inhibitory, activity, solubility in water at pH 6.8 and plasma concentration on oral administration were determined
Experimental Example 1 ACAT Inhibitory Activity
A high cholesterol feed [a feed added with cholesterol (1%), Clea Japan, Inc.] was fed to male Japanese white rabbits weighing 2-2.5 kg at 100 g per day and the rabbits were bred for 4 weeks. The rabbits were killed by bleeding under anesthesia and small intestine was removed. The mucosal membrane of small intestine was peeled, collected and homogenated. The homogenate was centrifuged at 4° C. and 10,000 rpm for 15 min. The obtained supernatant was further centrifuged at 4° C. and 41,000 rpm for 30 minutes to give microsomal fractions. The microsomal suspension as an enzyme sample, dimethyl sulfoxide (DMSO, 5μl) or a test compound dissolved in DMSO (test compound solution 5μl), and reaction substrate [1-14C] oleoyl CoA were added to 0.15M phosphate buffer to the total amount of 500 μl. After incubation at 37° C. for 7 minutes, a chloroform-methanol mixture was added to slop the reaction. Water was added thereto and mixed, and chloroform layer was separated. The solvent was evaporated to dryness, and the residue was it-dissolved in a-hexane. The mixture was subjected to thin layer chromatography using a silica gel plate. The spots of cholesteryl oleate on the silica gel plate were scraped, and quantitatively assayed on a liquid scintillation counter. The ACAT inhibitory activity of the test compound was expressed as a proportion (%) of inhibition of cholesterol oleate, namely, the proportion of inhibition of cholesteryl oleate production as compared to control, the results of which are shown in Table 14.
TABLE 14
Test compound ACAT inhibition (%)
Example 1 99.2
Example 3 92.5
Example 4 93.6
Example 36 94.0
Example 40 92.7
Example 76 94.7
Example 116 92.0
Example 120 92.3
Example 121 92.5
Example 122 92.0
Example 125 93.0
YM-750 92.0
YM-750: 1-cycloheptyl-1-[(2-fluorenyl)methyl]-3-(2,4,6-trimethyl-phenyl) urea
Experimental Example 2 Serum Total Cholesterol Reducing Effect
Mile Wister rats weighing 180-200 g were bred under free access to a high cholesterol feed [added with cholesterol (1%), cholic acid (0.5%) and coconut oil (10%), Clea Japan, Inc.] for 3 days, during which period a test compound (3 mg/kg and 10 mg/kg) suspended in 5% gum arabic solution was forcibly administered once a day orally for 3 days. Only 5% gum arabic solution was administered to control animals. After final administration, the test animals were fasted and blood was taken 5 hours later. The serum total cholesterol level was determined using a commercially available assay lit (cholesterol-CII-Test Wako, Wako Pure Chemical Industries, Ltd.). The activity of the test compound was expressed as a proportion (%) of reduction of serum total cholesterol level, namely, the proportion of reduction of serum total cholesterol as compared to control, the results of which are shown in Table 15.
TABLE 15
Reduction (%) of serum total cholesterol
Test compound 3 mg/kg/day 10 mg/kg/day
Example 1 52.8 57.1
Example 3 54.2 61.2
Example 4 58.8 57.5
Example 18 45.1 56.6
Example 25 45.0 52.3
Example 36 60.0 58.9
Example 40 51.3 56.2
Example 71 26.5 52.3
Example 81 31.7 53.8
Example 116 26.5 50.9
Example 120 45.8 44.6
Example 121 87.8 48.1
Example 122 88.2 50.0
Example 125 30.2 47.9
Example 155 55.2 58.5
Example 159 53.8 57.5
YM-750 37.7 46.4
YM-750: 1-cycloheptyl-1-[(2-fluorenyl)methyl]-3-(2,4,6-trimethyl-phenyl) urea
Experimental Example 3 In vitro Plasma Lipoperoxidation Inhibitory Activity
Under ether anesthesia, blood was taken from male Wister rats weighing 160-190 g that had been fasted for 16 hours, and heparinized plasma was separated by conventional method. DMSO (10 μl) or a test compound (final concentration 10−5M) dissolved in DMSO (test compound solution 10 μl) was added to plasma (1.0 ml), and the mixture was incubated at 37° C. for 5 minutes. Distilled water (10 μl) or aqueous solution (10 μl) of (copper sulfate (final concentration 1M) was added, followed by incubation at 37° C. for 4 minutes. After incubation, the concentration of lipid peroxide in the sample was determined using a commercially available assay kit (Lipoperoxide Test Wako, Wako Pure Chemical industries, Ltd.). Specifically, lipid peroxide in the sample was allowed to develop color by thiobarbiturate method and assayed as malondialdehyde. The activity of the test compound was expressed as a proportion (%) of inhibition of malondialdehyde production, namely, the proportion of inhibition of malondialdehyde production as compared to control, the results of which are shown in Table 16.
TABLE 16
Test compound Inhibition (%) of plasma lipoperoxidation
Example 1 51.7
Example 3 49.2
Example 4 51.2
Example 11 44.5
Example 18 44.0
Example 25 63.5
Example 36 41.5
Example 71 48.1
Example 76 51.7
Example 81 47.1
Example 116 45.5
Example 121 41.6
Example 125 48.0
Example 155 47.7
Example 159 48.3
Experimental Example 4 Ex vivo Plasma Lipoperoxidation Inhibitory Activity
A test compound suspended in 5% gum arabic solution was forcibly administered orally to male Wister rats weighing 160-190 g that had been fasted for 16 hr. Only 5% gum arabic solution was administered to control animals. At 1 hour after administration, blood was taken under ether anesthesia and heparinized plasma was separated by conventional method. The plasma (1.0 ml) was processed in the same manner as in Experimental Example 3 and the amount of produced malondialdehyde was determined. The activity of the test compound was expressed as a proportion (%) of inhibition of malondialdehyde production, namely, the proportion of inhibition of malondialdehyde production as compared to control, the results of which are shown in Table 17.
TABLE 17
Inhibition (%) of plasma lipoperoxidation
Dose Example 4 Example 18 Example 36 Probucol
 10 mg/kg 39.0 27.1 41.6 —
100 mg/kg — — — 15.4
Probucol: 4,4-isopropylidenedithiobis(2,6-di-t-butylphenol)
Experimental Example 5 Solubility
A pulverized test compound (10 mg) was added to buffer (1 ml, pH 6.8), and the mixture was shaken for 1 br at 25° C. The mixture was passed through a membrane filter and the concentration of the test compound in the filtrate was determined by high performance liquid chromatography, the results of which are shown in Table 18.
TABLE 18
Test compound Solubility (mg/ml)
Example 4 6.9
Example 18 7.3
Example 25 0.8
Example 36 4.2
Example 71 0.1
YM-750 <0.01
YM-750: 1-cycloheptyl-1-[(2-fluorenyl)methyl]-3-(2,4,6-trimethyl-phenyl) urea
Experimental Example 6 Oral Administration
A test compound (30 mg)kg) suspended in 5% gum arabic solution was forcibly administered orally to male Wister rats weighing 200-250 g that had been fasted for 16 hr. At 0.5, 1, 2, 4 and 6 hours after administration, blood was taken and heparinized plasma was separated by conventional method. The concentration of the test compound in the plasma was determined by high performance liquid chromatography, the results of which are shown in Table 19.
TABLE 19
Test compound Highest concentration in plasma (μg/ml)
Example 4 1.4
Example 36 2.2
Experimental Example 7 Oral Administration
A test compound (30 mg/kg) suspended in 5% gum arabic solution was forcibly administered orally to male SD rats weighing 200-250 g that had been fasted for 16 hr. At 0.5, 1, 2, 4 and 6 hours after administration, blood was taken and heparinized plasma was separated by conventional method. The concentration of the test compound in the plasma was determined by high performance liquid chromatography, the results of which are shown in Table 20.
TABLE 20
Test compound Highest concentration in plasma (μg/ml)
Example 4 13.6
Example 36 12.2

Claims (30)

1. A heterocyclic compound of the formula (I)
Figure USRE038970-20060207-C00041
wherein
one of R1, R2 and R3 is hydroxy, carboxy, alkoxycarbonyl, a group of the formula —NR9R10 wherein R9 and R10 are each independently hydrogen atom or lower alkyl, or alkyl or alkenyl substituted by hydroxy, carboxy, sulfonic add group or phosphoric acid group, alkoxy-carbonyl or a group of the formula —NR9R10 wherein R9 and R10 are each independently hydrogen atom or lower alkyl, and the other two are each independently hydrogen atom, lower alkyl or lower alkoxy;
either R3 or R4 is a group of the formula —NHCOR7 wherein R7 is alkyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl or a group of the formula —NHR8 wherein R8 is alkyl, cycloalkyl, cycloalkylalkyl, aryl or arylalkyl, and the other is hydrogen atom, lower alkyl or lower alkoxy;
R6 is alkyl, alkenyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, cycloalkylalkyl or arylalkyl; and Z is
Figure USRE038970-20060207-C00042
or a pharmaceutically acceptable salt thereof, provided that when one of R1, R2 and R3 its carboxy or alkoxycarbonyl, Z should be a group of the formula
Figure USRE038970-20060207-C00043
2. The heterocyclic compound of claim 1, wherein, in the formula (I), one of R1, R2 and R3 is alkyl or alkenyl substituted by hydroxy, carboxy, sulfonic acid group or phosphoric acid group, alkoxycarbonyl or a group of the formula —NR9R10 wherein R9 and R10 are each independently hydrogen atom or loaner alkyl, and the other two are each independently hydrogen atom, lower alkyl or lower alkoxy, or a pharmaceutically acceptable salt thereof.
3. The heterocyclic compound of claim 2, wherein, in the formula (I), Z is
Figure USRE038970-20060207-C00044
or a pharmaceutically acceptable salt thereof.
4. The heterocyclic compound of claim 3, wherein, in the formula (I), one of R1, R2 and R3 is alkyl substituted by hydroxy, carboxy, alkoxycarbonyl or a group of the formula —NR9R10 wherein R9 and R10 are each independently lower alkyl, and the other two are each independently hydrogen atom, lower alkyl or lower alkoxy, and either R3 or R4 is a group of the formula —NHCOR7 wherein R7 is alkyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, cycloalkylalkyl aryl, arylalkyl or a group of the formula —NHR8 wherein R8 is alkyl, and the other is hydrogen atom, lower alkyl or lower alkoxy, or a pharmaceutically acceptable salt thereof.
5. The heterocyclic compound of claim 4, wherein, in the formula (I), R2 and R3 are each independently hydrogen atom, lower alkyl or lower alkoxy, either R2 or R5 is alkyl substituted by hydroxy, carboxy, alkoxycarbonyl or a group of the formula —NR9R10 wherein R9 and R10 are each independently lower alkyl, and the other is hydrogen atom, lower alkyl or lower alkoxy, and R4 is a group of the formula —NHCOR7 wherein R7 is alkyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, cycloalkylalkyl, a arylalkyl or a group of the formula —NHR8 wherein R8 is alkyl, or a pharmaceutically acceptable salt thereof.
6. The heterocyclic compound of claim 5, wherein, in the formula (I), either R2 or R3 is alkyl substituted by hydroxy, carboxy, alkoxycarbonyl or a group of the formula —NR9R10 wherein R9 and R10 are each independently lower alkyl, and the other is hydrogen atom, or a pharmaceutically acceptable salt thereof.
7. The heterocyclic compound of claim 6, wherein, in the formula (I), R1 and R3 are each independently hydrogen atom or lower alkyl, either R2 or R5 is alkyl substituted by hydroxy, carboxy, alkoxycarbonyl or a group of the formula —NR9R10 wherein R9 and R10 are each independently lower alkyl, and the others hydrogen atom, R4 is a group of the formula —NHCOR7 wherein R7 is alkyl, cycloalkyl or cycloalkylalkyl, and R6 is alkyl, cycloalkyl or cycloalkylalkyl, or a pharmaceutically acceptable salt thereof.
8. The heterocyclic compound of claim 7, wherein, in the formula (I), R2 is alkyl substituted by hydroxy, carboxy, alkoxycarbonyl or a group of the formula —NR9R10 wherein R9 and R10 are each independently lower alkyl, and R5 is hydrogen atom, or a pharmaceutically acceptable salt thereof.
9. The heterocyclic compound of claim 8, which is represented by the formula (IIa)
Figure USRE038970-20060207-C00045
wherein R1a is hydrogen atom or lower alkyl, R3a is lower alkyl, R2a is alkyl substituted by hydroxy or carboxy, R4a is a group of the formula —NHCOR7a wherein R7a is alkyl, cycloalkyl or cycloalkylalkyl, and R6a is alkyl, cycloalkyl or cycloalkylalkyl, or a pharmaceutically acceptable salt thereof.
10. The heterocyclic compound of claim 9, wherein, in the formula (IIa), R3a is hydrogen atom or lower alkyl, R3a lower alkyl, R2a is alkyl substituted by hydroxy or carboxy, R4a is a group of the formula —NHCOR7a wherein R7a is alkyl, and R6a is alkyl, or a pharmaceutically acceptable salt thereof.
11. The A heterocyclic compound of claim 10, wherein the compound of the formula (IIa) is selected from the group consisting of:
(1) N-(1-hexyl-5-carboxythyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide,
(1) N-( 1 -hexyl- 5 -carboxymethyl- 4,6 -dimethylindolin- 7 -yl)- 2,2 -dimethylpropanamide,
(2) N-(1-heptyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide,
(3) N-(1-octyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide,
(4) N-(1-nonyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide,
(5) N-(1-decyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide,
(6) N-(1-undecyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide, and
(7) N-(1-dodecyl-5-carboxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide,
(8) N-(1-hexyl-5-hydroxymethyl-6-methylindolin-7-yl)-2,2-dimethylpropanamide,
(9) N-(1-hexyl-5-hydroxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide,
(10) N-(1-heptyl-5-hydroxymethyl-6-methylindolin-7-yl)-2,2-dimethylpropanamide,
(11) N-(1-heptyl-5-hydroxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide,
(12) N-(1-octyl-5-hydroxymethyl-6-methylindolin-7-yl)-2,2-dimethylpropanamide, and
(13) N-(1-octyl-5-hydroxymethyl-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide,
or a pharmaceutically acceptable salt thereof.
12. The heterocyclic compound of claim 1, wherein, in the formula (I), one of R1, R2 and R3 is hydroxy, carboxy, alkoxycarbonyl or a gripof the formula —NR 9R10 wherein R9 and R10 are each, independently hydrogen atom or lower alkyl, and the other two are each independently hydrogen atom, lower alkyl or lower alkoxy, or a pharmaceutically acceptable salt thereof.
13. The heterocyclic compound of claim 12, which is represented by the formula (IIc)
Figure USRE038970-20060207-C00046
wherein one of R1c, R2c and R3c is hydroxy, carboxy, alkoxycarbonyl or a group of the formula —NR9cR10c wherein R9c and R10c are each independently hydrogen atom or lower alkyl and the other two are each independently hydrogen atom, lower alkyl or lower alkoxy, either R3c or R4c is a group of the formula —NHCOR7c, wherein R7c is alkyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl or a group of the formula —NHR8c wherein R8c is alkyl, cycloalkyl, cycloalkylalkyl, aryl or arylalkyl and the other is hydrogen atom, lower alkyl or lower alkoxy, and R6c is alkyl, alkenyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, cycloalkylalkyl or arylalkyl, or a pharmaceutically acceptable salt thereof.
14. The heterocyclic compound of claim 13, wherein, in the formula (IIc), R1c and R3c are each independently hydrogen atom, lower alkyl or lower alkoxy, R5c is carboxy, R4c is a group of the formula —NHCOR7c wherein R7c is alkyl, cycloalkyl or cycloalkylalkyl, R6c is hydrogen atom, and R6c is alkyl, cycloalkyl or cycloalkylalkyl, or a pharmaceutically acceptable salt thereof.
15. The heterocyclic compound of claim 14, wherein, in the formula (IIc), R1c is hydrogen atom or lower alkyl, R3c is lower alkyl, R2c is carboxyl, R4c is a group of the formula —NHCOR7c wherein R7c is alkyl, R5c is hydrogen atom, and R6c is alkyl, or a pharmaceutically acceptable salt thereof.
16. The heterocyclic compound of claim 15, wherein the compound of the formula (IIc) is selected from the group consisting of:
(1) N-(1-hexyl-5-carboxy-6-methylindolin-7-yl)-2,2-dimethylpropanamide,
(2) N-(1-octyl-5-carboxy-6-methylindolin-7-yl)-2,2-dimethylpropanamide,
(3) N-(1-decyl-5-carboxy-6-methylindolin-7-yl)-2,2-dimethylpropanamide,
(4) N-(1-hexyl-5-carboxy-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide,
(5) N-(1-octyl-5-carboxy-4,6-dimethylindolin-7-yl)-2,2-dimethylpropanamide, and
(6) N-(1-decyl-5-carboxy-4,6dimethylindolin-7-yl)-2,2-dimethylpropanamide,
or a pharmaceutically acceptable salt thereof.
17. A pharmaceutical composition comprising an effective amount of a heterocyclic compound of claim 1 11 or a pharmaceutically acceptable salt thereof.
18. A method of inhibiting acyl-CoA:cholesterol acyl-transferase in a patient in need of same which comprises administering to such patient the composition of claim 17.
19. A method of inhibiting lipoperoxidation in a patient in need of same which comprises administering to such patient the composition of claim 17.
20. The heterocyclic compound of claim 11 wherein the compound is in the form of a pharmaceutically acceptable salt which is an acid addition malt with an acid selected from the group consisting of hydrochloric acid, sulfuric acid, phosphoric acid and nitric acid.
21. The heterocyclic compound of claim 11, which is N-( 1 -hexyl- 5 -carboxymethyl- 4,6 -dimethylindolin- 7 -yl)- 2,2 -dimethylpropanamide or its pharmaceutically acceptable salt.
22. The heterocyclic compound of claim 11, which is N-( 1 -heptyl- 5 -carboxymethyl- 4,6 -dimethylindolin- 7 -yl)- 2,2 -dimethylpropanamide or its pharmaceutically acceptable salt.
23. The heterocyclic compound of claim 11, which is N-( 1 -octyl- 5 -carboxymethyl- 4,6 -dimethylindolin- 7 -yl)- 2,2 -dimethylpropanamide or its pharmaceutically acceptable salt.
24. The heterocyclic compound of claim 11, which is N-( 1 -nonyl- 5 -carboxymethyl- 4,6 -dimethylindolin- 7 -yl)- 2,2 -dimethylpropanamide or its pharmaceutically acceptable salt.
25. The heterocyclic compound of claim 11, which is N-( 1 -decyl- 5 -carboxymethyl- 4,6 -dimethylindolin- 7 -yl)- 2,2 -dimethylpropanamide or its pharmaceutically acceptable salt.
26. The heterocyclic compound of claim 11, which is N-( 1 -undecyl- 5 -carboxymethyl- 4,6 -dimethylindolin- 7 -yl)- 2,2 -dimethylpropanamide or its pharmaceutically acceptable salt.
27. The heterocyclic compound of claim 11, which is N-( 1 -dodecyl- 5 -carboxymethyl- 4,6 -dimethylindolin- 7 -yl)- 2,2 -dimethylpropanamide or its pharmaceutically acceptable salt.
28. The heterocyclic compound of claim 11, which is a hydrochloric acid addition salt of N-( 1 -octyl- 5 -carboxymethyl- 4,6 -dimethylindolin- 7 -yl)- 2,2 -dimethylpropanamide.
29. The heterocyclic compound of claim 11, which is a sulfuric acid addition salt of N-( 1 -octyl- 5 -carboxymethyl- 4,6 -dimethylindolin- 7 -yl)- 2,2 -dimethylpropanamide.
30. The heterocyclic compound of claim 11, which is a nitric acid addition salt of N-( 1 -octyl- 5 -carboxymethyl- 4,6 -dimethylindolin- 7 -vl)- 2,2 -dimethylpropanamide.
US10/609,224 1995-10-05 1996-09-30 Indolyl or indolinyl derivatives and medicinal use thereof as ACAT or lipid peroxidation inhibitors Expired - Fee Related USRE38970E1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP25908295 1995-10-05
JP5801896 1996-03-14
JP19433196 1996-07-24
US09/051,202 US6063806A (en) 1995-10-05 1996-09-30 Indolyl or indolinyl derivatives and medicinal use thereof as ACAT or lipid peroxidation inhibitors
PCT/JP1996/002852 WO1997012860A1 (en) 1995-10-05 1996-09-30 Novel heterocyclic derivatives and medicinal use thereof

Publications (1)

Publication Number Publication Date
USRE38970E1 true USRE38970E1 (en) 2006-02-07

Family

ID=27296460

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/051,202 Ceased US6063806A (en) 1995-10-05 1996-09-30 Indolyl or indolinyl derivatives and medicinal use thereof as ACAT or lipid peroxidation inhibitors
US10/609,224 Expired - Fee Related USRE38970E1 (en) 1995-10-05 1996-09-30 Indolyl or indolinyl derivatives and medicinal use thereof as ACAT or lipid peroxidation inhibitors
US09/506,839 Expired - Fee Related US6200988B1 (en) 1995-10-05 2000-02-18 Heterocyclic derivatives and pharmaceutical use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/051,202 Ceased US6063806A (en) 1995-10-05 1996-09-30 Indolyl or indolinyl derivatives and medicinal use thereof as ACAT or lipid peroxidation inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
US09/506,839 Expired - Fee Related US6200988B1 (en) 1995-10-05 2000-02-18 Heterocyclic derivatives and pharmaceutical use thereof

Country Status (20)

Country Link
US (3) US6063806A (en)
EP (1) EP0866059B1 (en)
KR (1) KR100388345B1 (en)
CN (2) CN1097043C (en)
AT (1) ATE210116T1 (en)
BR (1) BR9610846A (en)
CZ (1) CZ292632B6 (en)
DE (1) DE69617731T2 (en)
DK (1) DK0866059T3 (en)
ES (1) ES2164920T3 (en)
HK (2) HK1015781A1 (en)
HU (1) HUP9900617A3 (en)
IL (1) IL123939A (en)
NO (1) NO310818B1 (en)
NZ (1) NZ318874A (en)
PL (1) PL190034B1 (en)
PT (1) PT866059E (en)
TR (1) TR199800655T2 (en)
TW (1) TW429250B (en)
WO (1) WO1997012860A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3720395B2 (en) * 1994-09-20 2005-11-24 京都薬品工業株式会社 Novel heterocyclic derivative, production method thereof and pharmaceutical use thereof
AR008331A1 (en) * 1997-01-23 1999-12-29 Smithkline Beecham Corp ANTAGONIST COMPOUNDS OF AN IL-8 RECEPTOR, USE OF THE SAME FOR THE MANUFACTURE OF MEDICINES, PROCEDURE FOR THEIR OBTAINING, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
US5929250A (en) * 1997-01-23 1999-07-27 Smithkline Beecham Corporation IL-8 receptor antagonists
AR015425A1 (en) * 1997-09-05 2001-05-02 Smithkline Beecham Corp BENZOTIAZOL COMPOUNDS, PHARMACEUTICAL COMPOSITION CONTAINING THEM, ITS USE IN THE MANUFACTURE OF A MEDICINAL PRODUCT, PROCEDURE FOR PREPARATION, INTERMEDIARY COMPOUNDS AND PROCEDURE FOR PREPARATION
AU5265599A (en) 1998-04-08 1999-11-01 Takeda Chemical Industries Ltd. Amine compounds, their production and their use as somatostatin receptor antagonists or agonists
CA2338741A1 (en) * 1998-07-23 2000-02-03 Smithkline Beecham Corporation Il-8 receptor antagonists
FR2783519B1 (en) * 1998-09-23 2003-01-24 Sod Conseils Rech Applic NOVEL AMIDINE DERIVATIVES, THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2002020009A1 (en) * 2000-09-01 2002-03-14 Sankyo Company, Limited Medicinal compositions
TW200600497A (en) * 2001-02-02 2006-01-01 Sankyo Co Preparation of indoline derivative
WO2002072147A1 (en) * 2001-03-14 2002-09-19 Sankyo Company, Limited Medicinal compositions containing bile acid transporter inhibitor
EP2335700A1 (en) * 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
BR0212254A (en) * 2001-08-28 2004-10-19 Sankyo Co Pharmaceutical Composition
JP2004002365A (en) * 2002-04-05 2004-01-08 Sankyo Co Ltd Pharmaceutical composition composed of acat inhibitor and insulin-resistant improving agent
US20050119314A1 (en) * 2002-04-05 2005-06-02 Sankyo Company, Limited Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent
KR20040099394A (en) * 2002-04-05 2004-11-26 상꾜 가부시키가이샤 Medicinal composition comprising acat inhibitor and insuline resistance improving agent
AU2003252638B8 (en) * 2002-07-17 2009-03-05 Kyoto Pharmaceutical Industries, Ltd. Novel indoline compound and medicinal use thereof
US20050192245A1 (en) * 2002-07-18 2005-09-01 Sankyo Company, Limited Medicinal composition for treating arteriosclerosis
KR20050025604A (en) * 2002-07-18 2005-03-14 상꾜 가부시키가이샤 Medicinal composition for treating arteriosclerosis
US7223785B2 (en) * 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7098231B2 (en) * 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
CA2546601A1 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
WO2005077359A1 (en) * 2004-02-17 2005-08-25 Sankyo Company, Limited Stabilized pharmaceutical composition containing indoline compound
EP1718608B1 (en) * 2004-02-20 2013-07-17 Boehringer Ingelheim International GmbH Viral polymerase inhibitors
EP2343553A1 (en) 2004-10-06 2011-07-13 The Brigham and Women's Hospital Relevance of achieved levels of markers of systemic inflammation following treatment
EP1806332A4 (en) * 2004-10-27 2010-03-31 Daiichi Sankyo Co Ltd Benzene compound having 2 or more substituents
JP5015154B2 (en) * 2005-08-12 2012-08-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Viral polymerase inhibitor
WO2007146230A2 (en) * 2006-06-14 2007-12-21 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
FR2918890A1 (en) * 2007-07-19 2009-01-23 Galderma Res & Dev USE OF PACTIMIBE FOR THE PREPARATION OF A MEDICAMENT FOR THE PREVENTION OR TREATMENT OF DISEASE DUE TO DYSFUNCTION OF SEBATED GLANDS IN MAN OR ANIMAL
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
US8343706B2 (en) * 2010-01-25 2013-01-01 International Business Machines Corporation Fluorine-free fused ring heteroaromatic photoacid generators and resist compositions containing the same
WO2011161964A1 (en) * 2010-06-24 2011-12-29 興和株式会社 Agent for improving insulin resistance with acat inhibitor as active component
WO2014139388A1 (en) * 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
JP2018052818A (en) * 2015-01-28 2018-04-05 武田薬品工業株式会社 Sulfonamide compound
CN108440373B (en) * 2018-03-23 2021-05-14 昆明学院 Iron-catalyzed cyanoalkylindoline and preparation method thereof

Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4803218A (en) * 1982-09-29 1989-02-07 Mcneilab, Inc. 3-aminoalkyl-1H-indole-5-urea and amide derivatives
EP0325397A1 (en) 1988-01-20 1989-07-26 Yamanouchi Pharmaceutical Co. Ltd. Diurea derivatives useful as medicaments and processes for the preparation thereof
EP0354994A2 (en) 1988-07-12 1990-02-21 Takeda Chemical Industries, Ltd. Quinoline derivatives, their production and use
JPH02117651A (en) * 1988-01-20 1990-05-02 Yamanouchi Pharmaceut Co Ltd Diurea derivative and its production
EP0375113A2 (en) 1988-12-22 1990-06-27 Springs Industries Inc. Corespun yarn for fire resistant safety apparel and method
JPH037259A (en) * 1988-07-12 1991-01-14 Takeda Chem Ind Ltd Acat inhibitor, quinoline derivative and production thereof
CA2029660A1 (en) 1989-11-10 1991-05-11 Alex Junino Dyeing compositions for keratinic fibers containing dye precursors obtained by oxydation and couplers derived from 4-hydroxyindole, and dyeing process to use them
JPH03148247A (en) * 1989-08-31 1991-06-25 Warner Lambert Co Acat inhibitor
EP0447116A1 (en) 1990-03-12 1991-09-18 Yamanouchi Pharmaceutical Co. Ltd. Urea derivatives, their production, and pharmaceutical compositions containing them
EP0472116A1 (en) 1990-08-17 1992-02-26 Takeda Chemical Industries, Ltd. Thienopyridine Derivatives, their production and use
JPH0466568A (en) * 1990-06-29 1992-03-02 Takeda Chem Ind Ltd Central antioxidant compound
EP0512570A1 (en) 1991-05-10 1992-11-11 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
JPH04327564A (en) * 1991-03-08 1992-11-17 Adir New acylaminophenol compounds, method of manufacturing same and medicinal composition containing same
JPH0532666A (en) * 1990-08-17 1993-02-09 Takeda Chem Ind Ltd Thienopyridine derivative, production thereof and acat inhibitor
JPH0597802A (en) * 1991-03-26 1993-04-20 Lipha (Lyon Ind Pharmaceut) Indol derivative, preparation thereof, and medicinal product containing same
US5356920A (en) 1990-11-28 1994-10-18 Farmitalia Carlo Erba Srl. Imidazol-2-yl derivatives of substituted bicyclic compounds
EP0622356A1 (en) * 1993-04-28 1994-11-02 Sumitomo Pharmaceuticals Company, Limited Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange
EP0635501A1 (en) 1993-07-21 1995-01-25 American Home Products Corporation Tris carbamic acid esters: inhibitors of cholesterol absorption; inhibitors of ACAT and CEH
WO1996009287A1 (en) * 1994-09-20 1996-03-28 Kyoto Pharmaceutical Industries, Ltd. Novel heterocyclic derivatives, process for producing the same, and medicinal use thereof
EP0708091A1 (en) * 1994-10-18 1996-04-24 Sumitomo Pharmaceuticals Company, Limited Indoloylguanidine derivatives
JPH08208602A (en) * 1994-10-18 1996-08-13 Sumitomo Pharmaceut Co Ltd Indoloylguanidine derivative
EP0793140A1 (en) * 1996-03-04 1997-09-03 Fuji Photo Film Co., Ltd. Processing composition for silver halide photographic light-sensitive material, developer and processing method using the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956372A (en) * 1987-10-02 1990-09-11 Kyorin Pharmaceutical Co., Ltd. Cyclic anthranilic acid derivatives and process for their preparation
CN1068000A (en) * 1991-06-27 1993-01-13 重庆人民广播电台 Dynamic balance switch, amplitude modulation, floating carrier brodcasting tv transmitter
US5767129A (en) * 1995-08-24 1998-06-16 Warner-Lambert Company Substituted quinolines and isoquinolines as calcium channel blockers, their preparation and the use thereof

Patent Citations (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4803218A (en) * 1982-09-29 1989-02-07 Mcneilab, Inc. 3-aminoalkyl-1H-indole-5-urea and amide derivatives
EP0325397A1 (en) 1988-01-20 1989-07-26 Yamanouchi Pharmaceutical Co. Ltd. Diurea derivatives useful as medicaments and processes for the preparation thereof
JPH02117651A (en) * 1988-01-20 1990-05-02 Yamanouchi Pharmaceut Co Ltd Diurea derivative and its production
EP0354994A2 (en) 1988-07-12 1990-02-21 Takeda Chemical Industries, Ltd. Quinoline derivatives, their production and use
JPH037259A (en) * 1988-07-12 1991-01-14 Takeda Chem Ind Ltd Acat inhibitor, quinoline derivative and production thereof
US5254565A (en) 1988-07-12 1993-10-19 Takeda Chemical Industries, Ltd. Quinoline derivatives, their production and use
EP0375113A2 (en) 1988-12-22 1990-06-27 Springs Industries Inc. Corespun yarn for fire resistant safety apparel and method
US5153226A (en) * 1989-08-31 1992-10-06 Warner-Lambert Company Acat inhibitors for treating hypocholesterolemia
JPH03148247A (en) * 1989-08-31 1991-06-25 Warner Lambert Co Acat inhibitor
US5609649A (en) 1989-11-10 1997-03-11 L'oreal Tinctorial composition for keratinous fibers containing oxidation dye precursors and couplers derived from 4-hydroxyindole, and dyeing method using them
CA2029660A1 (en) 1989-11-10 1991-05-11 Alex Junino Dyeing compositions for keratinic fibers containing dye precursors obtained by oxydation and couplers derived from 4-hydroxyindole, and dyeing process to use them
EP0447116A1 (en) 1990-03-12 1991-09-18 Yamanouchi Pharmaceutical Co. Ltd. Urea derivatives, their production, and pharmaceutical compositions containing them
JPH04234839A (en) * 1990-03-12 1992-08-24 Yamanouchi Pharmaceut Co Ltd Urea derivative or salt thereof
JPH0466568A (en) * 1990-06-29 1992-03-02 Takeda Chem Ind Ltd Central antioxidant compound
EP0472116A1 (en) 1990-08-17 1992-02-26 Takeda Chemical Industries, Ltd. Thienopyridine Derivatives, their production and use
JPH0532666A (en) * 1990-08-17 1993-02-09 Takeda Chem Ind Ltd Thienopyridine derivative, production thereof and acat inhibitor
US5356920A (en) 1990-11-28 1994-10-18 Farmitalia Carlo Erba Srl. Imidazol-2-yl derivatives of substituted bicyclic compounds
US5254590A (en) 1991-03-08 1993-10-19 Adir Et Compagnie Acylaminophenol compounds
JPH04327564A (en) * 1991-03-08 1992-11-17 Adir New acylaminophenol compounds, method of manufacturing same and medicinal composition containing same
JPH0597802A (en) * 1991-03-26 1993-04-20 Lipha (Lyon Ind Pharmaceut) Indol derivative, preparation thereof, and medicinal product containing same
US5219859A (en) * 1991-03-26 1993-06-15 Lipha, Lyonnaise Industrielle Pharmaceutique Indole derivatives, preparation processes and medicinal products containing them
EP0512570A1 (en) 1991-05-10 1992-11-11 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same
JPH05140102A (en) * 1991-05-10 1993-06-08 Fujisawa Pharmaceut Co Ltd Urea derivative and its production
EP0622356A1 (en) * 1993-04-28 1994-11-02 Sumitomo Pharmaceuticals Company, Limited Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange
EP0635501A1 (en) 1993-07-21 1995-01-25 American Home Products Corporation Tris carbamic acid esters: inhibitors of cholesterol absorption; inhibitors of ACAT and CEH
US5952354A (en) 1993-07-21 1999-09-14 American Home Products Corporation Tris carbamic acid esters: inhibitors of cholesterol absorption
EP0782986A1 (en) 1994-09-20 1997-07-09 Kyoto Pharmaceutical Industries, Ltd. Novel heterocyclic derivatives, process for producing the same, and medicinal use thereof
JPH0892210A (en) * 1994-09-20 1996-04-09 Kyoto Yakuhin Kogyo Kk New heterocyclic derivative, its production and its pharmaceutical use
WO1996009287A1 (en) * 1994-09-20 1996-03-28 Kyoto Pharmaceutical Industries, Ltd. Novel heterocyclic derivatives, process for producing the same, and medicinal use thereof
US5990150A (en) 1994-09-20 1999-11-23 Sankyo Company, Ltd. Heterocyclic derivatives, method of production thereof and pharmaceutical use thereof
US6127403A (en) 1994-09-20 2000-10-03 Sankyo Company, Ltd. Method for inhibiting acyl-CoA : cholesterol acyltransferase
JPH08208602A (en) * 1994-10-18 1996-08-13 Sumitomo Pharmaceut Co Ltd Indoloylguanidine derivative
EP0708091A1 (en) * 1994-10-18 1996-04-24 Sumitomo Pharmaceuticals Company, Limited Indoloylguanidine derivatives
EP0793140A1 (en) * 1996-03-04 1997-09-03 Fuji Photo Film Co., Ltd. Processing composition for silver halide photographic light-sensitive material, developer and processing method using the same

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
"Potential Antiatheroscelerotic Agents. 5.<SUP>1 </SUP>An acyl-CoA:Cholesterol O-Acyltransferase Inhibitor with Hypocholesterolemic Activity", J. Med. Chem. vol. 29, pp. 1131-1133. 1986. *
"Potential Antiatheroscelerotic Agents. 5.1 An acyl-CoA:Cholesterol O-Acyltransferase Inhibitor with Hypocholesterolemic Activity", J. Med. Chem. vol. 29, pp. 1131-1133. 1986. *
Communications to the Editor, "Potential Antiatheroscelerotic Agents. 5.<SUP>1 </SUP>An acyl-CoA:Cholesterol O-Acyltransferase Inhibitor with Hypocholesterolemic Activity", J. Med. Chem. vol. 29, pp. 1131-1133 (1986).
Communications to the Editor, "Potential Antiatheroscelerotic Agents. 5.1 An acyl-CoA:Cholesterol O-Acyltransferase Inhibitor with Hypocholesterolemic Activity", J. Med. Chem. vol. 29, pp. 1131-1133 (1986).
F. Brown et al., "Evolution of a Series of Peptidoleukotriene Antagonists: Synthesis and Structure-Activity Relationships of 1,6-Disubstituted Indoles and Indazoles", Journal of Medicinal Chemistry, vol. 33, No. 6, pp. 1771-1781 (1990).
F. Brown et al., "Evolution of a Series of Peptidoleukotriene Antagonists: Synthesis and Structure-Activity Relationships of 1,6-Disubstituted Indoles and Indazoles", Journal of Medicinal Chemistry, vol. 33, No. 6, pp. 1771-1781, 1990. *
K. Yee et al., "Novel Series of Selective Leukotriene Antagonists: Exploration and Timization of the Acidic Region in 1,6-Disubstituted Indoles and Indazoles", Journal of Medicinal Chemistry, vol. 33, No. 9, pp. 2437-2451, 1990. *
Matassa et al., "Evolution of a Series of Peptidoleukotriene Antagonists: Synthesis and Structure/Activity Relationships of 1,3, 5-substituted Indoles and Indazoles", Journal of Medicinal Chemistry, vol. 33, No. 6, pp. 1781-1790 (1990).
V. Matassa et al., "Evolution of a Series of Peptidoleukotriene Antagonists: Synthesis and Structure/Activity Relationships of 1,3, 5-substituted Indoles and Indazoles", Journal of Medicinal Chemistry, vol. 33, No. 6, pp. 1781-1790, 1990. *
Yee et al., "A Novel Series of Selective Leukotriene Antagonists: Exploration and Timization of the Acidic Region in 1,6-Disubstituted Indoles and Indazoles", Journal of Medicinal Chemistry, vol. 33, No. 9, pp. 2437-2451 (1990).

Also Published As

Publication number Publication date
EP0866059A1 (en) 1998-09-23
KR19990063987A (en) 1999-07-26
DE69617731D1 (en) 2002-01-17
NO981485L (en) 1998-06-02
PT866059E (en) 2002-03-28
DE69617731T2 (en) 2002-08-08
KR100388345B1 (en) 2004-03-30
HK1048989A1 (en) 2003-04-25
EP0866059B1 (en) 2001-12-05
EP0866059A4 (en) 1998-12-02
TW429250B (en) 2001-04-11
US6200988B1 (en) 2001-03-13
PL326000A1 (en) 1998-08-17
TR199800655T2 (en) 1999-09-21
CN1097043C (en) 2002-12-25
PL190034B1 (en) 2005-10-31
CN1193018C (en) 2005-03-16
DK0866059T3 (en) 2002-03-25
CN1203587A (en) 1998-12-30
US6063806A (en) 2000-05-16
CZ292632B6 (en) 2003-11-12
IL123939A (en) 2001-11-25
HK1015781A1 (en) 1999-10-22
CN1361100A (en) 2002-07-31
AU7097796A (en) 1997-04-28
WO1997012860A1 (en) 1997-04-10
HUP9900617A2 (en) 1999-06-28
HK1048989B (en) 2005-10-28
CZ99698A3 (en) 1998-08-12
ES2164920T3 (en) 2002-03-01
ATE210116T1 (en) 2001-12-15
BR9610846A (en) 1999-07-13
NZ318874A (en) 1999-09-29
HUP9900617A3 (en) 2001-12-28
NO310818B1 (en) 2001-09-03
AU708571B2 (en) 1999-08-05
NO981485D0 (en) 1998-04-01

Similar Documents

Publication Publication Date Title
USRE38970E1 (en) Indolyl or indolinyl derivatives and medicinal use thereof as ACAT or lipid peroxidation inhibitors
US6489475B2 (en) Method of producing heterocyclic derivatives
EP0031741A1 (en) Substituted imino-acids, process for their preparation and their use as enzyme inhibitors
HU193409B (en) Process for producing 2-square bracket -n-cyclohexyl-4-bracket-oxo-1,2,3,5-tetrahydro-imidazo-square bracket-2,1-b-square bracket closed-quinazolin-7-yl-bracket closed-oxy-alkqne-carboxamidyl-square bracket closed-alkan-acides
US4183858A (en) α-Vinyl tryptophanes
EP0402232A1 (en) Pyridobenzoindole derivatives, their preparation and compositions containing them
RU2173316C2 (en) Novel heterocyclic derivatives and their pharmaceutical using
JP2968050B2 (en) Novel heterocyclic derivatives and their pharmaceutical uses
US7429612B2 (en) Indoline compound and medicinal use thereof
CA2233842C (en) Novel heterocyclic derivatives having indoline, indole or tetrahydroquinoline ring and pharmaceutical use thereof
MXPA98002729A (en) Heterociclic novedous derivatives and pharmaceutical use of mis
AU705798B2 (en) Novel heterocyclic derivatives
US4629735A (en) Compositions containing substituted aminobenzoates and use thereof as inhibitors of lipoxygenase
SU791228A3 (en) Method of preparing aminopropanol derivatives or their salts
BE869191A (en) NEW IMIDAZO-ISOQUINOLEINE-DIONES, METHODS FOR THEIR PREPARATION AND THEIR USE AS MEDICINAL PRODUCTS

Legal Events

Date Code Title Description
FPAY Fee payment

Year of fee payment: 8

CC Certificate of correction
REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees